

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number
WO 2004/081199 A2

- (51) International Patent Classification⁷: C12N (74) Agent: CARPENTER, David, A.; Genentech, Inc., MS 49, 1 DNA Way, South San Francisco, CA 94080 (US).
- (21) International Application Number: PCT/US2004/007862 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 10 March 2004 (10.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/454,025 11 March 2003 (11.03.2003) US
- (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BALDWIN, Daryl [US/US]; 1595 Euclid Avenue, Berkeley, CA 94708 (US). BODARY, Sarah [US/US]; 1951 Camino de los Robles, Menlo Park, CA 94025 (US). CLARK, Hilary [US/US]; 1504 Noe St., San Francisco, CA 94131 (US). FONG, Sherman [US/US]; 19 Basinside Way, Alameda, CA 94502 (US). GURNEY, Austin, L. [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). WILLIAMS, P., Mickey [US/US]; 509 Alto Avenue, Half Moon Bay, CA 94019 (US).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/081199 A2

(54) Title: NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASE

(57) Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASE

5

Field of the Invention

The present invention relates to compositions and methods useful for the diagnosis and alleviation of immune related disease.

10

Background of the Invention

Immune related and inflammatory diseases are the manifestation or consequence of fairly complex, often multiple interconnected biological pathways which in normal physiology are critical to respond to insult or injury, initiate repair from insult or injury, and mount innate and acquired defense against foreign organisms. Disease or pathology occurs when these normal physiological pathways cause additional insult or injury either as directly related to the intensity of the response, as a consequence of abnormal regulation or excessive stimulation, as a reaction to self, or as a combination of these.

Though the genesis of these diseases often involves multistep pathways and often multiple different biological systems/pathways, intervention at critical points in one or more of these pathways can have an ameliorative or therapeutic effect. Therapeutic intervention can occur by either antagonism of a detrimental process/pathway or stimulation of a beneficial process/pathway.

Many immune related diseases are known and have been extensively studied. Such diseases include immune-mediated inflammatory diseases, non-immune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, *etc.*

T lymphocytes (T cells) are an important component of a mammalian immune response. T cells recognize antigens which are associated with a self-molecule encoded by genes within the major histocompatibility complex (MHC). The antigen may be displayed together with MHC molecules on the surface of antigen presenting cells, virus infected cells, cancer cells, grafts, *etc.* The T cell system eliminates these altered cells which pose a health threat to the host mammal. T cells include helper T cells and cytotoxic T cells. Helper T cells proliferate extensively following recognition of an antigen-MHC complex on an antigen presenting cell. Helper T cells also secrete a variety of cytokines, *i.e.*, lymphokines, which play a central role in the activation of B cells, cytotoxic T cells and a variety of other cells which participate in the immune response.

Several diseases of the skin are correlated with an aberrant T cell response and to autoimmunity. Psoriasis is thought to be an autoimmune disease. Specifically, T-cells of the immune system recognize a protein in the skin and attack the area where that protein is found, causing the too-rapid growth of new skin cells and painful, elevated, scaly lesions. These lesions are characterized by hyperproliferation of keratinocytes and the accumulation of activated T-cells in the epidermis of the psoriatic lesions. There are several forms of psoriasis; guttate is the one that most commonly occurs in children and teens. It is sometimes preceded by an upper respiratory infection. Guttate psoriasis is noncontagious and characterized by small drop-like lesions, usually scattered over the trunk, limbs and scalp. According to the National

Psoriasis Foundation, approximately seven million people in the United States have psoriasis. About 20,000 children are diagnosed with psoriasis annually, and many of the cases are attributed to upper respiratory infections. It is estimated that only about 1.5 million people with psoriasis actually seek treatment, primarily due to lack of or dissatisfaction with current treatments. Although the initial molecular cause of disease is unknown, genetic linkages have been mapped to at least 7 psoriasis susceptibility loci (Psor1 on 6p21.3, Psor2 on 17q, Psor3 on 4q, Psor4 on 1 cent-q21, Psor5 on 3q21, Psor6 on 19p13, and Psor7 on 1p). Some of these loci overlap with other autoimmune/inflammatory diseases including rheumatoid arthritis, atopic dermatitis, and irritable bowel disease. In this application, experiments determine that a gene is upregulated in psoriatic skin vs. normal skin.

The term inflammatory bowel disorder ("IBD") describes a group of chronic inflammatory disorders of unknown causes in which the intestine (bowel) becomes inflamed, often causing recurring cramps or diarrhea. The prevalence of IBD in the US is estimated to be about 200 per 100,000 population. Patients with IBD can be divided into two major groups, those with ulcerative colitis ("UC") and those with Crohn's disease ("CD").

In patients with UC, there is an inflammatory reaction primarily involving the colonic mucosa. The inflammation is typically uniform and continuous with no intervening areas of normal mucosa. Surface mucosal cells as well as crypt epithelium and submucosa are involved in an inflammatory reaction with neutrophil infiltration. Ultimately, this situation typically progresses to epithelial damage with loss of epithelial cells resulting in multiple ulcerations, fibrosis, dysplasia and longitudinal retraction of the colon.

CD differs from UC in that the inflammation extends through all layers of the intestinal wall and involves mesentery as well as lymph nodes. CD may affect any part of the alimentary canal from mouth to anus. The disease is often discontinuous, i.e., severely diseased segments of bowel are separated from apparently disease-free areas. In CD, the bowel wall also thickens which can lead to obstructions. In addition, fistulas and fissures are not uncommon.

Clinically, IBD is characterized by diverse manifestations often resulting in a chronic, unpredictable course. Bloody diarrhea and abdominal pain are often accompanied by fever and weight loss. Anemia is not uncommon, as is severe fatigue. Joint manifestations ranging from arthralgia to acute arthritis as well as abnormalities in liver function are commonly associated with IBD. Patients with IBD also have an increased risk of colon carcinomas compared to the general population. During acute "attacks" of IBD, work and other normal activity are usually impossible, and often a patient is hospitalized.

Although the cause of IBD remains unknown, several factors such as genetic, infectious and immunologic susceptibility have been implicated. IBD is much more common in Caucasians, especially those of Jewish descent. The chronic inflammatory nature of the condition has prompted an intense search for a possible infectious cause. Although agents have been found which stimulate acute inflammation, none has been found to cause the chronic inflammation associated with IBD. The hypothesis that IBD is an autoimmune disease is supported by the previously mentioned extraintestinal manifestation of IBD as joint arthritis, and the known positive response to IBD by treatment with therapeutic agents such as adrenal glucocorticoids, cyclosporine and azathioprine, which are known to suppress immune response. In addition, the GI tract, more than any other organ of the body, is continuously exposed to potential antigenic substances such as proteins from food, bacterial byproducts (LPS), etc.

Once the diagnosis has been made, typically by endoscopy, the goals of therapy are to induce and maintain a remission. The least toxic agents which patients are typically treated with are the aminosalicylates. Sulfasalazine (Azulfidine), typically administered four times a day, consists of an active molecule of aminosalicylate (5-ASA) which is linked by an azo bond to a sulfapyridine. Anaerobic bacteria in the colon split the azo bond to release active 5-ASA. However, at least 20% of patients cannot tolerate sulfapyridine because it is associated with significant side-effects such as reversible sperm abnormalities, dyspepsia or allergic reactions to the sulpha component. These side effects are reduced in patients taking olsalazine. However, neither sulfasalazine nor olsalazine are effective for the treatment of small bowel inflammation. Other formulations of 5-ASA have been developed which are released in the small intestine (e.g. mesalamine and asacol). Normally it takes 6-8 weeks for 5-ASA therapy to show full efficacy. Patients who do not respond to 5-ASA therapy, or who have a more severe disease, are prescribed corticosteroids. However, this is a short term therapy and cannot be used as a maintenance therapy. Clinical remission is achieved with corticosteroids within 2-4 weeks, however the side effects are significant and include a Cushing goldface, facial hair, severe mood swings and sleeplessness. The response to sulfasalazine and 5-aminosalicylate preparations is poor in Crohn's disease, fair to mild in early ulcerative colitis and poor in severe ulcerative colitis. If these agents fail, powerful immunosuppressive agents such as cyclosporine, prednisone, 6-mercaptopurine or azathioprine (converted in the liver to 6-mercaptopurine) are typically tried. For Crohn's disease patients, the use of corticosteroids and other immunosuppressives must be carefully monitored because of the high risk of intra-abdominal sepsis originating in the fistulas and abscesses common in this disease. Approximately 25% of IBD patients will require surgery (colectomy) during the course of the disease.

Further, the risk of colon cancer is elevated ($\geq 32X$) in patients with severe ulcerative colitis, particularly if the disease has existed for several years. About 20-25% of patients with IBD eventually require surgery for removal of the colon because of massive bleeding, chronic debilitating illness, perforation of the colon, or risk of cancer. Surgery is also sometimes performed when other forms of medical treatment fail or when the side effects of steroids or other medications threaten the patient's health. As surgery is invasive and drastically life altering, it is not a highly desirable treatment regimen, and is typically the treatment of last resort.

In addition to pharmaceutical medicine and surgery, nonconventional treatments for IBD such as nutritional therapy have also been attempted. For example, Flexical[®], a semi-elemental formula, has been shown to be as effective as the steroid prednisolone. Sanderson *et al.*, *Arch. Dis. Child.* 51:123-7 (1987). However, semi-elemental formulas are relatively expensive and are typically unpalatable - thus their use has been restricted. Nutritional therapy incorporating whole proteins has also been attempted to alleviate the symptoms of IBD. Giafer *et al.*, *Lancet* 335: 816-9 (1990). U.S.P. 5,461,033 describes the use of acidic casein isolated from bovine milk and TGF-2. Beattie *et al.*, *Aliment. Pharmacol. Ther.* 8: 1-6 (1994) describes the use of casein in infant formula in children with IBD. U.S.P. 5,952,295 describes the use of casein in an enteric formulation for the treatment of IBD. However, while nutritional therapy is non-toxic, it is only a palliative treatment and does not treat the underlying cause of the disease.

Despite the above identified advances in immune research, there is a great need for additional diagnostic and therapeutic agents capable of detecting the presence of an immune related disease in a

mammal and for effectively inhibiting these afflictions. Accordingly, it is an objective of the present invention to identify polypeptides that are overexpressed in immune related disease states as compared to normal tissue, and to use those polypeptides, and their encoding nucleic acids, to produce compositions of matter useful in the therapeutic treatment and diagnostic detection of immune related disease in mammals.

5

Summary of the Invention

A. Embodiments

The present invention concerns compositions and methods useful for the diagnosis and treatment of immune related disease in mammals, including humans. The present invention is based on the identification of proteins (including agonist and antagonist antibodies) which are a result of immune related disease in mammals. Immune related diseases such as psoriasis or IBD may be treated by suppressing the immune response. Molecules that enhance the immune response stimulate or potentiate the immune response to an antigen. Molecules which stimulate the immune response can be used therapeutically where enhancement of the immune response would be beneficial. Alternatively, molecules that suppress the immune response attenuate or reduce the immune response to an antigen (*e.g.*, neutralizing antibodies) can be used therapeutically where attenuation of the immune response would be beneficial (*e.g.*, inflammation). Accordingly, the PRO polypeptides, agonists and antagonists thereof are also useful to prepare medicines and medicaments for the treatment of immune related disease. In a specific aspect, such medicines and medicaments comprise a therapeutically effective amount of a PRO polypeptide, agonist or antagonist thereof with a pharmaceutically acceptable carrier. Preferably, the admixture is sterile.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprises contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native sequence PRO polypeptide. In a specific aspect, the PRO agonist or antagonist is an anti-PRO antibody.

In another embodiment, the invention concerns a composition of matter comprising a PRO polypeptide or an agonist or antagonist antibody which binds the polypeptide in admixture with a carrier or excipient. In one aspect, the composition comprises a therapeutically effective amount of the polypeptide or antibody. In a further aspect, when the composition comprises a immune related disease inhibiting molecule, the composition is useful for: (a) reducing the amount of psoriasis or affected colon tissue in a mammal in need thereof, (b) inhibiting or reducing an auto-immune response in a mammal in need thereof, In another aspect, the composition comprises a further active ingredient, which may, for example, be a further antibody or a cytotoxic or chemotherapeutic agent. Preferably, the composition is sterile.

In another embodiment, the invention concerns a method of treating immune related disease in a mammal in need thereof, comprising administering to the mammal an effective amount of a PRO polypeptide, an agonist thereof, or an antagonist thereto.

In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody. In one aspect, the present invention concerns an isolated antibody which binds a PRO polypeptide. In another aspect, the antibody mimics the activity of a

PRO polypeptide (an agonist antibody) or conversely the antibody inhibits or neutralizes the activity of a PRO polypeptide (an antagonist antibody). In another aspect, the antibody is a monoclonal antibody, which preferably has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues. The antibody may be labeled and may be immobilized on a solid support. In a further aspect, the antibody is an antibody fragment, a monoclonal antibody, a single-chain antibody, or an anti-idiotypic antibody.

In yet another embodiment, the present invention provides a composition comprising an anti-PRO antibody in admixture with a pharmaceutically acceptable carrier. In one aspect, the composition comprises a therapeutically effective amount of the antibody. Preferably, the composition is sterile. The composition may be administered in the form of a liquid pharmaceutical formulation, which may be preserved to achieve extended storage stability. Alternatively, the antibody is a monoclonal antibody, an antibody fragment, a humanized antibody, or a single-chain antibody.

In a further embodiment, the invention concerns an article of manufacture, comprising:

- (a) a composition of matter comprising a PRO polypeptide or agonist or antagonist thereof;
- (b) a container containing said composition; and
- (c) a label affixed to said container, or a package insert included in said container referring to the use of said PRO polypeptide or agonist or antagonist thereof in the treatment of an immune related disease. The composition may comprise a therapeutically effective amount of the PRO polypeptide or the agonist or antagonist thereof.

In yet another embodiment, the present invention concerns a method of diagnosing immune related disease in a mammal, comprising detecting the level of expression of a gene encoding a PRO polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample as compared to the control sample indicates the presence of immune related disease in the mammal from which the test tissue cells were obtained.

In another embodiment, the present invention concerns a method of diagnosing immune related disease in a mammal, comprising (a) contacting an anti-PRO antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and a PRO polypeptide, in the test sample; wherein the formation of said complex is indicative of the presence or absence of said immune related disease. The detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A larger quantity of complexes formed in the test sample indicates the presence or absence of immune related disease in the mammal from which the test tissue cells were obtained. The antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. The test sample is usually obtained from an individual suspected of having immune related disease.

In another embodiment, the invention provides a method for determining the presence of a PRO polypeptide in a sample comprising exposing a test sample of cells suspected of containing the PRO polypeptide to an anti-PRO antibody and determining the binding of said antibody to said cell sample. In a specific aspect, the sample comprises a cell suspected of containing the PRO polypeptide and the antibody

binds to the cell. The antibody is preferably detectably labeled and/or bound to a solid support.

In another embodiment, the present invention concerns an immune related disease diagnostic kit, comprising an anti-PRO antibody and a carrier in suitable packaging. The kit preferably contains instructions for using the antibody to detect the presence of the PRO polypeptide. Preferably the carrier is pharmaceutically acceptable.

In another embodiment, the present invention concerns a diagnostic kit, containing an anti-PRO antibody in suitable packaging. The kit preferably contains instructions for using the antibody to detect the PRO polypeptide.

In another embodiment, the invention provides a method of diagnosing an immune related disease in a mammal which comprises detecting the presence or absence of a PRO polypeptide in a test sample of tissue cells obtained from said mammal, wherein the presence or absence of the PRO polypeptide in said test sample is indicative of the presence of immune related disease in said mammal.

In another embodiment, the present invention concerns a method for identifying an agonist of a PRO polypeptide comprising:

(a) contacting cells and a test compound to be screened under conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and

(b) determining the induction of said cellular response to determine if the test compound is an effective agonist, wherein the induction of said cellular response is indicative of said test compound being an effective agonist.

In another embodiment, the invention concerns a method for identifying a compound capable of inhibiting the activity of a PRO polypeptide comprising contacting a candidate compound with a PRO polypeptide under conditions and for a time sufficient to allow these two components to interact and determining whether the activity of the PRO polypeptide is inhibited. In a specific aspect, either the candidate compound or the PRO polypeptide is immobilized on a solid support. In another aspect, the non-immobilized component carries a detectable label. In a preferred aspect, this method comprises the steps of:

(a) contacting cells and a test compound to be screened in the presence of a PRO polypeptide under conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and

(b) determining the induction of said cellular response to determine if the test compound is an effective antagonist.

In another embodiment, the invention provides a method for identifying a compound that inhibits the expression of a PRO polypeptide in cells that normally express the polypeptide, wherein the method comprises contacting the cells with a test compound and determining whether the expression of the PRO polypeptide is inhibited. In a preferred aspect, this method comprises the steps of:

(a) contacting cells and a test compound to be screened under conditions suitable for allowing expression of the PRO polypeptide; and

(b) determining the inhibition of expression of said polypeptide.

In yet another embodiment, the present invention concerns a method for treating immune related disease in a mammal that suffers therefrom comprising administering to the mammal a nucleic acid molecule that codes for either (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide or (c) an antagonist of a PRO polypeptide, wherein said agonist or antagonist may be an anti-PRO antibody. In a preferred

embodiment, the mammal is human. In another preferred embodiment, the nucleic acid is administered via *ex vivo* gene therapy. In a further preferred embodiment, the nucleic acid is comprised within a vector, more preferably an adenoviral, adeno-associated viral, lentiviral or retroviral vector.

5 In yet another aspect, the invention provides a recombinant viral particle comprising a viral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide, or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein the viral vector is in association with viral structural proteins. Preferably, the signal sequence is from a mammal, such as from a native PRO polypeptide.

10 In a still further embodiment, the invention concerns an *ex vivo* producer cell comprising a nucleic acid construct that expresses retroviral structural proteins and also comprises a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein said producer cell packages the retroviral vector in association with the structural proteins to produce recombinant retroviral particles.

15 B. Additional Embodiments

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions
20 suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a
25 Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

In yet other embodiments, the invention provides oligonucleotide probes useful for isolating
30 genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.

In other embodiments, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least
35 about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid
40 sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about

90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity,

alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide
5 sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the
10 complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60
15 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160
20 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500
25 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide
30 sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise
35 a binding site for an anti-PRO antibody.

In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences herein above identified.

In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino
40 acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least

about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs as disclosed herein.

In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as herein before described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

5 In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

10 In a still further embodiment, the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as herein before described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO62782 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA275062".

20 Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO36822 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA226359".

Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

25 Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO37226 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA226763".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

30 Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO71142 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA304716".

Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO38477 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA228014".

35 Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO10275 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA143498".

40 Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

Figure 13A-B shows a nucleotide sequence (SEQ ID NO:13) of a native sequence PRO81407 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA324792".

Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13A-B.

5 Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PRO69584 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA287319".

Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

10 Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO88263 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA333620".

Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PRO80958 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA324275".

15 Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PRO38415 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA227952".

20 Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PRO4834 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA103507".

Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

25 Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PRO36719 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA226256".

Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

30 Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO81414 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA324799".

Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PRO50891 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA255836".

35 Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

Figure 31A-B shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PRO91480 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA339972".

40 Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31A-B.

Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO80648 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA323910".

Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

5 Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PRO36735 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA226272".

Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

10 Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PRO12050 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA151772".

Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

Figure 39A-B shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PRO83903 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA327983".

15 Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39A-B.

Figure 41A-C shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PRO37509 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA227046".

20 Figure 42A-B shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 4A-C

Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO37760 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA227297".

Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

25 Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PRO92173 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA340442".

Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

30 Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO10849 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA324641".

Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO83649 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA327651".

35 Figure 50 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO86795 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA331909".

40 Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO36574 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA226111".

Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

5 Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO69541 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA287270".

Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

10 Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PRO84948 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA329369".

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.

Figure 59A-B shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PRO85817 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA330645".

15 Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59A-B.

Figure 61A-B shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PRO38371 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA227908".

20 Figure 62A-B shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61A-B.

Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO90951 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA340375".

Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 63.

25

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. Definitions

The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein.

30

35

40

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide

variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech,

Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

5 In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

10

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X," "Y" and "Z" each represent different hypothetical amino acid residues.

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters,

wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

"PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least
 5 about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.

“Percent (%) nucleic acid sequence identity” with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with
 10 the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are
 15 generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech,
 20 Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence
 25 D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

30 where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5,
 35 demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated “Comparison DNA” to the nucleic acid sequence designated “PRO-DNA”, wherein “PRO-DNA” represents a hypothetical PRO-encoding nucleic acid sequence of interest, “Comparison DNA” represents the nucleotide sequence of a nucleic acid molecule against which the “PRO-DNA” nucleic acid molecule of interest is being compared, and “N”, “L” and “V” each represent different hypothetical nucleotides.

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and

wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

“Isolated,” when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An “isolated” PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term “antibody” is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polypeptopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below). The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the

population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

“Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

“Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt’s solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

“Moderately stringent conditions” may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt’s solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term “epitope tagged” when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a “tag polypeptide”. The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term “immunoadhesin” designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin

constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is “heterologous”), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

“Active” or “activity” for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein “biological” activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an “immunological” activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.

The term “antagonist” is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein. In a similar manner, the term “agonist” is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.

“Treatment” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

“Chronic” administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

“Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

“Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids;

antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONIC™.

“Antibody fragments” comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies (Zapata et al., *Protein Eng.* 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')₂ fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

“Fv” is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V_H-V_L dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')₂ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The “light chains” of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

“Single-chain Fv” or “sFv” antibody fragments comprise the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) in the same polypeptide chain (V_H - V_L). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

The term "immune related disease" means a disease in which a component of the immune system of a mammal causes, mediates or otherwise contributes to a morbidity in the mammal. Also included are diseases in which stimulation or intervention of the immune response has an ameliorative effect on

progression of the disease. Included within this term are immune-mediated inflammatory diseases, non-immune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, *etc.*

The term "T cell mediated disease" means a disease in which T cells directly or indirectly mediate or otherwise contribute to a morbidity in a mammal. The T cell mediated disease may be associated with cell mediated effects, lymphokine mediated effects, *etc.*, and even effects associated with B cells if the B cells are stimulated, for example, by the lymphokines secreted by T cells.

As used herein the term "psoriasis" is defined as a condition characterized by the eruption of circumscribed, discreet and confluent, reddish, silvery-scaled macropapules preeminently on the elbows, knees, scalp and trunk.

As used herein the term "Inflammatory bowel disease" is defined as inflammatory disorders in which the intestine (bowel) becomes inflamed, often causing recurring cramps or diarrhea.

The term "effective amount" is a concentration or amount of a PRO polypeptide and/or agonist/antagonist which results in achieving a particular stated purpose. An "effective amount" of a PRO polypeptide or agonist or antagonist thereof may be determined empirically. Furthermore, a "therapeutically effective amount" is a concentration or amount of a PRO polypeptide and/or agonist/antagonist which is effective for achieving a stated therapeutic effect. This amount may also be determined empirically.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (*e.g.*, I^{131} , I^{125} , Y^{90} and Re^{186}), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include adriamycin, doxorubicin, epirubicin, 5-fluorouracil, cytosine arabinoside ("Ara-C"), cyclophosphamide, thiotepa, busulfan, cytoxan, taxoids, *e.g.*, paclitaxel (Taxol, Bristol-Myers Squibb Oncology, Princeton, NJ), and doxetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France), taxotere, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycins, esperamicins (see U.S. Pat. No. 4,675,187), melphalan and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors such as tamoxifen and onapristone.

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially cancer cell overexpressing any of the genes identified herein, either *in vitro* or *in vivo*. Thus, the growth inhibitory agent is one which significantly reduces the percentage of cells overexpressing such genes in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in *The Molecular Basis of Cancer*, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogens, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p.

13.

The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- α and - β ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- β ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- α and TGF- β ; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon- α , - β , and - γ ; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 α , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF- α or TNF- β ; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (*i.e.*, is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

As used herein, the term "inflammatory cells" designates cells that enhance the inflammatory response such as mononuclear cells, eosinophils, macrophages, and polymorphonuclear neutrophils (PMN).

30

Table 1

```

/*
5  *
  * C-C increased from 12 to 15
  * Z is average of EQ
  * B is average of ND
  * match with stop is _M; stop-stop = 0; J (joker) match = 0
10 */
#define _M      -8      /* value of a match with a stop */

int      _day[26][26] = {
/*      A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
15 /* A */      { 2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2, -1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0},
/* B */      { 0, 3, -4, 3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5, 0, -3, 1},
/* C */      {-2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6, -5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5},
/* D */      { 0, 3, -5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 2},
/* E */      { 0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3, -2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3},
20 /* F */      {-4, -5, -4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3, 0, -1, 0, 0, 7, -5},
/* G */      { 1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2, -4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0},
/* H */      {-1, 1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1, 0, -2, -3, 0, 0, 2},
/* I */      {-1, -2, -2, -2, -2, 1, -3, -2, 5, 0, -2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2},
/* J */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
25 /* K */      {-1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0, 1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0},
/* L */      {-2, -3, -6, -4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3, -1, 0, 2, -2, 0, -1, -2},
/* M */      {-1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0, 4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1},
/* N */      { 0, 2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0, -2, -4, 0, -2, 1},
/* O */      {_M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M},
30 /* P */      { 1, -1, -3, -1, -1, -5, -1, 0, -2, 0, -1, -3, -2, -1, _M, 6, 0, 0, 1, 0, 0, -1, -6, 0, -5, 0},
/* Q */      { 0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1, _M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3},
/* R */      {-2, 0, -4, -1, -1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0, -4, 0},
/* S */      { 1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M, 1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0},
/* T */      { 1, 0, -2, 0, 0, -3, 0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3, 0},
35 /* U */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */      { 0, -2, -2, -2, -2, -1, -1, -2, 4, 0, -2, 2, 2, -2, _M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2},
/* W */      {-6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4, _M, -6, -5, 2, -2, -5, 0, -6, 17, 0, 0, -6},
/* X */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */      {-3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4, -4, -3, -3, 0, -2, 0, 0, 10, -4},
40 /* Z */      { 0, 1, -5, 2, 3, -5, 0, 2, -2, 0, 0, -2, -1, 1, _M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4}
};

```

45

50

55

Table 1 (cont')

```

/*
*/
#include <stdio.h>
5  #include <ctype.h>

#define MAXJMP      16      /* max jumps in a diag */
#define MAXGAP      24      /* don't continue to penalize gaps larger than this */
#define JMPS        1024    /* max jmps in an path */
10  #define MX        4      /* save if there's at least MX-1 bases since last jmp */

#define DMAT         3      /* value of matching bases */
#define DMIS         0      /* penalty for mismatched bases */
#define DINS0        8      /* penalty for a gap */
15  #define DINS1        1    /* penalty per base */
#define PINS0        8      /* penalty for a gap */
#define PINS1        4      /* penalty per residue */

struct jmp {
20      short          n[MAXJMP];      /* size of jmp (neg for dely) */
      unsigned short  x[MAXJMP];      /* base no. of jmp in seq x */
};                                     /* limits seq to 2^16 -1 */

struct diag {
25      int            score;           /* score at last jmp */
      long            offset;          /* offset of prev block */
      short           jmp;             /* current jmp index */
      struct jmp       jp;             /* list of jmps */
};

30  struct path {
      int             spc;             /* number of leading spaces */
      short           n[JMPS];         /* size of jmp (gap) */
      int             x[JMPS];         /* loc of jmp (last elem before gap) */
35  };

char      *ofile;                     /* output file name */
char      *nameex[2];                 /* seq names: getseqs() */
char      *prog;                      /* prog name for err msgs */
40  char      *seqx[2];                 /* seqs: getseqs() */
int        dmax;                      /* best diag: nw() */
int        dmax0;                     /* final diag */
int        dna;                       /* set if dna: main() */
int        endgaps;                   /* set if penalizing end gaps */
45  int        gapx, gapy;              /* total gaps in seqs */
int        len0, len1;                /* seq lens */
int        ngapx, ngapy;              /* total size of gaps */
int        smax;                      /* max score: nw() */
int        *xbm;                     /* bitmap for matching */
50  long       offset;                 /* current offset in jmp file */
struct     diag    *dx;               /* holds diagonals */
struct     path    pp[2];             /* holds path for seqs */

char      *calloc(), *malloc(), *index(), *strcpy();
55  char      *getseq(), *g_calloc();

```

60

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
*
* usage: progs file1 file2
5  * where file1 and file2 are two dna or two protein sequences.
* The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ';', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
10 * Output is in the file "align.out"
*
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/
15 #include "nw.h"
#include "day.h"

static _dbval[26] = {
20 1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};

static _pbval[26] = {
25 1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)
30     main
    int    ac;
    char   *av[ ];
{
    prog = av[0];
35     if (ac != 3) {
        fprintf(stderr, "usage: %s file1 file2\n", prog);
        fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
        fprintf(stderr, "The sequences can be in upper- or lower-case\n");
        fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
40         fprintf(stderr, "Output is in the file 'align.out'\n");
        exit(1);
    }
    namex[0] = av[1];
    namex[1] = av[2];
45     seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
    xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                                /* 1 to penalize endgaps */
50     ofile = "align.out";                       /* output file */

    nw();                                         /* fill in the matrix, get the possible jumps */
    readjumps();                                /* get the actual jumps */
    print();                                     /* print stats, alignment */
55     cleanup();                                /* unlink any tmp files */
}
60

```

Table 1 (cont')

```

/* do the alignment, return best score: main()
* dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
* pro: PAM 250 values
5  * When scores are equal, we prefer mismatches to any gap, prefer
* a new gap to extending an ongoing gap, and prefer a gap in seqx
* to a gap in seq y.
*/
nw()
10  {
    char      *px, *py;      /* seqs and ptrs */
    int        *ndely, *dely; /* keep track of dely */
    int        ndelx, delx;   /* keep track of delx */
    int        *tmp;         /* for swapping row0, row1 */
    int        mis;          /* score for each type */
    int        ins0, ins1;    /* insertion penalties */
    register   id;           /* diagonal index */
    register   ij;           /* jmp index */
    register   *col0, *col1;  /* score for curr, last row */
    register   xx, yy;       /* index into seqs */

    dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag));

25  ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
    dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
    col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
    col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
    ins0 = (dna)? DINS0 : PINS0;
    ins1 = (dna)? DINS1 : PINS1;

    smax = -10000;
    if (endgaps) {
35      for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
          col0[yy] = dely[yy] = col0[yy-1] - ins1;
          ndely[yy] = yy;
      }
      col0[0] = 0;      /* Waterman Bull Math Biol 84 */
    }
    else
40      for (yy = 1; yy <= len1; yy++)
          dely[yy] = -ins0;

    /* fill in match matrix
    */
45  for (px = seqx[0]; xx = 1; xx <= len0; px++, xx++) {
        /* initialize first entry in col
        */
        if (endgaps) {
50          if (xx == 1)
              col1[0] = delx = -(ins0+ins1);
          else
              col1[0] = delx = col0[0] - ins1;
          ndelx = xx;
60          }
        else {
            col1[0] = 0;
            delx = -ins0;
            ndelx = 0;
        }
    }

```


Table 1 (cont')**...nw**

```

5      for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
        mis = col0[yy-1];
        if (dna)
            mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
        else
            mis += _day[*px-'A'][*py-'A'];

10      /* update penalty for del in x seq;
        * favor new del over ongoing del
        * ignore MAXGAP if weighting endgaps
        */
        if (endgaps || ndely[yy] < MAXGAP) {
15            if (col0[yy] - ins0 >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else {
                dely[yy] -= ins1;
20                ndely[yy]++;
            }
        } else {
            if (col0[yy] - (ins0+ins1) >= dely[yy]) {
25                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else
                ndely[yy]++;
        }

30      /* update penalty for del in y seq;
        * favor new del over ongoing del
        */
        if (endgaps || ndelx < MAXGAP) {
            if (col1[yy-1] - ins0 >= delx) {
35                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
            } else {
                delx -= ins1;
                ndelx++;
40            }
        } else {
            if (col1[yy-1] - (ins0+ins1) >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
45            } else
                ndelx++;
        }

50      /* pick the maximum score; we're favoring
        * mis over any del and delx over dely
        */

```

55

60

Table 1 (cont')

...nw

```

5      id = xx - yy + len1 - 1;
      if (mis >= delx && mis >= dely[yy])
          col1[yy] = mis;
      else if (delx >= dely[yy]) {
          col1[yy] = delx;
          ij = dx[id].ijmp;
          if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
10      && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
              dx[id].ijmp++;
              if (++ij >= MAXJMP) {
                  writejumps(id);
                  ij = dx[id].ijmp = 0;
15      dx[id].offset = offset;
                  offset += sizeof(struct jmp) + sizeof(offset);
              }
          }
          dx[id].jp.n[ij] = ndelx;
          dx[id].jp.x[ij] = xx;
          dx[id].score = delx;
      }
      else {
25      col1[yy] = dely[yy];
          ij = dx[id].ijmp;
          if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
              && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
              dx[id].ijmp++;
              if (++ij >= MAXJMP) {
30      writejumps(id);
                  ij = dx[id].ijmp = 0;
                  dx[id].offset = offset;
                  offset += sizeof(struct jmp) + sizeof(offset);
              }
          }
          dx[id].jp.n[ij] = -ndely[yy];
          dx[id].jp.x[ij] = xx;
          dx[id].score = dely[yy];
      }
40      if (xx == len0 && yy < len1) {
          /* last col
          */
          if (endgaps)
              col1[yy] -= ins0+ins1*(len1-yy);
          if (col1[yy] > smax) {
45      smax = col1[yy];
              dmax = id;
          }
      }
50      }
      if (endgaps && xx < len0)
          col1[yy-1] -= ins0+ins1*(len0-xx);
      if (col1[yy-1] > smax) {
          smax = col1[yy-1];
55      dmax = id;
      }
      tmp = col0; col0 = col1; col1 = tmp;
  }
  (void) free((char *)ndely);
  (void) free((char *)dely);
60  (void) free((char *)col0);
  (void) free((char *)col1);
  }

```

Table 1 (cont')

```

/*
*
* print() -- only routine visible outside this module
5  *
* static:
* getmat() -- trace back best path, count matches: print()
* pr_align() -- print alignment of described in array p[ ]: print()
* dumpblock() -- dump a block of lines with numbers, stars: pr_align()
10 * nums() -- put out a number line: dumpblock()
* putline() -- put out a line (name, [num], seq, [num]): dumpblock()
* stars() -- put a line of stars: dumpblock()
* stripname() -- strip any path and prefix from a seqname
*/
15
#include "nw.h"

#define SPC      3
#define P_LINE  256    /* maximum output line */
20 #define P_SPC   3      /* space between name or num and seq */

extern  _day[26][26];
int     olen;          /* set output line length */
FILE    *fx;           /* output file */
25

print()

    print
{
    int     lx, ly, firstgap, lastgap;    /* overlap */
30
    if ((fx = fopen(ofile, "w")) == 0) {
        fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
35
    fprintf(fx, "<first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], len1);
    olen = 60;
    lx = len0;
    ly = len1;
40
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) {    /* leading gap in x */
        pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
45
    else if (dmax > len1 - 1) {    /* leading gap in y */
        pp[1].spc = firstgap = dmax - (len1 - 1);
        lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) {    /* trailing gap in x */
50
        lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
    }
    else if (dmax0 > len0 - 1) {    /* trailing gap in y */
55
        lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
    getmat(lx, ly, firstgap, lastgap);
    pr_align();
}
60

```

Table 1 (cont')

```

/*
 * trace back the best path, count matches
 */
5 static
getmat(lx, ly, firstgap, lastgap)                                     getmat
    int    lx, ly;          /* "core" (minus endgaps) */
    int    firstgap, lastgap; /* leading trailing overlap */
{
10     int    nm, i0, i1, siz0, siz1;
    char    outx[32];
    double   pct;
    register n0, n1;
    register char *p0, *p1;
15
    /* get total matches, score
    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1].spc;
20     p1 = seqx[1] + pp[0].spc;
    n0 = pp[1].spc + 1;
    n1 = pp[0].spc + 1;

    nm = 0;
25     while ( *p0 && *p1 ) {
        if (siz0) {
            p1++;
            n1++;
            siz0--;
30         }
        else if (siz1) {
            p0++;
            n0++;
            siz1--;
35         }
        else {
            if (xbm[*p0-'A']&xbm[*p1-'A'])
                nm++;
            if (n0++ == pp[0].x[i0])
                siz0 = pp[0].n[i0++];
40             if (n1++ == pp[1].x[i1])
                siz1 = pp[1].n[i1++];
            p0++;
            p1++;
45         }
    }

    /* pct homology:
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
    if (endgaps)
        lx = (len0 < len1)? len0 : len1;
    else
55         lx = (lx < ly)? lx : ly;
    pct = 100.*((double)nm/((double)lx);
    fprintf(fx, "\n");
    fprintf(fx, "<%d match%s in an overlap of %d: %.2f percent similarity\n",
60         nm, (nm == 1)? "" : "es", lx, pct);

```


Table 1 (cont')

```

    fprintf(fx, "<gaps in first sequence: %d", gapx);
    if (gapx) {
5      (void) sprintf(outx, " (%d %s%s)",
        ngapx, (dna)? "base":"residue", (ngapx == 1)? "" : "s");
        fprintf(fx, "%s", outx);

    fprintf(fx, ", gaps in second sequence: %d", gapy);
10    if (gapy) {
        (void) sprintf(outx, " (%d %s%s)",
        ngapy, (dna)? "base":"residue", (ngapy == 1)? "" : "s");
        fprintf(fx, "%s", outx);
    }
15    if (dna)
        fprintf(fx,
        "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
        smax, DMAT, DMIS, DINSO, DINS1);
    else
20      fprintf(fx,
        "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
        smax, PINSO, PINS1);
    if (endgaps)
25      fprintf(fx,
        "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
        firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s",
        lastgap, (dna)? "base" : "residue", (lastgap == 1)? "" : "s");
    else
        fprintf(fx, "<endgaps not penalized\n");
30 }
    static nm; /* matches in core -- for checking */
    static lmax; /* lengths of stripped file names */
    static ij[2]; /* jmp index for a path */
    static nc[2]; /* number at start of current line */
35    static ni[2]; /* current elem number -- for gapping */
    static siz[2];
    static char *ps[2]; /* ptr to current element */
    static char *po[2]; /* ptr to next output char slot */
    static char out[2][P_LINE]; /* output line */
40    static char star[P_LINE]; /* set by stars() */

    /*
    * print alignment of described in struct path pp[ ]
    */
45    static
    pr_align()
    {
        int nn; /* char count */
        int more;
50        register i;

        for (i = 0, lmax = 0; i < 2; i++) {
            nn = stripname(nameex[i]);
            if (nn > lmax)
55                lmax = nn;

            nc[i] = 1;
            ni[i] = 1;
            siz[i] = ij[i] = 0;
60            ps[i] = seqx[i];
            po[i] = out[i];
        }

```

...getmat

pr_align

Table 1 (cont')

```

5      for (nn = nm = 0, more = 1; more; ) {
        for (i = more = 0; i < 2; i++) {
            /*
            * do we have more of this sequence?
            */
            if (!*ps[i])
10                continue;

            more++;

            if (pp[i].spc) { /* leading space */
                *po[i]++ = ' ';
                pp[i].spc--;
            }
            else if (siz[i]) { /* in a gap */
                *po[i]++ = '-';
                siz[i]--;
20            }
            else { /* we're putting a seq element
                    */
                *po[i] = *ps[i];
                if (islower(*ps[i]))
                    *ps[i] = toupper(*ps[i]);
                po[i]++;
                ps[i]++;

                /*
                * are we at next gap for this seq?
                */
                if (ni[i] == pp[i].x[ij[i]]) {
                    /*
                    * we need to merge all gaps
                    * at this location
                    */
                    siz[i] = pp[i].n[ij[i]++];
                    while (ni[i] == pp[i].x[ij[i]])
                        siz[i] += pp[i].n[ij[i]++];
40                }
                ni[i]++;
            }
        }
        if (++nn == olen || !more && nn) {
            dumpblock();
            for (i = 0; i < 2; i++)
                po[i] = out[i];
            nn = 0;
50        }
    }

    /*
    * dump a block of lines, including numbers, stars: pr_align()
    */
55    static
    dumpblock()
        dumpblock
    {
        register i;
        for (i = 0; i < 2; i++)
            *po[i]-- = '\0';
60

```

...pr_align

Table 1 (cont')

...dumpblock

```

5      (void) putc('\n', fx);
      for (i = 0; i < 2; i++) {
          if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
              if (i == 0)
                  nums(i);
              if (i == 0 && *out[1])
                  stars();
10             putline(i);
              if (i == 0 && *out[1])
                  fprintf(fx, star);
              if (i == 1)
                  nums(i);
15             }
          }
      }

20  /*
   * put out a number line: dumpblock()
   */
   static
   nums(ix)
25     int      ix;      /* index in out[ ] holding seq line */
   {
       char      nline[P_LINE];
       register  i, j;
       register char *pn, *px, *py;
30
       for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
           *pn = ' ';
       for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
           if (*py == ' ' || *py == '-')
35             *pn = ' ';
           else {
               if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                   j = (i < 0)? -i : i;
                   for (px = pn; j /= 10, px--)
40                     *px = j%10 + '0';
                   if (i < 0)
                       *px = '-';
               }
               else
45                 *pn = ' ';
               i++;
           }
       }
       *pn = '\0';
       nc[ix] = i;
       for (pn = nline; *pn; pn++)
50         (void) putc(*pn, fx);
       (void) putc('\n', fx);
   }

55  /*
   * put out a line (name, [num], seq, [num]): dumpblock()
   */
   static
   putline(ix)
60     int      ix;      {

```

nums

putline

Table 1 (cont')

...putline

```

5      int          i;
      register char *px;

      for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
          (void) putc(*px, fx);
10     for (; i < lmax+P_SPC; i++)
          (void) putc(' ', fx);

      /* these count from 1:
       * ni[ ] is current element (from 1)
       * nc[ ] is number at start of current line
       */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
20 }

/*
 * put a line of stars (seqs always in out[0], out[1]): dumpblock()
 */
25 static
stars()
{
    stars
    {
30        int          i;
        register char *p0, *p1, cx, *px;

        if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
            !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
            return;
35        px = star;
        for (i = lmax+P_SPC; i; i--)
            *px++ = ' ';

        for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
40            if (isalpha(*p0) && isalpha(*p1)) {

                if (xbm[*p0-'A']&xbm[*p1-'A']) {
                    cx = '*';
                    nm++;
45                }
                else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
                    cx = ':';
                else
                    cx = ' ';
50            }
            else
                cx = ' ';
            *px++ = cx;
55        }
        *px++ = '\n';
        *px = '\0';
    }
}
60

```


Table 1 (cont')

```
/*
 * strip path or prefix from pn, return len: pr_align()
 */
5 static
  stripname(pn)
      stripname
      char *pn; /* file name (may be path) */
10 {
      register char *px, *py;

      py = 0;
      for (px = pn; *px; px++)
          if (*px == '/')
15             py = px + 1;
      if (py)
          (void) strcpy(pn, py);
      return(strlen(pn));
20 }

25

30

35

40

45

50

55

60
```

Table 1 (cont')

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
5  * g_calloc() -- calloc() with error checkin
 * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
10 #include <sys/file.h>

char    *jname = "/tmp/homgXXXXXX";          /* tmp file for jumps */
FILE    *fj;

15 int    cleanup();                          /* cleanup tmp file */
long    lseek();

/*
 * remove any tmp file if we blow
20 */
cleanup(i)
    int    i;
{
    if (fj)
25         (void) unlink(jname);
    exit(i);
}

/*
30 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
char    *
35 getseq(file, len)
    char    *file;    /* file name */
    int     *len;      /* seq len */
{
    char    line[1024], *pseq;
40     register char    *px, *py;
    int     natgc, tlen;
    FILE    *fp;

    if ((fp = fopen(file, "r")) == 0) {
45         fprintf(stderr, "%s: can't read %s\n", prog, file);
        exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
50         if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
55     }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1);
    }
60     pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';

```

cleanup

getseq

Table 1 (cont')

...getseq

```

5      py = pseq + 4;
      *len = tlen;
      rewind(fp);

      while (fgets(line, 1024, fp)) {
          if (*line == ';' || *line == '<' || *line == '>')
              continue;
10         for (px = line; *px != '\n'; px++) {
              if (isupper(*px))
                  *py++ = *px;
              else if (islower(*px))
                  *py++ = toupper(*px);
15         if (index("ATGCU",*(py-1)))
              natgc++;
          }
      }
      *py++ = '\0';
      *py = '\0';
      (void) fclose(fp);
      dna = natgc > (tlen/3);
      return(pseq+4);
25 }

char *
g_calloc(msg, nx, sz)
      char *msg;          /* program, calling routine */
      int nx, sz;         /* number and size of elements */
30 {
      char *px, *calloc();

      if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
          if (*msg) {
35             fprintf(stderr, "%s: g_calloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
              exit(1);
          }
      }
      return(px);
40 }

/*
 * get final jmps from dx[ ] or tmp file, set pp[ ], reset dmax: main()
 */
45 readjmps()
    readjmps
    {
        int fd = -1;
        int siz, i0, i1;
50     register i, j, xx;

        if (fj) {
            (void) fclose(fj);
            if ((fd = open(jname, O_RDONLY, 0)) < 0) {
55                 fprintf(stderr, "%s: can't open() %s\n", prog, jname);
                    cleanup(1);
            }
        }
        for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; ; i++) {
60             while (1) {
                for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)
                    ;
            }
        }
    }

```

g_calloc

Table 1 (cont')

...readjumps

```

5         if (j < 0 && dx[dmax].offset && fj) {
            (void) lseek(fd, dx[dmax].offset, 0);
            (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
            (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
            dx[dmax].ijmp = MAXJMP-1;
        }
10        else
            break;
    }
    if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1);
15    }
    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz;
20        if (siz < 0) { /* gap in second seq */
            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1
            */
            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy -= siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
30            i1++;
        }
        else if (siz > 0) { /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
            gapx++;
            ngapx += siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
40            i0++;
        }
    }
    else
        break;
}

45    /* reverse the order of jumps
    */
    for (j = 0, i0--; j < i0; j++, i0--) {
50        i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
        i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
    }
    for (j = 0, i1--; j < i1; j++, i1--) {
        i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
55        i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
    }
    if (fd >= 0)
        (void) close(fd);
    if (fj) {
60        (void) unlink(jname);
        fj = 0;
        offset = 0;
    }
}

```


Table 1 (cont')

```

5  /*
   * write a filled jmp struct offset of the prev one (if any): nw()
   */
   writejumps(ix)
       writejumps
       int      ix;
10  {
       char      *mktemp();

       if (!fj) {
           if (mktemp(jname) < 0) {
15               fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);
               cleanup(1);
           }
           if ((fj = fopen(jname, "w")) == 0) {
               fprintf(stderr, "%s: can't write %s\n", prog, jname);
               exit(1);
20           }
       }
       (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
       (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
       }
25

```

Table 2

5	PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
	Comparison Protein	XXXXXXYYYYYYY	(Length = 12 amino acids)
	% amino acid sequence identity =		

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) = 5 divided by 15 = 33.3%

Table 3

15	PRO	XXXXXXXXXX	(Length = 10 amino acids)
	Comparison Protein	XXXXXXYYYYYYZZYZ	(Length = 15 amino acids)
	% amino acid sequence identity =		

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) = 5 divided by 10 = 50%

Table 4

25	PRO-DNA	NNNNNNNNNNNNNNNN	(Length = 14 nucleotides)
	Comparison DNA	NNNNNNLLLLLLLLLL	(Length = 16 nucleotides)

% nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) = 6 divided by 14 = 42.9%

Table 5

35	PRO-DNA	NNNNNNNNNNNNNN	(Length = 12 nucleotides)
	Comparison DNA	NNNNLLLLVV	(Length = 9 nucleotides)

% nucleic acid sequence identity =

40

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) = 4 divided by 12 = 33.3%

5 II. Compositions and Methods of the Invention

 A. Full-Length PRO Polypeptides

 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples
10 below. However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.

 As disclosed in the Examples below, the sequence of various cDNA clones have been disclosed.
15 The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

 B. PRO Polypeptide Variants

 In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated
20 that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

 Variations in the native full-length sequence PRO or in various domains of the PRO described
25 herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally, the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO.
30 Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine,
35 i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

 PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-
40 terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native

protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.

PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	Original Residue	Exemplary Substitutions	Preferred Substitutions
20	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
25	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
30	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
35	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
40	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- 5 (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

10 The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

15 Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)].

20 Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

C. Modifications of PRO

25 Covalent modifications of PRO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa.

30 Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparaginy residues to the

35 corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al.,

Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an alpha-tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

15 D. Preparation of PRO

The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.

1. Isolation of DNA Encoding PRO

DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., *supra*; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives

are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like ^{32}P -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaCl_2 , CaPO_4 , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli*

strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan^r*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan^r*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982).

Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC

CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* α -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR

activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)].

The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope.

5. Purification of Polypeptide

Forms of PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced.

E. Tissue Distribution

The location of tissues expressing the PRO can be identified by determining mRNA expression in various human tissues. The location of such genes provides information about which tissues are most likely to be affected by the stimulating and inhibiting activities of the PRO polypeptides. The location of a gene in a specific tissue also provides sample tissue for the activity blocking assays discussed below.

As noted before, gene expression in various tissues may be measured by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, *Proc. Natl. Acad. Sci. USA*, 77:5201-5205 [1980]), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.

Gene expression in various tissues, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence of a PRO polypeptide or against a synthetic peptide based on the DNA sequences encoding the PRO polypeptide or against an exogenous sequence fused to a DNA encoding a PRO polypeptide and encoding a specific antibody epitope. General techniques for generating antibodies, and special protocols for Northern blotting and *in situ* hybridization are provided below.

F. Antibody Binding Studies

The activity of the PRO polypeptides can be further verified by antibody binding studies, in which the ability of anti-PRO antibodies to inhibit the effect of the PRO polypeptides, respectively, on tissue cells is tested. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies, the preparation of which will be described hereinbelow.

Antibody binding studies may be carried out in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp.147-158 (CRC Press, Inc., 1987).

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of target protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, *e.g.*, US Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For

example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

G. Cell-Based Assays

5 Cell-based assays and animal models for immune related diseases such as psoriasis can be used to further understand the relationship between the genes and polypeptides identified herein and the development and pathogenesis psoriasis.

10 In a different approach, cells of a cell type known to be involved in immune related disease are transfected with the cDNAs described herein, and the ability of these cDNAs to stimulate or inhibit immune related disease is analyzed. Suitable cells can be transfected with the desired gene, and monitored for such functional activity. Such transfected cell lines can then be used to test the ability of poly- or monoclonal antibodies or antibody compositions to inhibit or stimulate psoriasis. Cells transfected with the coding sequences of the genes identified herein can further be used to identify drug candidates for the treatment of immune related disease.

15 In addition, primary cultures derived from transgenic animals (as described below) can be used in the cell-based assays herein, although stable cell lines are preferred. Techniques to derive continuous cell lines from transgenic animals are well known in the art (see, *e.g.*, Small *et al.*, *Mol. Cell. Biol.* 5: 642-648 [1985]).

H. Animal Models

20 The results of cell based in vitro assays can be further verified using *in vivo* animal models and assays for immune related disease. A variety of well known animal models can be used to further understand the role of the genes identified herein in the development and pathogenesis of immune related disease, and to test the efficacy of candidate therapeutic agents, including antibodies, and other antagonists of the native polypeptides, including small molecule antagonists. The *in vivo* nature of such models makes
25 them predictive of responses in human patients. Animal models of immune related diseases include both non-recombinant and recombinant (transgenic) animals. Non-recombinant animal models include, for example, rodent, *e.g.*, murine models. Such models can be generated by introducing cells into syngeneic mice using standard techniques, *e.g.*, subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, *etc.*

30 Graft-versus-host disease occurs when immunocompetent cells are transplanted into immunosuppressed or tolerant patients. The donor cells recognize and respond to host antigens. The response can vary from life threatening severe inflammation to mild cases of diarrhea and weight loss. Graft-versus-host disease models provide a means of assessing T cell reactivity against MHC antigens and minor transplant antigens. A suitable procedure is described in detail in Current Protocols in Immunology,
35 above, unit 4.3.

An animal model for skin allograft rejection is a means of testing the ability of T cells to mediate *in vivo* tissue destruction and a measure of their role in transplant rejection. The most common and accepted models use murine tail-skin grafts. Repeated experiments have shown that skin allograft rejection is mediated by T cells, helper T cells and killer-effector T cells, and not antibodies. Auchincloss, H. Jr. and
40 Sachs, D. H., *Fundamental Immunology*, 2nd ed., W. E. Paul ed., Raven Press, NY, 1989, 889-992. A

suitable procedure is described in detail in *Current Protocols in Immunology*, above, unit 4.4. Other transplant rejection models which can be used to test the compounds of the invention are the allogeneic heart transplant models described by Tanabe, M. *et al*, *Transplantation* (1994) 58:23 and Tinubu, S. A. *et al*, *J. Immunol.* (1994) 4330-4338.

5 Contact hypersensitivity is a simple delayed type hypersensitivity *in vivo* assay of cell mediated immune function. In this procedure, cutaneous exposure to exogenous haptens which gives rise to a delayed type hypersensitivity reaction which is measured and quantitated. Contact sensitivity involves an initial sensitizing phase followed by an elicitation phase. The elicitation phase occurs when the T lymphocytes encounter an antigen to which they have had previous contact. Swelling and inflammation occur, making
10 this an excellent model of human allergic contact dermatitis. A suitable procedure is described in detail in *Current Protocols in Immunology*, Eds. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, John Wiley & Sons, Inc., 1994, unit 4.2. See also Grabbe, S. and Schwarz, T, *Immun. Today* 19 (1): 37-44 (1998).

 Additionally, the compounds of the invention can be tested on animal models for immune related
15 disease like psoriasis. Evidence suggests a T cell pathogenesis for psoriasis, therefore the compounds of the invention can be tested in the scid/scid mouse model described by Schon, M. P. *et al*, *Nat. Med.* (1997) 3:183, in which the mice demonstrate histopathologic skin lesions resembling psoriasis. Another suitable model is the human skin/scid mouse chimera prepared as described by Nickoloff, B. J. *et al*, *Am. J. Path.* (1995) 146:580.

20 Recombinant (transgenic) animal models can be engineered by introducing the coding portion of the genes identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals. Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, *e.g.*, baboons, chimpanzees and monkeys. Techniques known in the art to introduce a transgene into such animals include
25 pronucleic microinjection (Hoppe and Wanger, U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (*e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci. USA* 82, 6148-615 [1985]); gene targeting in embryonic stem cells (Thompson *et al.*, *Cell* 56, 313-321 [1989]); electroporation of embryos (Lo, *Mol. Cel. Biol.* 3, 1803-1814 [1983]); sperm-mediated gene transfer (Lavitrano *et al.*, *Cell* 57, 717-73 [1989]). For review, see, for example, U.S. Patent No. 4,736,866.

30 For the purpose of the present invention, transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals"). The transgene can be integrated either as a single transgene, or in concatamers, *e.g.*, head-to-head or head-to-tail tandems. Selective introduction of a transgene into a particular cell type is also possible by following, for example, the technique of Lasko *et al.*, *Proc. Natl. Acad. Sci. USA* 89, 6232-636 (1992).

35 The expression of the transgene in transgenic animals can be monitored by standard techniques. For example, Southern blot analysis or PCR amplification can be used to verify the integration of the transgene. The level of mRNA expression can then be analyzed using techniques such as *in situ* hybridization, Northern blot analysis, PCR, or immunocytochemistry.

 The animals may be further examined for signs of immune disease pathology, for example by
40 histological examination to determine infiltration of immune cells into specific tissues. Blocking

experiments can also be performed in which the transgenic animals are treated with the compounds of the invention to determine the extent of the T cell proliferation stimulation or inhibition of the compounds. In these experiments, blocking antibodies which bind to the PRO polypeptide, prepared as described above, are administered to the animal and the effect on immune function is determined.

5 Alternatively, "knock out" animals can be constructed which have a defective or altered gene encoding a polypeptide identified herein, as a result of homologous recombination between the endogenous gene encoding the polypeptide and altered genomic DNA encoding the same polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding a particular polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques. A portion of the
10 genomic DNA encoding a particular polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see *e.g.*, Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced DNA
15 has homologously recombined with the endogenous DNA are selected [see *e.g.*, Li *et al.*, *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras [see *e.g.*, Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a
20 "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the polypeptide.

25 I. ImmunoAdjuvant Therapy

In one embodiment, the immunostimulating compounds of the invention can be used in immunoadjuvant therapy for the treatment of tumors (cancer). It is now well established that T cells recognize human tumor specific antigens. One group of tumor antigens, encoded by the MAGE, BAGE and GAGE families of genes, are silent in all adult normal tissues, but are expressed in significant amounts in
30 tumors, such as melanomas, lung tumors, head and neck tumors, and bladder carcinomas. DeSmet, C. *et al.*, (1996) *Proc. Natl. Acad. Sci. USA*, 93:7149. It has been shown that costimulation of T cells induces tumor regression and an antitumor response both *in vitro* and *in vivo*. Melero, I. *et al.*, *Nature Medicine* (1997) 3:682; Kwon, E. D. *et al.*, *Proc. Natl. Acad. Sci. USA* (1997) 94: 8099; Lynch, D. H. *et al.*, *Nature Medicine* (1997) 3:625; Finn, O. J. and Lotze, M. T., *J. Immunol.* (1998) 21:114. The stimulatory compounds of the
35 invention can be administered as adjuvants, alone or together with a growth regulating agent, cytotoxic agent or chemotherapeutic agent, to stimulate T cell proliferation/activation and an antitumor response to tumor antigens. The growth regulating, cytotoxic, or chemotherapeutic agent may be administered in conventional amounts using known administration regimes. Immunostimulating activity by the compounds of the invention allows reduced amounts of the growth regulating, cytotoxic, or chemotherapeutic agents thereby
40 potentially lowering the toxicity to the patient.

J. Screening Assays for Drug Candidates

Screening assays for drug candidates are designed to identify compounds that bind to or complex with the polypeptides encoded by the genes identified herein or a biologically active fragment thereof, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds, including peptides, preferably soluble peptides, (poly)peptide-immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art. All assays are common in that they call for contacting the drug candidate with a polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, *e.g.*, on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the polypeptide and drying. Alternatively, an immobilized antibody, *e.g.*, a monoclonal antibody, specific for the polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, *e.g.*, the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, *e.g.*, by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labelled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular protein encoded by a gene identified herein, its interaction with that protein can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers [Fields and Song, *Nature (London)* 340, 245-246 (1989); Chien *et al.*, *Proc. Natl. Acad. Sci. USA* 88, 9578-9582 (1991)] as disclosed by Chevray and Nathans, *Proc. Natl. Acad. Sci. USA* 89, 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, while the other one functioning as the transcription activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate

activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for β -galactosidase. A complete kit (MATCHMAKERTM) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

In order to find compounds that interfere with the interaction of a gene identified herein and other intra- or extracellular components can be tested, a reaction mixture is usually prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a test compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described above. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

K. Compositions and Methods for Treatment

The compositions useful in the treatment of immune related disease include, without limitation, proteins, antibodies, small organic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, triple helix molecules, *etc.* that inhibit immune function, for example, T cell proliferation/activation, lymphokine release, or immune cell infiltration.

For example, antisense RNA and RNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation initiation site, *e.g.*, between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, *e.g.*, Rossi, *Current Biology* 4, 469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, *e.g.*, PCT publication No. WO 97/33551, *supra*.

These molecules can be identified by any or any combination of the screening assays discussed above and/or by any other screening techniques well known for those skilled in the art.

L. Anti-PRO Antibodies

The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

1. Polyclonal Antibodies

5 The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to
10 conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without
15 undue experimentation.

2. Monoclonal Antibodies

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized
20 with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes
25 are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that
30 inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression
35 of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al.,

Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

3. Human and Humanized Antibodies

The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.

5 Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found

10 neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region

15 (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an

20 "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeven et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has

25 been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of

30 human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody

35 production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

40

The antibodies may also be affinity matured using known selection and/or mutagenesis methods as described above. Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.

5

4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

10

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

15

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

20

25

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

30

35

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the

40

dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Fab' fragments may be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby *et al.*, *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.*, *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber *et al.*, *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.*, *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein. Alternatively, an anti-PRO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).

5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be

prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5

6. Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, *J. Exp. Med.*, 176: 1191-1195 (1992) and Shopes, *J. Immunol.*, 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.*, *Cancer Research*, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.*, *Anti-Cancer Drug Design*, 3: 219-230 (1989).

15

7. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

20

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

25

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, *Science*, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

30

35

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient,

40

followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).

8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, J. National Cancer Inst., 81(19): 1484 (1989).

M. Pharmaceutical Compositions

The active PRO molecules of the invention (e.g., PRO polypeptides, anti-PRO antibodies, and/or variants of each) as well as other molecules identified by the screening assays disclosed above, can be administered for the treatment of immune related disease, in the form of pharmaceutical compositions.

Therapeutic formulations of the active PRO molecule, preferably a polypeptide or antibody of the invention, are prepared for storage by mixing the active molecule having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG).

Compounds identified by the screening assays disclosed herein can be formulated in an analogous manner, using standard techniques well known in the art.

Lipofections or liposomes can also be used to deliver the PRO molecule into cells. Where antibody fragments are used, the smallest inhibitory fragment which specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable region sequences of an antibody, peptide

molecules can be designed which retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology (see, *e.g.*, Marasco *et al.*, *Proc. Natl. Acad. Sci. USA* 90, 7889-7893 [1993]).

5 The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise a cytotoxic agent, cytokine or growth inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

10 The active PRO molecules may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

15 The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations of the PRO molecules may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of
20 sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ -ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate
25 and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S
30 bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

N. Methods of Treatment

35 It is contemplated that the polypeptides, antibodies and other active compounds of the present invention may be used to treat psoriasis, IBD and related conditions, such as T cell mediated diseases, including those characterized by infiltration of inflammatory cells into a tissue.

Spondyloarthropathies are a group of disorders with some common clinical features and the common association with the expression of HLA-B27 gene product. The disorders include: ankylosing spondylitis, Reiter's syndrome (reactive arthritis), arthritis associated with inflammatory bowel disease,
40 spondylitis associated with psoriasis, juvenile onset spondyloarthropathy and undifferentiated

spondyloarthropathy. Distinguishing features include sacroileitis with or without spondylitis; inflammatory asymmetric arthritis; association with HLA-B27 (a serologically defined allele of the HLA-B locus of class I MHC); ocular inflammation, and absence of autoantibodies associated with other rheumatoid disease. The cell most implicated as key to induction of the disease is the CD8+ T lymphocyte, a cell which targets antigen presented by class I MHC molecules. CD8+ T cells may react against the class I MHC allele HLA-B27 as if it were a foreign peptide expressed by MHC class I molecules. It has been hypothesized that an epitope of HLA-B27 may mimic a bacterial or other microbial antigenic epitope and thus induce a CD8+ T cells response.

Systemic sclerosis (scleroderma) has an unknown etiology. A hallmark of the disease is induration of the skin; likely this is induced by an active inflammatory process. Scleroderma can be localized or systemic; vascular lesions are common and endothelial cell injury in the microvasculature is an early and important event in the development of systemic sclerosis; the vascular injury may be immune mediated. An immunologic basis is implied by the presence of mononuclear cell infiltrates in the cutaneous lesions and the presence of anti-nuclear antibodies in many patients. ICAM-1 is often upregulated on the cell surface of fibroblasts in skin lesions suggesting that T cell interaction with these cells may have a role in the pathogenesis of the disease. Other organs involved include: the gastrointestinal tract: smooth muscle atrophy and fibrosis resulting in abnormal peristalsis/motility; kidney: concentric subendothelial intimal proliferation affecting small arcuate and interlobular arteries with resultant reduced renal cortical blood flow, results in proteinuria, azotemia and hypertension; skeletal muscle: atrophy, interstitial fibrosis; inflammation; lung: interstitial pneumonitis and interstitial fibrosis; and heart: contraction band necrosis, scarring/fibrosis.

Autoimmune or Immune-mediated Skin Disease including Bullous Skin Diseases, Erythema Multiforme, and Contact Dermatitis are mediated by auto-antibodies, the genesis of which is T lymphocyte-dependent.

Psoriasis is proposed to be a T lymphocyte-mediated inflammatory disease. Lesions contain infiltrates of T lymphocytes, macrophages and antigen processing cells, and some neutrophils.

Transplantation associated diseases, including Graft rejection and Graft-Versus-Host-Disease (GVHD) are T lymphocyte-dependent; inhibition of T lymphocyte function is ameliorative.

The compounds of the present invention, *e.g.*, polypeptides or antibodies, are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation (intranasal, intrapulmonary) routes. Intravenous or inhaled administration of polypeptides and antibodies is preferred.

In immunoadjuvant therapy, other therapeutic regimens, such administration of an anti-cancer agent, may be combined with the administration of the proteins, antibodies or compounds of the instant invention. For example, the patient to be treated with a the immunoadjuvant of the invention may also receive an anti-cancer agent (chemotherapeutic agent) or radiation therapy. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in *Chemotherapy Service* Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992).

The chemotherapeutic agent may precede, or follow administration of the immunoadjuvant or may be given simultaneously therewith. Additionally, an anti-estrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) may be given in dosages known for such molecules.

It may be desirable to also administer antibodies against other immune disease associated or tumor associated antigens, such as antibodies which bind to CD20, CD11a, CD18, ErbB2, EGFR, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more antibodies binding the same or two or more different antigens disclosed herein may be coadministered to the patient. Sometimes, it may be beneficial to also administer one or more cytokines to the patient. In one embodiment, the PRO polypeptides are coadministered with a growth inhibitory agent. For example, the growth inhibitory agent may be administered first, followed by a PRO polypeptide. However, simultaneous administration or administration first is also contemplated. Suitable dosages for the growth inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth inhibitory agent and the PRO polypeptide.

For the treatment or reduction in the severity of immune related disease, the appropriate dosage of an a compound of the invention will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the agent is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the compound, and the discretion of the attending physician. The compound is suitably administered to the patient at one time or over a series of treatments.

For example, depending on the type and severity of the disease, about 1 $\mu\text{g/kg}$ to 15 mg/kg (*e.g.*, 0.1-20 mg/kg) of polypeptide or antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 $\mu\text{g/kg}$ to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

O. Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing materials (*e.g.*, comprising a PRO molecule) useful for the diagnosis or treatment of the disorders described above is provided. The article of manufacture comprises a container and an instruction. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for diagnosing or treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is usually a polypeptide or an antibody of the invention. An instruction or label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

P. Diagnosis and Prognosis of Immune Related Disease

Cell surface proteins, such as proteins which are overexpressed in immune related disease, are excellent targets for drug candidates or disease treatment. The same proteins along with secreted proteins encoded by the genes amplified in immune related disease find additional use in the diagnosis and prognosis of this disease. For example, antibodies directed against the protein products of genes amplified in immune related disease, can be used as diagnostics or prognostics.

For example, antibodies, including antibody fragments, can be used to qualitatively or quantitatively detect the expression of proteins encoded by amplified or overexpressed genes ("marker gene products"). The antibody preferably is equipped with a detectable, e.g., fluorescent label, and binding can be monitored by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. These techniques are particularly suitable, if the overexpressed gene encodes a cell surface protein. Such binding assays are performed essentially as described above.

In situ detection of antibody binding to the marker gene products can be performed, for example, by immunofluorescence or immunoelectron microscopy. For this purpose, a histological specimen is removed from the patient, and a labeled antibody is applied to it, preferably by overlaying the antibody on a biological sample. This procedure also allows for determining the distribution of the marker gene product in the tissue examined. It will be apparent for those skilled in the art that a wide variety of histological methods are readily available for *in situ* detection.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

EXAMPLE 1: Microarray analysis

Skin biopsies from psoriatic patients and from healthy donors (henceforth, "normal skin") were obtained. For each psoriatic patient, skin samples were taken from lesional and non-lesional sites, in order to identify disease specific genes which are differentially expressed in psoriatic tissue. All of the psoriatic skin samples were analyzed for Keratin 16 staining via immunohistochemistry and epidermal thickness. All samples were stored at -70 °C until ready for RNA isolation. The skin biopsies were homogenized in 600µl of RLT buffer (+ BME) and RNA was isolated using Qiagen™ Rneasy Mini columns (Qiagen) with on-column DNase treatment following the manufacturer's guidelines. Following RNA isolation, RNA was quantitated using RiboGreen™ (Molecular Probes) following the manufacturer's guidelines and checked on agarose gels for integrity. The RNA yields ranged from 19 to 54 µg for psoriatic lesional skin, 7.7 to 24 µg for non-lesional matched control skin and 5.4 to 10µg for normal skin. 4µg of RNA was labeled for microarray analysis and samples were run on proprietary Genentech microarray and Affymetrics

microarrays. Genes were compared whose expression was upregulated or downregulated in psoritic skin vs non-lesional skin, thus comparing expression profiles of non-lesional skin and psoriatic skin from the same patient, and also comparing against normal skin biopsies of normal healthy donors as a further control.

To test the PRO polypeptides and nucleic acids of the invention for their role in Inflammatory Bowel Disease, a microarray assay was used to find genes that are overexpressed in IBD as compared to normal bowel tissue. Biopsies from patients with IBD were obtained. For each IBD patient, samples were taken from disease (either ulcerative colitis (UC) or Crohn's) tissue and from healthy bowel, so that expression patterns could be better compared. All samples were stored at -70°C until ready for RNA isolation. The biopsies were homogenized in 600µl of RLT buffer (+ BME) and RNA was isolated using Qiagen™ Rneasy Mini columns (Qiagen) with on-column DNase treatment following the manufacturer's guidelines. Following RNA isolation, RNA was quantitated using RiboGreen™ (Molecular Probes) following the manufacturer's guidelines and checked on agarose gels for integrity. Appropriate amounts of RNA were labeled for microarray analysis and samples were run on proprietary Genentech microarray and Affymetrics™ microarrays. Genes were compared whose expression was upregulated in UC or Crohn's tissue vs normal bowel, matching biopsies from normal bowel and disease tissue from the same patient.

In an experiment to test the expression of the PRO polypeptides and associated nucleotides of the invention upon co-stimulation, CD4+ T cells were purified from a single donor using the RossetteSep™ protocol from (Stem Cell Technologies, Vancouver BC) which contains anti-CD8, anti-CD16, anti-CD19, anti-CD36 and anti-CD56 antibodies used to produce a population of isolated CD4 + T cells. Isolated CD4+ T cells were activated with an anti-CD3 antibody (used at a concentration that does not stimulate proliferation) together with either ICAM-1 or anti-CD28 antibody. At 24 or 72 hours cells were harvested, RNA extracted and analysis run on Affimax™ (Affymetrix Inc. Santa Clara, CA) microarrays. Non-stimulated (resting) cells were harvested immediately after purification, and subjected to the same analysis. Genes were compared whose expression was upregulated at either of the two timepoints in activated vs. resting cells.

To examine the expression of the PRO polypeptides and associated nucleic acids for Rheumatoid Arthritis (RA), a proprietary database containing gene expression information (GeneExpress®, Gene Logic Inc., Gaithersburg, MD) was analyzed to identify polypeptides (and their encoding nucleic acids) whose expression is significantly upregulated in RA as compared to normal tissues. Specifically, analysis of the GeneExpress® database was conducted using either software available through Gene Logic Inc., Gaithersburg, MD, for use with the GeneExpress® database or with proprietary software written and developed at Genentech, Inc. for use with the GeneExpress® database. The rating of positive hits in the analysis is based upon several criteria including, for example; expression level, tissue specificity, and expression level in normal essential and/or normal proliferating tissues. The following is a list of molecules whose tissue expression profile as determined from an analysis of the GeneExpress® database evidences high tissue expression and significant upregulation of expression in PBMC from twelve RA patients as compared to normal PBMC taken from twenty-five healthy individuals and optionally relatively low expression in normal essential and/or normal proliferating tissues. As such, the molecules listed below are excellent polypeptide targets for the diagnosis and alleviation of RA in mammals.

The conclusion of these experiments for the nucleic acids and encoded PRO polypeptides of Figures 1-64 are summarized below.

- 5 DNA275062) Figure 1 (SEQ ID NO:1) PRO62782) Figure 2 (SEQ ID NO:2)
DNA275062 is down-regulated 2 fold in colon samples from Crohn's disease and ulcerative colitis patients as compared to normal colon. It is also down-regulated 3 fold upon activation of CD4 T cells with CD28 or ICAM.
- 10 DNA226359) Figure 3 (SEQ ID NO:3) PRO36822) Figure 4 (SEQ ID NO:4)
DNA226359 is down-regulated 2 fold in colon samples from Crohn's disease and ulcerative colitis patients as compared to normal colon. It is also down-regulated 3 fold upon activation of CD4 T cells with CD28 or ICAM, and down-regulated 4 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.
- 15 DNA226763 Figure 5 (SEQ ID NO:5) PRO37226 Figure 6 (SEQ ID NO:6)
DNA226763 is up-regulated 2 fold in colon samples from ulcerative colitis patients as compared to normal colon. It is also up-regulated 2 fold in memory T cells as compared to naïve CD4 T cells, and up-regulated 6 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media or activation with LPS.
- 20 DNA304716 Figure 7 (SEQ ID NO:7) PRO71142 Figure 8 (SEQ ID NO:8)
DNA304716 is up-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 2 fold in colon samples from ulcerative colitis patients as compared to normal colon. It is also up-regulated 2 fold in CD4 T cells activated with CD28 and ICAM, up-regulated 8 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media, up-regulated 2 fold upon activation of monocytes with LPS and up-regulated 2 fold upon activation of dendritic cells with LPS.
- 25 DNA228014 Figure 9 (SEQ ID NO:9) PRO38477 Figure 10 (SEQ ID NO:10)
DNA228014 is up-regulated 2 fold in colon samples from ulcerative colitis patients as compared to normal colon and down-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 3 fold upon activation of CD4 T cells with CD28 or ICAM, and down-regulated 3000 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media.
- 35 DNA143498 Figure 11 (SEQ ID NO:11) PRO10275 Figure 12 (SEQ ID NO:12)
DNA143498 is up-regulated 1.5 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also up-regulated 1.5 fold upon activation of CD4 T cells with CD28 or ICAM and up-regulated 2 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media.
- 40 DNA324792 Figure 13 (SEQ ID NO:13) PRO81407 Figure 14 (SEQ ID NO:14)
DNA324792 is up-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 1.5 fold upon activation of CD4 T cells with CD28 or ICAM and up-regulated 1.3 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media and up-regulated 2 fold upon activation of both monocytes and dendritic cells with LPS.
- 45 DNA287319 Figure 15 (SEQ ID NO:15) PRO69584 Figure 16 (SEQ ID NO:16)
DNA287319 is up-regulated 2 fold in colon samples from ulcerative colitis patients and 1.5 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also up-regulated 1.5 fold upon activation of CD4 T cells with CD28 or ICAM.
- 50 DNA333620 Figure 17 (SEQ ID NO:17) PRO88263 Figure 18 (SEQ ID NO:18)
DNA333620 is up-regulated 1.3 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 1.5 fold in colon samples from Crohn's disease patients as compared to normal colon and up-regulated 1.3 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 2 fold in NK cells upon activation with IL15 or IL12, down-regulated 3 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media and up-regulated 8 fold upon activation of dendritic cells with LPS.
- 55

- 5 DNA324275 Figure 19 (SEQ ID NO:19) PRO80958 Figure 20 (SEQ ID NO:20)
DNA324275 is up-regulated 1.8 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also up-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM.
- 10 DNA227952 Figure 21 (SEQ ID NO:21) PRO38415 Figure 22 (SEQ ID NO:22)
DNA227952 is up-regulated 2 fold in colon samples from ulcerative colitis patients and 1.2 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also up-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM and up-regulated 2.5 fold upon activation of B cells with IL4.
- 15 DNA103507 Figure 23 (SEQ ID NO:23) PRO4834 Figure 24 (SEQ ID NO:24)
DNA103507 is up-regulated 1.3 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 1.8 fold in colon samples from ulcerative colitis patients as compared to normal colon. It is also up-regulated 3 fold in dendritic cells upon activation with LPS.
- 20 DNA226256 Figure 25 (SEQ ID NO:25) PRO36719 Figure 26 (SEQ ID NO:26)
DNA226256 is up-regulated 1.3 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 1.5 fold in colon samples from ulcerative colitis patients and 2 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also down-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM and down-regulated 4 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media or upon activation with LPS.
- 25 DNA324799 Figure 27 (SEQ ID NO:27) PRO81414 Figure 28 (SEQ ID NO:28)
DNA324799 is up-regulated 1.2 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 1.5 fold in colon samples from ulcerative colitis patients as compared to normal colon. It is also down-regulated 2 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media and up-regulated 4 fold in dendritic cells upon activation with LPS.
- 30 DNA255836 Figure 29 (SEQ ID NO:29) PRO50891 Figure 30 (SEQ ID NO:30)
DNA255836 is up-regulated 2 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 2.2 fold in colon samples from ulcerative colitis patients as compared to normal colon. It is also up-regulated 1.8 fold in B cells upon activation with IL4, down-regulated 2 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media and up-regulated 3 fold in dendritic cells upon activation with LPS.
- 35 DNA339972 Figure 31 (SEQ ID NO:31) PRO91480 Figure 32 (SEQ ID NO:32)
DNA339972 is down-regulated 1.8 fold in lesional skin as compared to non-lesional skin from psoriasis patients and down-regulated 1.5 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also down-regulated 2 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.
- 40 DNA323910 Figure 33 (SEQ ID NO:33) PRO80648 Figure 34 (SEQ ID NO:34)
DNA323910 is up-regulated 4 fold in lesional skin as compared to non-lesional skin from psoriasis patients and down-regulated 1.5 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 10 fold upon activation of CD4 T cells with CD28 or ICAM, down-regulated 10 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media and up-regulated 2 fold upon activation of monocytes with LPS.
- 45 DNA226272 Figure 35 (SEQ ID NO:35) PRO36735 Figure 36 (SEQ ID NO:36)
DNA226272 is up-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 1.8 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 1.5 fold upon activation of CD4 T cells with CD28 or ICAM and down-regulated 2.5 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media.
- 50 DNA151772 Figure 37 (SEQ ID NO:37) PRO12050 Figure 38 (SEQ ID NO:38)
DNA151772 is up-regulated 1.2 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 2 fold in colon samples from Crohn's disease patients as compared to normal colon. It is also up-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM, up-regulated 2 fold

upon differentiation of monocytes into macrophages after 7 days in differentiation media and up-regulated 2.5 fold upon activation of monocytes and dendritic cells with LPS.

DNA327983 Figure 39 (SEQ ID NO:39) PRO83903 Figure 40 (SEQ ID NO:40)

- 5 DNA327983 is up-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 1.3 fold in colon samples from Crohn's disease patients as compared to normal colon and up-regulated 1.3 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 1.5 fold upon activation of CD4 T cells with CD28 or ICAM and down-regulated 2 fold upon activation of monocytes with LPS.

10

DNA227046 Figure 41 (SEQ ID NO:41) PRO37509 Figure 42 (SEQ ID NO:42)

- 15 DNA227046 is down-regulated 1.8 fold in lesional skin as compared to non-lesional skin from psoriasis patients, down-regulated 1.3 fold in colon samples from both ulcerative colitis and Crohn's disease patients as compared to normal colon and down-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM, down-regulated 1.5 fold in B cells upon activation with IL4 and down-regulated 4 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.

DNA227297 Figure 43 (SEQ ID NO:43) PRO37760 Figure 44 (SEQ ID NO:44)

- 20 DNA227297 is up-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 1.3 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 1.3 fold in both monocytes and dendritic cells upon activation with LPS.

25 DNA340442 Figure 45 (SEQ ID NO:45) PRO92173 Figure 46 (SEQ ID NO:46)

- 30 DNA340442 is up-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients and 2.5 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 2.2 fold upon activation of CD4 T cells with CD28 or ICAM and down-regulated 12 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.

DNA324641 Figure 47 (SEQ ID NO:47) PRO10849 Figure 48 (SEQ ID NO:48)

- 35 DNA324641 is down-regulated 1.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 1.5 fold in colon samples from both ulcerative colitis and Crohn's disease patients as compared to normal colon and down-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM, down-regulated 2 fold upon activation of NK cells with IL15 or IL2 and down-regulated 3 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.

40 DNA275257 Figure 49 (SEQ ID NO:49) PRO62943 Figure 50 (SEQ ID NO:50)

- 45 DNA275257 is up-regulated 4 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 2 fold upon activation of CD4 T cells with CD28 or ICAM, down-regulated 6 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media and up-regulated 4 fold upon activation of monocytes with LPS.

DNA331909 Figure 51 (SEQ ID NO:51) PRO86795 Figure 52 (SEQ ID NO:52)

- 50 DNA331909 is up-regulated 2.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 10 fold in colon samples from ulcerative colitis patients as compared to normal colon and up-regulated 1.5 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also down-regulated 9 fold upon activation of CD4 T cells with CD28 or ICAM, down-regulated 2 fold upon activation of NK cells with IL15 or IL2 and down-regulated 4 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.

55 DNA226111 Figure 53 (SEQ ID NO:53) PRO36574 Figure 54 (SEQ ID NO:54)

- DNA226111 is up-regulated 2.5 fold in lesional skin as compared to non-lesional skin from psoriasis patients. It is also up-regulated 8 fold upon differentiation of monocytes into macrophages after 7 days in differentiation media.

DNA287270 Figure 55 (SEQ ID NO:55) PRO69541 Figure 56 (SEQ ID NO:56)

DNA287270 is up-regulated 1.2 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 1.2 fold in colon samples from Crohn's disease patients and up-regulated 1.8 fold in ulcerative colitis patients as compared to normal colon. It is also up-regulated 1.8 fold upon activation of CD4 T cells with CD28 or ICAM and up-regulated 2 fold upon activation of NK cells with IL15 or IL2.

DNA329369 Figure 57 (SEQ ID NO:57) PRO84948 Figure 58 (SEQ ID NO:58)

DNA329369 is up-regulated 2 fold in lesional skin as compared to non-lesional skin from psoriasis patients, up-regulated 1.5 fold in colon samples from Crohn's disease patients as compared to normal colon and up-regulated 1.5 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 1.5 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media and up-regulated 1.5 fold upon activation of monocytes with LPS.

DNA330645 Figure 59 (SEQ ID NO:59) PRO85817 Figure 60 (SEQ ID NO:60)

DNA330645 is up-regulated 1.8 fold in lesional skin as compared to non-lesional skin from psoriasis patients and up-regulated 2 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 2.3 fold upon activation of CD4 T cells with CD28 or ICAM and up-regulated 2 fold upon activation of monocytes and 4 fold upon activation of dendritic cells with LPS.

DNA227908 Figure 61 (SEQ ID NO:61) PRO38371 Figure 62 (SEQ ID NO:62)

DNA227908 is up-regulated 2.5 fold in white blood cells from rheumatoid arthritis patients as compared to those from normal donors. It is also up-regulated 2.5 fold upon differentiation of monocytes into macrophages after 1 day in differentiation media.

DNA340375 Figure 63 (SEQ ID NO:63) PRO90951 Figure 64 (SEQ ID NO:64)

DNA340375 expression increases 100 fold in both Crohn's and Ulcerative colitis colon samples versus normal colon. Expression is highest in B cells and T cells. In B cells, expression decreases 1.5 fold on activation with IL-4. In T cells, expression decreases 2 fold upon activation with CD28 or ICAM.

EXAMPLE 2: Use of PRO as a hybridization probe

The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.

DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.

EXAMPLE 3: Expression of PRO in *E. coli*

This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is

pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH₄)₂SO₄, 0.71 g sodium citrate•2H₂O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO₄) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole.

Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 4: Expression of PRO in mammalian cells

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl₂. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO₄, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 $\mu\text{Ci/ml}$ ^{35}S -cysteine and 200 $\mu\text{Ci/ml}$ ^{35}S -methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 μg pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 $\mu\text{g/ml}$ bovine insulin and 0.1 $\mu\text{g/ml}$ bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as CaPO_4 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as ^{35}S -methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 promoter/enhancer containing vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 promoter/enhancer containing vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be concentrated and purified by any selected method, such as by Ni^{2+} -chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in

CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO
5 cells using commercially available transfection reagents Superfect® (Quiagen), Dosper® or Fugene® (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately 3×10^7 cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mL of media and centrifuged at
10 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 μ m filtered PS20 with 5% 0.2 μ m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with 3×10^5 cells/mL. The cell media is exchanged with
15 fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2×10^6 cells/mL. On day 0, pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35%
20 polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22 μ m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen).
25 Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10
30 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration
35 buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 μ l of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

40 Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 5: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

EXAMPLE 6: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO in Baculovirus-infected insect cells.

The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO can then be purified, for example, by Ni²⁺-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl₂; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and

sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 μ m filter. A Ni²⁺-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer.

5 The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A₂₈₀ with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A₂₈₀ baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-

10 PAGE and silver staining or Western blot with Ni²⁺-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His₁₀-tagged PRO are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

15 EXAMPLE 7: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified PRO, fusion proteins

20 containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research,

25 Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be

30 injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma

35 hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to

40 produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be

grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

5

EXAMPLE 8: Purification of PRO Polypeptides Using Specific Antibodies

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

30

EXAMPLE 9: Drug Screening

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can

examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

EXAMPLE 10: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of a PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror
5 image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO
10 polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any
15 constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the
20 art from the foregoing description and fall within the scope of the appended claims.

What is claimed:

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13A-B (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31A-B (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39A-B (SEQ ID NO:39), Figure 41A-C (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59A-B (SEQ ID NO:59), Figure 61A-B (SEQ ID NO:61) or Figure 63 (SEQ ID NO:63).
2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence consisting of the full-length coding sequence of the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13A-B (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31A-B (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39A-B (SEQ ID NO:39), Figure 41A-C (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59A-B (SEQ ID NO:59), Figure 61A-B (SEQ ID NO:61) or Figure 63 (SEQ ID NO:63).
3. Isolated nucleic acid consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13A-B (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31A-B (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39A-B (SEQ ID NO:39), Figure 41A-C (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59A-B (SEQ ID NO:59), Figure 61A-B (SEQ ID NO:61) or Figure 63 (SEQ ID NO:63).
4. A vector comprising the nucleic acid of Claim 1.

5. The vector of Claim 4 operably linked to control sequences recognized by a host cell transformed with the vector.
6. A host cell comprising the vector of Claim 4.
7. The host cell of Claim 6, wherein said cell is a CHO cell, an *E.coli* cell or a yeast cell.
8. A process for producing a PRO polypeptide comprising culturing the host cell of Claim 6 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
9. An isolated polypeptide having at least 80% amino acid sequence identity to any one of the amino acid sequence of the polypeptides shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62A-B (SEQ ID NO:62) or Figure 64 (SEQ ID NO:64).
10. A chimeric molecule comprising a polypeptide according to Claim 9 fused to a heterologous amino acid sequence.
11. The chimeric molecule of Claim 9, wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.
12. An antibody which specifically binds to a polypeptide according to Claim 9.
13. The antibody of Claim 12, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.
14. A composition of matter comprising (a) a polypeptide of Claim 9, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, in combination with a carrier.
15. The composition of matter of Claim 14, wherein said carrier is a pharmaceutically acceptable carrier.

16. The composition of matter of Claim 15 comprising a therapeutically effective amount of (a), (b), (c) or (d).

5 17. An article of manufacture, comprising:
a container;
a label on said container; and
a composition of matter comprising (a) a polypeptide of Claim 9, (b) an agonist of said polypeptide,
10 (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said
container, wherein label on said container indicates that said composition of matter can be used for treating
psoriasis.

18. A method of identifying a compound that inhibits the expression of a gene encoding a
PRO polypeptide of the invention as described in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure
15 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure
14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20),
Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID
NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36
(SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42),
20 Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID
NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58
(SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62A-B (SEQ ID NO:62) or Figure 64 (SEQ ID
NO:64), said method comprising contacting cells which normally express said polypeptide with a candidate
compound, and determining the lack of expression said gene.

25 19. The method of Claim 23, wherein said candidate compound is an antisense nucleic acid.

20. A method of alleviating psoriasis in a mammal in need thereof comprising administering
to said mammal a therapeutically effective amount of (a) a polypeptide of the invention as shown in Figure 8
30 (SEQ ID NO:8), Figure 18 (SEQ ID NO:18), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26),
Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID
NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B
(SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48),
Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID
35 NO:56), Figure 58 (SEQ ID NO:58) or Figure 60 (SEQ ID NO:60), (b) an antagonist of said polypeptide, or
(c) an antibody that binds to said polypeptide.

21. A method of diagnosing psoriasis in a mammal, said method comprising detecting the
level of expression of a gene encoding a PRO polypeptide of the invention as described in Figure 8 (SEQ ID
40 NO:8), Figure 18 (SEQ ID NO:18), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28

(SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56),
 5 Figure 58 (SEQ ID NO:58) or Figure 60 (SEQ ID NO:60) (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of psoriasis in the mammal from which the test tissue cells were obtained.

10 22. A method of diagnosing an psoriasis in a mammal, said method comprising (a) contacting a PRO polypeptide of the invention as described in Figure 8 (SEQ ID NO:8), Figure 18 (SEQ ID NO:18), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44),
 15 Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58) or Figure 60 (SEQ ID NO:60) anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of psoriasis in the mammal from which the test tissue
 20 cells were obtained.

23. A method of alleviating Crohn's disease in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of (a) a polypeptide of the invention as shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 12 (SEQ ID NO:12), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 32 (SEQ ID NO:32), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), or Figure 64 (SEQ ID NO:64), (b) an antagonist of said polypeptide, or (c) an antibody that binds to said polypeptide.

30 24. A method of diagnosing Crohn's disease in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide of the invention as described in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 12 (SEQ ID NO:12), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 32 (SEQ ID NO:32), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), or Figure 64 (SEQ ID NO:64) (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of Crohn's disease in the mammal from which the test tissue cells were obtained.

25. A method of diagnosing Crohn's disease in a mammal, said method comprising (a) contacting a PRO polypeptide of the invention as described in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 12 (SEQ ID NO:12), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 32 (SEQ ID NO:32), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), or Figure 64 (SEQ ID NO:64) anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of Crohn's disease in the mammal from which the test tissue cells were obtained.

10

26. A method of alleviating Ulcerative Colitis in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of (a) a polypeptide of the invention as shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 16 (SEQ ID NO:16), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 52 (SEQ ID NO:52), or Figure 64 (SEQ ID NO:64), (b) an antagonist of said polypeptide, or (c) an antibody that binds to said polypeptide.

15

27. A method of diagnosing Ulcerative Colitis in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide of the invention as described in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 16 (SEQ ID NO:16), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 52 (SEQ ID NO:52), or Figure 64 (SEQ ID NO:64), (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of Ulcerative Colitis in the mammal from which the test tissue cells were obtained.

25

28. A method of diagnosing Ulcerative Colitis in a mammal, said method comprising (a) contacting a PRO polypeptide of the invention as described in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 16 (SEQ ID NO:16), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 42A-B (SEQ ID NO:42), Figure 48 (SEQ ID NO:48), Figure 52 (SEQ ID NO:52), or Figure 64 (SEQ ID NO:64), anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of Ulcerative Colitis in the mammal from which the test tissue cells were obtained.

30

35

29. A method of alleviating rheumatoid arthritis in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of (a) a polypeptide of the invention as shown in Figure 10 (SEQ ID NO:10), Figure 14 (SEQ ID NO:14), Figure 18 (SEQ ID NO:18), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), or Figure 62A-B (SEQ ID NO:62) (b) an antagonist of said polypeptide, or (c) an antibody that binds to said polypeptide.

30. A method of diagnosing rheumatoid arthritis in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide of the invention as described in Figure 10 (SEQ ID NO:10), Figure 14 (SEQ ID NO:14), Figure 18 (SEQ ID NO:18), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), or Figure 62A-B (SEQ ID NO:62) (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of rheumatoid arthritis in the mammal from which the test tissue cells were obtained.

31. A method of diagnosing rheumatoid arthritis in a mammal, said method comprising (a) contacting a PRO polypeptide of the invention as described in Figure 10 (SEQ ID NO:10), Figure 14 (SEQ ID NO:14), Figure 18 (SEQ ID NO:18), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 40 (SEQ ID NO:40), Figure 42A-B (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), or Figure 62A-B (SEQ ID NO:62) anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of rheumatoid arthritis in the mammal from which the test tissue cells were obtained.

FIGURE 1

GGGACGGCGACAGCGGGTCGGCGGGGCCGAGGAGGGGGTCATGGGTAAAGACTACTACCA
GACGTTGGGCCTGGCCCCGCGCGCGTCCGACGAGGAGATCAAGCGGGCCTACCGCCGCCA
GGCGCTGCGCTACCACCCGGACAAGAACAAGGAGCCCGCGCCGAGGAGAAGTTCAAGGA
GATCGCTGAGGCCTACGACGTGCTCAGCGACCCGCGCAAGCGCGAGATCTTCGACCGCTA
CGGGGAGGAAGGCCTAAAGGGGAGTGGCCCCAGTGGCGGTAGCGGCGGTGGTGCCAATGG
TACCTCTTTTTCAGCTACACATTCCATGGAGACCCTCATGCCATGTTTGCTGAGTTCTTCGG
TGGCAGAAATCCCTTTGACACCTTTTTTTGGGCAGCGGAACGGGGAGGAAGGCATGGACAT
TGATGACCCATTCTCTGGCTTCCCTATGGGCATGGGTGGCTTCACCAACGTGAACTTTGG
CCGCTCCCGCTCTGCCCAGAGCCCGCCCCGAAAGAAGCAAGATCCCCCAGTCACCCACGA
CCTTCGAGTCTCCCTTGAAGAGATCTACAGCGGCTGTACCAAGAAGATGAAAATCTCCCA
CAAGCGGCTAAACCCCGACGGAAGAGCATTCGAAACGAAGACAAAATATTGACCATCGA
AGTGAAGAAGGGGTGGAAAGAAGGAACCAAAATCACTTCCCCAAGGAAGGAGACCAGAC
CTCCAACAACATTCCAGCTGATATCGTCTTTGTTTAAAGGACAAGCCCCACAATATCTT
TAAGAGAGATGGCTCTGATGTCATTTATCCTGCCAGGATCAGCCTCCGGGAGGCTCTGTG
TGGCTGCACAGTGAACGTCCCCACTCTGGACGGCAGGACGATAACCGTCGTATTCAAAGA
TGTATCAGGCCTGGCATGCGGCGAAAAGTTCTTGAGAAAGGCCTCCCCCTCCCCAAAC
ACCCGAGAAACGTGGGGACCTCATTATTGAGTTTGAAGTGATCTTCCCCGAAAGGATTCC
CCAGACATCAAGAACCCTACTTGAGCAGGTTCTTCCAATATAGCTATCTGAGCTCCCCAA
GGACTGACCAGGGACCTTTCCAGAGCTCAAGGATTTCTGGACCTTTCTACCAGTTGTGGA
CCATGAGAGGGTGGGAGGGGCCAGGGAGGGCTTTTCGTACTGCTGAATGTTTTCCAGAGCA
TATATTACAATCTTTCAAAGTCGCACACTAGACTTCAGTGGTTTTTCGAGCTATAGGGCA
TCAGGTGGTGGGAACAGCAGGAAAAGGCATTCCAGTCTGCCCCACTGGGTCTGGCAGCCC
TCCCGGGATGGGCCCACATCCACCTCCAGTCCCTGGCCAGGGGTGAGAGGCAGACCAGCA
GATGGACTTGATCCCTCTGTGTCTTTGGGCTTCTGGCTGGTAGATAATGTCAACCTGCAG
TCTTGATTCCCAGACCCTGTACACTCCTCCTTTTTCTGTTGTGTGATCAGTTTGTGCTTTA
TTCTGTATTTGTCTCCCATGTCTTGCTCTTCTCCTGGAGAATTCTGTCTTCTCTTTGGCC
ATCTCAAATTGAGAACCTAAACTATTCTGTCAGAACTGCCTGGTTGGCGTCCACAAGCAA
TACCTCTCGTTCCAGCAGGACCAAGGGAGCCAGCCTCCAGTGAGTGACTCCAGCAAGTGC
AGCCACCTCTCCCTTGATGGTCTGGGAGCCTGGCCTCAGCAAGGGGCCTTCTGACCTCT
GGCTCCAGTGAAGCTGAATGTCCTCACTTTGTGGGTACACTCTTTACATTTCTGTAAGG
CAATCTTGGCACACGTGGGGCTTACCAGTGGCCCAGGTAATTTTTTGTTCATGGACTAT
GGACTCTTTCAAAGGGATCTGATCCTTTTGAATTTTGCACAGCCCTAGATACAATCCCTT
TTGATAAAAGGGTCTTTGCTTCTGATTACAGGAGCACTGTGGAACGTCTGTAAATATGTT
TTTATAATTCCATGTATAGTTGGTGTACACTCAAAACCTGTCCCCGGCAGCCAGTGCTCT
CTGTATAGGGCCATAATGGAATTCTGAAGAAATCTTGGGGAGGGAAGGGGAGTTGGAACA
AATGTCTGTTCCCTGGAGGCCAGTCCAGTGCTCAGACCTTTAGACTCATTGTAAGTTGCC
ACTGCCAACATGAGACCAAGTGTGTGACTAGTCAATGAAGTGCGACAGCATTAAGACT
GATGCTAAACCTC

FIGURE 2

MGKDYYQTLGLARGASDEEIKRAYRRQALRYHPDKNKEPGAEEKFKEIAEAYDVLSDPRK
REIFDRYGEGLKSGSPSGSGGGANGTSFSYTFHGDPHAMFAEFFGGRNPFDTFFGQRN
GEEGMDIDDPFSGFPMGMGGFTNVNFGSRSAQEPARKKQDPPVTHDLRVSLLEIYSGCT
KKMKISHKRLNPDGKSI RNEDKILTIEVKKGWKEGTKITFPKEGDQTSNNIPADIVFVLK
DKPHNIFKRDGSDVIYPARISLREALCGCTVNVPTLDGRTIPVVFKDVIRPGMRRKVPGE
GLPLPKTPEKRGDLIIEFEVIFPERIPQTSRTVLEQVLPI

signal sequence
none

Transmembrane domain
none

N-glycosylation site.
86-89

Glycosaminoglycan attachment site.
81-84

Tyrosine kinase phosphorylation site.
169-176
249-255

N-myristoylation site.
10-15
71-76
74-79
79-84
80-85
82-87
83-88
84-89
87-92
117-122
139-144
215-220
268-273

Cell attachment sequence.
311-313

Nt-dnaJ domain signature.
45-65

DnaJ domain
4-68

DnaJ C terminal region
216-338

FIGURE 3

AGAGTTGCACTGAGTGTGGCTGAAGCAGCGAGGCGGGAGTGGAGGTGCGCGGAGTCAGGC
AGACAGACAGACACAGCCAGCCAGCCAGGTCCGGCAGTATAGTCCGAACTGCAAATCTTAT
TTTCTTTTTCACCTTCTCTCTAACTGCCCAGAGCTAGCGCCTGTGGCTCCCGGGCTGGTGG
TTCGGGAGTGTCCAGAGAGCCTTGTCTCCAGCCGGCCCCGGGAGGAGAGCCCTGCTGCCC
AGGCGCTGTTGACAGCGGCGGAAAGCAGCGGTACCCACGCGCCCGCCGGGGGACGTCCG
CGAGCGGCTGCAGCAGCAAAGAACTTTCCCGGCGGGGAGGACCGGAGACAAGTGGCAGAG
TCCCGGAGCGAACTTTTGCAAGCCTTTCCTGCGTCTTAGGCTTCTCCACGGCGGTAAAGA
CCAGAAGGCGGCGGAGAGCCACGCAAGAGAAGAAGGACGTGCGCTCAGCTTCGCTCGCAC
CGGTTGTTGAACTTGGGCGAGCGCGAGCCGCGGCTGCCGGGCGCCCCCTCCCCCTAGCAG
CGGAGGAGGGGACAAGTCGTCCGAGTCCGGGCGGCCAAGACCCGCGCCGGCCGGCCACT
GCAGGGTCCGCACTGATCCGCTCCGCGGGGAGAGCCGCTGCTCTGGGAAAGTGAGTTCCGC
TGCGGACTCCGAGGAACCGCTGCGCCCCAAGAGCGCTCAGTGAGTGACCGCGACTTTTCA
AAGCCGGGTAGCGCGCGGAGTCGACAAGTAAGAGTGCGGGAGGCATCTTAATTAACCT
GCGCTCCCTGGAGCGAGCTGGTGAGGAGGGCGCAGCGGGGACGACAGCCAGCGGGTGCGT
GCGCTCTTAGAGAACTTTCCCTGTCAAAGGCTCCGGGGGCGCGGGTGTCCCCCGCTTG
CCAGAGCCCTGTTGCGGCCCCGAACTTGTGCGCGCACGCCAAACTAACCTCACGTGAAG
TGACGGACTGTTCTATGACTGCAAAGATGGAACGACCTTCTATGACGATGCCCTCAACG
CCTCGTTCCCTCCCGTCCGAGAGCGGACCTTATGGCTACAGTAACCCCAAGATCCTGAAAC
AGAGCATGACCCTGAACCTGGCCGACCCAGTGGGGAGCCTGAAGCCGCACCTCCGCGCCA
AGAACTCGGACCTCCTCACCTCGCCCCAGCTGGGGCTGCTCAAGCTGGCGTCGCCCCGAGC
TGGAGCGCCTGATAATCCAGTCCAGCAACGGGCACATCACCACCACGCCGACCCCCACCC
AGTTCCTGTGCCCCAAGAACGTGACAGATGAGCAGGAGGGGTTTCGCCGAGGGCTTCGTGC
GCGCCCTGGCCGAACCTGCACAGCCAGAACACGCTGCCCAGCGTCACGTCGGCGGCGCAGC
CGGTCAACGGGGCAGGCATGGTGGCTCCCGCGGTAGCCTCGGTGGCAGGGGGGACGCGGCA
GCGGCGGCTTCAGCGCCAGCCTGCACAGCGAGCCGCGGTCTACGCAAACCTCAGCAACT
TCAACCCAGGCGCGCTGAGCAGCGGCGGGGCGCCCTCCTACGGCGCGGCCGCGCTGG
CCTTTCCCGCGCAACCCAGCAGCAGCAGCAGCGCCGCGCACCACCTGCCCCAGCAGATGC
CCGTGCAGCACCCGCGGCTGCAGGCCCTGAAGGAGGAGCCTCAGACAGTGCCCCGAGATGC
CCGGCGAGACACCCGCCCTGTCCCCCATCGACATGGAGTCCCAGGAGCGGATCAAGGCGG
AGAGGAAGCGCATGAGGAACCGCATCGCTGCCCTCCAAGTGCCGAAAAAGGAAGCTGGAGA
GAATCGCCCGGCTGGAGGAAAAAGTGAAAACCTTGAAAGCTCAGAACTCGGAGCTGGCGT
CCACGGCCAACATGCTCAGGGAACAGGTGGCACAGCTTAAACAGAAAGTCATGAACCACG
TTAACAGTGGGTGCCAACTCATGCTAACGCAGCAGTTGCAAACATTTTGAAGAGAGACCG
TCGGGGGCTGAGGGGCAACGAAGAAAAAATAACACAGAGAGACAGACTTGAGAACTTG
ACAAGTTGCGACGGAGAGAAAAAAGAAGTGTCCGAGAACTAAAGCCAAGGGTATCCAAGT
TGGACTGGGTTCGGTCTGACGGCGCCCCCAGTGTGCACGAGTGGAAGGACTTGGTCGCG
CCCTCCCTTGGCGTGGAGCCAGGGAGCGGCCGCTGCGGGCTGCCCCGCTTTGCGGACGG
GCTGTCCCCGCGCAACGGAACGTTGGACTTTTCGTTAACATTGACCAAGAACTGCATGGA
CCTAACATTGATCTCATTCAGTATTAAAGGGGGGAGGGGGAGGGGTTACAAACTGCAA
TAGAGACTGTAGATTGCTTCTGTAGTACTCCTTAAGAACACAAAGCGGGGGGAGGGTTGG
GGAGGGGCGGCAGGAGGGAGGTTTGTGAGAGCGAGGCTGAGCCTACAGATGAACTCTTTC
TGGCCTGCTTTCGTTAACTGTGTATGTACATATATATATTTTTTAATTTGATTAAAGCTG
ATTACTGTCAATAAACAGCTTCATGCCTTTGTAAGTTATTTCTTGTGTTGTTGTTGGGT
ATCCTGCCCAGTGTGTTTGTAAATAAGAGATTTGGAGCACTCTGAGTTTACCATTGTA
ATAAGTATATAATTTTTTTATGTTTTGTTTCTGAAAATTCAGAAAGGATATTTAAGAA
AATACAATAAACTATTGGAAAGTACTCCCTAACCTCTTTTCTGCATCATCTGTAGATCC
TAGTCTATCTAGGTGGAGTTGAAAGAGTTAAGAATGCTCGATAAAATCACTCTCAGTGCT
TCTTACTATTAAGCAGTAAAACTGTTCTCTATTAGACTTAGAAATAAATGTACCTGATG
TACCTGATGCTATGTACGGCTTCATACTCCACGCTCCCCAGCGTATCTATATGGAATTG
CTTACCAAAGGCTAGTGCGATGTTTCAGGAGGCTGGAGGAAGGGGGGTTGCAGTGGAGAG
GGACAGCCCACTGAGAAGTCAAACATTTCAAAGTTTGGATTGCATCAAGTGGCATGTGCT
GTGACCATTATAATGTTAGAAATTTTACAATAGGTGCTTATTCTCAAAGCAGGAATTGG
TGGCAGATTTTACAAAAGATGTATCCTTCCAATTTGGAATCTTCTCTTTGACAATTCCTA
GATAAAAAGATGGCCTTTGTCTTATGAATATTTATAACAGCATTCTGTCACAATAAATGT
ATTCAAATACCAAT

FIGURE 4

MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDL
LTSPDVGLLKLASPELERLI IQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAE
LHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGA
LSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPOQMPVQHPRLOALKEEPQTVPEMPGETP
PLSPIDMESQERIKAEKRMNRNRIAASKCRKRKLERIARLEEKVKTLLKAQNSELASTANM
LREQVAQLKQKVMNHVNSGCQLMLTQQLQTF

signal sequence
none

Transmembrane domain
none

N-glycosylation site.
15-18
102-105
172-175

Glycosaminoglycan attachment site.
154-157
183-186

N-myristoylation site.
152-157
153-158
157-162
179-184
185-190

Leucine zipper pattern.
280-301
287-308

bZIP transcription factors basic domain signature.
257-272

Jun-like transcription factor
5-241

bZIP transcription factor
250-314

FIGURE 5

CTCGGCTCACCATGTGTCACTCTCGCAGCTGCCACCCGACCATGACCATCCTGCAGGCCC
CGACCCCGGCCCCCTCCACCATCCCGGGACCCCGGCGGGGCTCCGGTCCTGAGATCTTCA
CCTTCGACCCCTCTCCCGGAGCCCGCAGCGGCCCTGCGGGCGCCCCAGCGCCTCTCGCG
GGCACCGAAAGCGCAGCCGCAGGGTTCTCTACCCCTCGAGTGGTCCGGCGCCAGCTGCCAG
TCGAGGAACCGAACCAGCCAAAAGGCTTCTCTTTCTGCTGCTCACCATCGTCTTCTGCC
AGATCCTGATGGCTGAAGAGGGTGTGCCGGCGCCCCCTGCCTCCAGAGGACGCCCCCTAACG
CCGCATCCCTGGCGCCCACCCCTGTGTCCCCCGTCCTCGAGCCCTTTAATCTGACTTCGG
AGCCCTCGGACTACGCTCTGGACCTCAGCACTTTCCTCCAGCAACACCCGGCCGCCTTCT
AACTGTGACTCCCCGCACTCCCCAAAAAGAATCCGAAAAACCACAAAGAAACACCAGGCG
TACCTGGTGCGCGAGAGCGTATCCCCAACTGGGACTTCCGAGGCAACTTGAATCAGAAC
ACTACAGCGGAGACGCCACCCGGTGCTTGAGGCGGGACCGAGGCGCACAGAGACCGAGGC
GCATAGAGACCGAGGCACAGCCCACTGGGGCTAGGCCCGGTGGGAAGGAGAGCGTCGTT
AATTTATTTCTTATTGCTCCTAATTAATATTTATATGTATTTATGTACGTCCTCCTAGGT
GATGGAGATGTGTACGTAATATTTATTTAACTTATGCAAGGGTGTGAGATGTTCCCCCT
GCTGTAAATGCAGGTCTCTTGGTATTTATTGAGCTTTGTGGGACTGGTGGGAAGCAGGACA
CCTGGAACTGCGGCAAAGTAGGAGAAGAAATGGGGAGGACTCGGGTGGGGGAGGACGTCC
CGGCTGGGATGAAGTCTGGTGGTGGGTGCTAAGTTTAGGAGGTGACTGCATCCTCCAGCA
TCTCAACTCCGTCTGTCTACTGTGTGAGACTTCGGCGGACCATTAGGAATGAGATCCGTG
AGATCCTTCCATCTTCTTGAAGTCGCCTTTAGGGTGGCTACGAGGTAGAGGGGTGGGGT
TGGTGGGCTGTCACGGAGCGACTGTGAGATCGCCTAGTATGTTCTGTGAACACAAATAA
AATTGATTTACTGTCTGCTAAAAA

FIGURE 6

MCHSRSCHPTMTILQAPTPAPSTIPGPRRGSGPEIFTFDPLPEPAAAPAGRPSASRGHRK
RSRRVLYPRVRRQLPVEEPNPAKRLFLLLTIVFCQILMAEEGVPAPLPPEDAPNAASL
APTPVSPVLEPFNLTSSEPSDYALDLSTFLQQHPAAF

Signal sequence
none

Transmembrane domain
78-98

N-glycosylation site.

133-136

cAMP- and cGMP-dependent protein kinase phosphorylation site.

28-31
59-62

FIGURE 7

AGCTGAGGTGTGAGCAGCTGCCGAAGTCAGTTCCTTGTGGAGCCGGAGCTGGGCGCGGAT
TCGCCGAGGCACCGAGGCACTCAGAGGAGGTGAGAGAGCGGCGGCAGACAACAGGGGACC
CCGGGCCGCGCGGCCAGAGCCGAGCCAAGCGTGCCCGCGTGTGTCCCTGCGTGTCCGCGA
GGATGCGTGTTCGCGGGTGTGTGCTGCGTTACAGGTGTTTCTGCGGCAGGCGCCATGTC
AGAACCGGCTGGGGATGTCCGTGAGAACCCATGCGGCAGCAAGGCCTGCCGCCGCTCTT
CGGCCCAGTGGACAGCGAGCAGCTGAGCCGCGACTGTGATGCGCTAATGGCGGGCTGCAT
CCAGGAGGCCCGTGAGCGATGGAACCTTCGACTTTGTCAACGAGACACCACTGGAGGGTGA
CTTCGCCTGGGAGCGTGTGCGGGGCTTGGCCTGCCAAGCTCTACCTTCCCACGGGGCC
CCGGCGAGGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGCACCTCACCTGCTCTGCT
GCAGGGGACAGCAGAGGAAGACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTCG
CTCAGGGGAGCAGGCTGAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACG
GCGGCAGACCAGCATGACAGATTTCTACCACTCCAACGCCGCTGATCTTCTCCAAGAG
GAAGCCCTAATCCGCCCACAGGAAGCCTGCAGTCCTGGAAGCGCGAGGGCCTCAAAGGCC
CGCTCTACATCTTCTGCCTTAGTCTCAGTTTGTGTGTCTTAATTATTATTGTGTTTAA
TTTAAACACCTCCTCATGTACATACCCTGGCCGCCCCCTGCCCCCAGCCTCTGGCATT
GAATTATTTAAACAAAACTAGGCGGTTGAATGAGAGGTTCTTAAGAGTGCTGGGCATTT
TTATTTTATGAAATACTATTTAAAGCCTCCTCATCCCGTGTCTCCTTTTCTCTCTCCC
GGAGGTTGGGTGGGCGGCTTCATGCCAGCTACTTCTCCTCCCCACTTGTCCGCTGGGT
GGTACCCTCTGGAGGGGTGTGGCTCCTTCCCATCGCTGTACAGGCGGTTATGAAATTCA
CCCCCTTTCTGGACACTCAGACCTGAATTCTTTTTTCAATTTGAGAAGTAAACAGATGGCA
CTTTGAAGGGCCTCACCGAGTGGGGCATCATCAAAAATTTGGAGTCCCCTCACCTCC
TCTAAGGTTGGGCAGGGTGACCTGAAGTGAGCACAGCCTAGGGCTGAGCTGGGGACCTG
GTACCCTCCTGGCTCTTGATACCCCCTCTGTCTTGTGAAGGCAGGGGGAAGGTGGGGTC
CTGGAGCAGACCACCCGCTGCCCTCATGGCCCTCTGACCTGCACTGGGGAGCCCGTC
TCAGTGTTGAGCCTTTTCCCTCTTTGGCTCCCCTGTACCTTTTGAGGAGCCCCAGCTACC
CTTCTTCTCCAGCTGGGCTCTGCAATTCCTCTGTCTGTCCCTCCCCCTTGTCTTT
CCCTTCAGTACCCTCTCAGCTCCAGGTGGCTCTGAGGTGCCTGTCCCACCCCCACCCCA
GCTCAATGGACTGGAAGGGGAAGGGACACACAAGAAGAAGGGCACCTAGTTCTACCTCA
GGCAGCTCAAGCAGCGACCGCCCCCTCCTCTAGCTGTGGGGGTGAGGGTCCCATGTGGTG
GCACAGGCCCCCTTGAGTGGGGTTATCTCTGTGTTAGGGGTATATGATGGGGGAGTAGAT
CTTTCTAGGAGGGAGACACTGGCCCCCTCAAATCGTCCAGCGACCTTCTCATCCACCCCA
TCCCTCCCCAGTTCATTGCACTTTGATTAGCAGCGGAACAAGGAGTCAGACATTTTAAGA
TGGTGGCAGTAGAGGCTATGGACAGGGCATGCCACGTGGGCTCATATGGGGCTGGGAGTA
GTTGTCTTTCTGGCACTAACGTTGAGCCCCCTGGAGGCACTGAAGTGCTTAGTGTAATTG
GAGTATTGGGGTCTGACCCCAAACACCTTCCAGCTCCTGTAACATACTGGCCTGGACTGT
TTTCTCTCGGCTCCCCATGTGTCTGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTC
GAGGGCAGGGACCACACCTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCACAATGCTG
AATATACAGCAGGTGCTCAATAAATGATTCTTAGTGACTTTAAAAA

A

FIGURE 8

MSEPAGDVQRNPCGSKACRRLFGPVDSEQLSRDCDALMAGCIQEARERWNFDFVTETPLE
GDFAWERVRLGLPKLYLPTGPRRGRDELGGRRPGTSPALLQGTAEEDHVDLSLSCTLV
PRSGEQAEGLSPGGPGDSQGRKRRQTSMTDFYHSKRRLIFSKRKP

signal sequence
none

Transmembrane domain
none

cAMP- and cGMP-dependent protein kinase phosphorylation site.
142-145

N-myristoylation site.
14-19
96-101

Amidation site.
91-96
138-143

Cyclin-dependent kinase inhibitor
15-114

[illegible]

FIGURE 10

MATMVPSVLWPRACWTLLVCCLLTPGVQGQEFLLRVEPQNPVLSAGGSLFVNCSTDCPSS
EKIALETSLSKELVASGMGWAFFNLSNVTGNSRILCSVYCNGSQITGSSNITVYGLPERV
ELAPLPPWQPVGQNFTRLRCQVEGGSPRTSLTVVLLRWEEELSRQPAVEEPAEVTATVLAS
RDDHGAPFSCRTSLDMQPQGLGLFVNTSAPRQLRTFVLPVTPPRLVAPRFLEVETSWPVD
CTLDGLFPASEAQVYLALGDQMLNATVMNHGDTLTATATATARADQEGAREIVCNVTLGG
ERREARENLTVFSFLGPIVNLSEPTAHEGSTVTVSCMAGARVQVTLTGVPAAAPGQPAQL
QLNATESDDGRSFFCSATLEVDGEFLHRNSSVQLRVLYGPKIDRATCPQHLKWKDKTRHV
LQCQARGNPYPCLKEGSSREVPVGIPIFFVNVTHNGTYQCQASSSRGKYTLVVVMDIE
AGSSHFPVPFVAVLLTLGVVTIVLALMYVFREHQRSGSYHVREESTYLPLTSMQPTTEAMG
EEPSRAE

Signal sequence
1-29

Transmembrane domain
484-504

N-glycosylation site.

52-55
84-87
87-90
101-104
110-113
134-137
206-209
264-267
295-298
308-311
320-323
363-366
389-392
453-456
457-460

Glycosaminoglycan attachment site.
76-79

N-myristoylation site.

77-82
102-107
132-137
144-149
185-190
202-207
245-250
329-334
348-353
458-463

Intercellular adhesion molecule (ICAM)
12-119

Immunoglobulin domain
132-192
329-377

FIGURE 11

GTTCGGGGTTGTTTGGGATTAGTGAAGCTACTGCCTTTGCCGCCAGCGCAGCCTCAGAG
TTTGATTATTTGCAATGTCAGGCTTTGAAAACCTTAAACACGGATTTCTACCAGACAAGTT
ACAGCATCGATGATCAGTCACAGCAGTCTTATGATTATGGAGGAAGTGGAGGACCTTATA
GCAAACAGTATGCTGGCTATGACTATTTCGCAGCAAGGCAGATTTGTCCCTCCAGACATGA
TGCAGCCACAACAGCCATACACCGGGCAGATTTACCAGCCAACCTCAGGCATATACTCCAG
CTTCACCTCAGCCTTTCTATGGAAACAACCTTTGAGGATGAGCCACCTTTATTAGAAGAGT
TAGGTATCAATTTTGACCACATCTGGCAAAAAACACTAACAGTATTACATCCGTTAAAAG
TAGCAGATGGCAGCATCATGAATGAAACTGATTTGGCAGGTCCAATGGTTTTTTGCCTTG
CTTTTGGAGCCACATTGCTACTGGCTGGCAAAATCCAGTTTGGCTATGTATACGGGATCA
GTGCAATTGGATGTCTAGGAATGTTTTGTTTTATTAACTTAATGAGTATGACAGGTGTTT
CATTTGGTTGTGTGGCAAGTGTCTTGGATATTGTCTTCTGCCCATGATCCTACTTTCCA
GCTTTGCAGTGATATTTTCTTTGCAAGGAATGGTAGGAATCATTCTCACTGCTGGGATTA
TTGGATGGTGTAGTTTTTCTGCTTCCAAAATATTTATTTCTGCATTAGCCATGGAAGGAC
AGCAACTTTTAGTAGCATATCCTTGCGCTTTGTTATATGGAGTCTTTGCCCTGATTTCCG
TCTTTTGAAAATTTATCTGGGATGTGGACATCAGTGGGCCAGATGTACAAAAAGGACCTT
GAACTCTTAAATTGGACCAGCAAACCTGCTGCAGCGCAACTCTCATGCAGATTTACATTTG
ACTGTTGGAGCAATGAAAGTAAACGTGTATCTCTTGTTCATTTTTATAGAACTTTTGCAT
ACTATATTGGATTTACCTGCGGTGTGACTAGCTTTAAATGTTTGTGTTTATACAGATAAG
AAATGCTATTTCTTTCTGGTTCCTGCAGCCATTGAAAAACCTTTTTCCTTGCAAATTATA
ATGTTTTTGATAGATTTTTATCAACTGTGGGAAACCAAACACAAAGCTGATAACCTTTCT
TAAAAACGACCCAGTCACAGTAAAGAAGACACAAGACGGCCGGGCGTGGTAGCTCACGCC
TGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACAAGGGCAGGAGATCGAGAC
CATCCTGGTTAACACGGTGAAACCCCGACTCTACTAAACTACAAAAAAATTAGCTGGG
CGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAAGTGTGAA
CCCAGGAGGCGGAGCTTGCAGTGAGCCGAGATCACACCACTGCACTCCATCCAGCCTGGG
TGACAGGGTGAGACTCTGTCTCAAAAAAAAAAAAAAAAAAGGAGACACAAGACTTACTGCAA
AAATATTTTTCCAAGGATTTAGGAAAGAAAAATTGCCTTGTATTCTCAAGTCAGGTAAC
CAAAGCAAAAAAGTGATCCAAATGTAGAGTATGAGTTTGCCTCCAAAAATTTGACATTA
CTGTAAATTATCTCATGGAATTTTTGCTAAAATTCAGAGATACGGGAAGTTCACAATCTA
CCTCATTGTAGACATGAAATGCGAACACTTACTTACATATTAATGTAACTCAACCTTAG
GGACCTGGAATGGTTGCATTAATGCTATAATCGTTGGATCGCCACATTTCCCAAAAATAA
TAAAAAATCACTAACCTTTTTTAAGGAAAATATTTAAAGTTTTACAAAATTCATATTG
CAATTATCAATGTAAAGTACATTTGAATGCTTATTAAACTTTCCCAATTAATTTT

FIGURE 12

MSGFENLNTDFYQTSYSIDDSQQSYDYGGSGGPYSKQYAGYDYSQQGRFVPPDMMQPQQ
PYTGQIQPTQAYTPASPQPFYGNFEDPPLLEELGINFDHIWQKTLTVLHPLKVADGS
IMNETDLAGPMVFCCLAFGATLLLAGKIQFGYVYGISAIGCLGMFCLLNLMSTGVVSFGCV
ASVLGYCLLPMILLSSFAVIFSLQGMVGIILTAGIIGWCSFSASKIFISALAMEGQQLLV
AYPCALLYGVFALISVF

signal sequence
none

Transmembrane domain
129-149
160-180
177-197
193-213
235-255

N-glycosylation site.
123-126

N-myristoylation site.
32-37
119-124
174-179
178-183
208-213

Yip1 domain
96-240

[illegible]

FIGURE 13B

GGTGGAGATGGAGCACCTGCCCCCATGGCAGGGTACACTCTCCCCACAGCCTTCCTCCC
CACCATCCCGTGGGGACTCTCGGGATTTAAGCACTCGTCTCTCTGGGAGGCCAGACCCC
ACTCCATTTATAGGCACATCTCCTTCATTTCTTAGGTCACTGCCCCCTTGTTTACAGCTC
CTGCCTCCTCCCTTGACCACAGCCTGGTTTACAAATTCATCAGCTCCCAGCCCCACCTG
CCAAAGTCCCAGGTTTACAAGCCACGCTTACTTGCTGTGTCTGCGTGGAATTCTCTCCTC
TGTCCCTCCAGTCTCCTCATTGGAGTGACCTGAAGGTGTGGCTTCCTCCACTTTTCTC
AGTATTACTTTGCCTTAGTTTTCCCAAGAGGGAAGGCTGGAACCTTAACTCTGTACCC
CTTGATAGTTATTTAATTCTGTTTCTCCTAGTGGTTCACAATTGAACTGAATTGAGATGG
TGTCGGGTGGCTAAGGAGACACCTCACCTCTCCTTCCCCATTGTGCCGCCTTTATCAATT
GCCTGTTTGTGTTTGTGTTTAACTTCCATAATAAAATGGAGTTCTCTTC

FIGURE 14

MATIPDWKLQLLARRRQEEASVRGREKAERERLSQMPAWKRGLLERRRAKLGLSPGEPSP
VLGTVEAGPPDPDESAVLLEAIGPVHQNRFRQERQQQQQQQORSEELLAERKPGPLEAR
ERRPSPGEMRDQSPKGRESREERLSPRETRERRLGIGGAQELSLRPLEARDWRQSPGEVG
DRSSRLSEAWKWRLSPGETPERSLRLAESREQSPRRKEVESRLSPGESAYQKLGLTEAHK
WRPDSRESQEQSLVQLEATEWRLRSGEERQDYSEECGRKEEWPVPGVAPKETAESETLT
REAQGNSSAGVEAAEQRPVEDGERGMKPTGKWTLSNGKAREWTPRDIEAQTQKLEPPE
SAEKLLESPGVEAGEGEAEKEEAGAQRPLRALQNCSSVPSPLPPEDAGTGGLRQQEEEA
VELQPPPPAPLSPPPPAPTAPQPPGDPLMSRLFYGVKAGPGVGAPRRSGHTFTVNPRRSV
PPATPATPTSPATVDAAVPGAGKKRYPTAEELVLGGYLRLSRSLAKGSPERHHKQLKI
SFSETALETYYQYPSESSVLEELGPEPEVPSAPNPPAAQPDDEEDEEELLLLQPELQGGL
RTKALIVDESCRR

signal sequence
none

transmembrane domain
none

N-glycosylation site.
306-309

cAMP- and cGMP-dependent protein kinase phosphorylation site.
122-125

Tyrosine kinase phosphorylation site.
264-272

N-myristoylation site.
52-57
63-68
155-160
234-239
305-310
310-315
325-330
370-375
598-603

Amidation site.
276-279
501-504

FIGURE 15

GCGGCTCTCTGATCCAGCCCGGGAGAGGACCGAGCTGGAGGAGCTGGGTGTGGGGTGCGT
TGGGCTGGTGGGGAGGCCTAGTTTGGGTGCAAGTAGGTCTGATTGAGCTTGTGTTGTGCT
GAAGGGACAGCCCTGGGTCTAGGGGAGAGAGTCCCTGAGTGTGAGACCCGCCTTCCCCGG
TCCCAGCCCCCTCCAGTTCCCCCAGGGACGGCCACTTCCTGGTCCCCGACGCAACCATCG
CTGAAGAACAACCGCAGGTCTGAATTGTTTCGTGAAGGCTGGCAGTGATGGGGCCAAGATTG
GGAAGTGGCCATTCTCCCAGAGACTGTTTCATGGTACTGTGGCTCAAGGGAGTCACCTTCA
ATGTTACCACCGTTGACACCAAAAGGCGGACCGAGACAGTGCAGAAAGCTGTGCCAGGGG
GGCAGCTCCCATTCCTGCTGTATGGCACTGAAGTGCACACAGACACCAACAAGATTGAGG
AATTTCTGGAGGCAGTGCTGTGCCCTCCCAGGTACCCCAAGCTGGCAGCTCTGAACCTG
AGTCCAACACAGCTGGGCTGGACATATTTGCCAAATTTTCTGCCTACATCAAGAATTCAA
ACCCAGCACTCAATGACAATCTGGAGAAGGGACTCCTGAAAGCCCTGAAGGTTTTAGACA
ATTACTTAACATCCCCCTCCCAGAAGAAGTGGATGAAACCAGTGCTGAAGATGAAGGTG
TCTCTCAGAGGAAGTTTTTGGATGGCAACGAGCTCACCTGGCTGACTGCAACCTGTTGC
CAAAGTTACACATAGTACAGGTGGTGTGTAAGAAGTACCGGGGATTACCATCCCCGAGG
CCTTCCGGGGAGTGCATCGGTACTTGAGCAATGCCTACGCCCCGGAAGAATTCGCTTCCA
CCTGTCCAGATGATGAGGAGATCGAGCTCGCCTATGAGCAAGTGGCAAAGGCCCTCAAAT
AAGCCCCCTCCTGGGACTCCCTCAACCCCCCTCCATTTTCTCCACAAAGGCCCTGGTGGTTT
CCACATTGCTACCCAATGGACACACTCCAAAATGGCCAGTGGGCAGGGAATCCTGGAGCA
CTTGTTCCGGGATGGTGTGGTGGGAAGAGGGGATGAGGGAAAGAAATGGGGGGCCTGGGTC
AGATTTTATTTGTGGGGTGGGGTGAGTAGGACAACATATTTTCAGTAATAAAATACAGAAT
AAAAATCAAGTGTTTTTAAAAAAA

FIGURE 16

MAEEQPQVELFVKAGSDGAKIGNCPFSQRLEFVLWLKGVTFNVTTVDTKRRTETVQKLCP
GGQLPFLLYGTEVHTDTNKIEEFLEAVLCPPRYPKLAALNPESNTAGLDIFAKFSAYIKN
SNPALNDNLEKGLLKALKVLDNYLTSPLEEVDETSAEDEGVSQRKFLDGNELTLADCNL
LPKLHIVQVVCKKYRGFTIPEAFRGVHRYLSNAYAREEFASCTPDDEEIELAYEQVAKAL
K

Signal sequence
none

Transmembrane domain
22-42

N-glycosylation site.
42-45

cAMP- and cGMP-dependent protein kinase phosphorylation site.
49-52

N-myristoylation site.
15-20
18-23
38-43
132-137
170-175

FIGURE 17

CATCAGCTTTGAAAGCCAACACATCCTCCTGAGAGGGGACAAGACAAGCAGGGATATGTG
GGCCACTGGATCTTTGCCAGACTTCCCGGCTGCAGCCAAGTTCTTAGGGTTCCGTCAGCG
CTGCATCCCCAGGAGCCTCTGCCTCAGTGAGTGTCTCTGGAGCCCCCAAGCCTCACCCG
CCTCTGTGCCACTCTGAAGGACTGCCCCGGGACCCCTGGAAGTCAATTGTCTGTGAGTT
CCTGAGTGACCAGAGCCTGGAGACTCTACTGGACTGCTTACCTCAACTCCCTCAGCTGAG
CCTGCTGCAGCTGAGCCAGACGGGACTGTCCCCGAAAAGCCCCCTTCTGCTGGCCAACAC
CTTAAGCCTGTGTCCACGGGTAAAAAGGTGGATCTCAGGTCCCTGCACCATGCAACTTT
GCACTTCAGATCCAACGAGGAGGAGGAAGGCGTGTGCTGTGGTCTCTCAGCAAACCTGCT
GGGCGACAGCGGACTCAGATGCCTTCTGGAATGTCTGCCGAGGTGCCATCTCCGGTTT
GCTTGATCTGAGTCACAACAGCATTTCTCAGGAAAGTGCCCTGTACCTGCTGGAGACACT
GCCCTCCTGCCCACGTGTCCGGGAGGCCTCAGTGAACCTGGGCTCTGAGCAGAGCTTCCG
GATTCACCTTCTCCAGAGAGGACCAGGCTGGGAAGACACTCAGGCTAAGTGAGTGACAGCTT
CCGGCCAGAGCACGTGTCCAGGCTGGCCACCGGCTTGAGCAAGTCCCTGCAGCTGACGGA
GCTCACGCTGACCCAGTGCTGCCTGGGCCAGAAGCAGCTGGCCATCCTCCTGAGCTTGGT
GGGGCGACCCGAGGGCTGTTCACTCTCAGGGTGCAGGAGCCGTGGGCGGACAGAGCCAG
GGTCTCTCCCTGTTAGAAGTCTGCGCCAGGCCTCAGGCAGTGTGCTGAAATCAGCAT
CTCCGAGACCCAGCAGCAGCTCTGTGTCCAGCTGGAATTTCTCGCCAGGAAGAGAATCC
AGAAGCTGTGGCACTCAGGTTGGCTCACTGTGACCTTGGAGCCCACCACAGCCTTCTTGT
CGGGCAGCTGATGGAGACATGTGCCAGGCTGCAGCAGCTCAGCTTGTCTCAGGTTAACCT
CTGTGAGGACGATGATGCCAGTTCCCTGCTGCTGCAGAGCCTCCTGCTGTCCCTCTCTGA
GCTGAAGACATTTCCGGCTGACCTCCAGCTGTGTGAGCACCGAGGGCCTCGCCACCTGGC
ATCTGGTCTGGGCCACTGCCACCACCTTGAGGAGCTGGACTTGTCTAACAATCAATTTGA
TGAGGAGGGCACCAAGGCGCTGATGAGGGCCCTTGAGGGGAAATGGATGCTAAAGAGGCT
GGACCTCAGTCACCTTCTGCTGAACAGCTCCACCTTGGCCTTGCTTACTCACAGACTAAG
CCAGATGACCTGCCTGCAGAGCCTCAGACTGAACAGGAACAGTATCGGTGATGTCCGGTTG
CTGCCACCTTTCTGAGGCTCTCAGGGCTGCCACCAGCCTAGAGGAGCTGGACTTGAGCCA
CAACCAGATTGGAGACGCTGGTGTCCAGCACTTAGCTACCATCCTGCCTGGGCTGCCAGA
GCTCAGGAAGATAGACCTCTCAGGGAATAGCATCAGCTCAGCCGGGGGAGTGCAAGTTGGC
AGAGTCTCTCGTTCTTTGCAGGCGCCTGGAGGAGTTGATGCTTGGCTGCAATGCCCTGGG
GGATCCACAGCCCTGGGGCTGGCTCAGGAGCTGCCCCAGCACCTGAGGGTCTTACACCT
ACCATTACAGCCATCTGGGCCCAGGTGGGGCCCTGAGCCTGGCCCAGGCCCTGGATGGATT
CCCCCATTTGGAAGAGATCAGCTTGGCGGAAAACAACCTGGCTGGAGGGGTCTTGCCTT
CTGTATGGAGCTCCCGCTGCTCAGACAGATAGACCTGGTTTCTGTAAAGATTGACAACCA
GACTGCCAAGCTCCTCACCTCCAGCTTCACGAGCTGCCCTGCCCTGGAAGTAATCTTGCT
GTCTTGGAATCTCCTCGGGGATGAGGCAGCTGCCGAGCTGGCCCAGGTGCTGCCGCAGAT
GGGCCGGCTGAAGAGAGTGGACCCGGAGAAGAATCAGATCACAGCTTTGGGGGCCTGGCT
CCTGGCTGAAGGACTGGCCCAGGGGTCTAGCATCCAAGTCATCCGCCTCTGGAATAACCC
CATTCCTGCGACATGGCCCAGCACCTGAAGAGCCAGGAGCCAGGCTGGACTTTGCCTT
CTTTGACAACCAGCCCCAGGCCCTTGGGGTACTTGATGGCCCCCTCAAGACCTTTGGAA
TCCAGCCAAGTGATGCACCCAAATGATCCACCTTTCGCCCACTGGGATAAATGACTCAGG
AAAGAAGAGCCTCGGCAGGGCGCTCTGCACTCCACCCAGGAGGAAGGATACGTGTGTCTT
GCTGCAGTCTCAGGGAGAACTTTTTTGGGAACCAGGAGCTGGGTCTGGACAAAGGAGTA
CCCTGCATTACGTGGGATATGTGTGATCAATTGGGGACATGCGACACACAATGAGGGTGT
CATGACAATGCATGACACGTACGGTTATATGTGGCAGTGTGACCCCTTGACATGTGGCGT
TACATGAAAGTCAGTGTGGCACGTGTTCTGTGGCATGGGTGCTGGCATCCCAAGTGGCAG
GATACATGATTGTTGGTCTATATATGACACATGACAAATGTCCATGTCACAGGACTCATG
GCTGGCCAGATGACCTCAGGCTGGCCCAAGATCTAATTTATTAATTTTAAAGCAAATAC
ATATTTATAGATTGTGTGTATGGAGCAGCTAAGTCAGGAAAAGTCTTCCGCCCGAGCTGG
GAGGGGAGAGTGTCCATGCACTGACCAGTCCAGGGGCTCAAGGGCCAGGGCTCTGGAACA
AGCCAGGGACTCAGCCATTAAGTCCCCTCCTGCCTCAATCCTCAGCCTACCCATCTATAA
ACTTGATGACTCCTCCCTTACTTACATACTAGCTTCCAAGGACAGGTGGAGGTAGGGCCA
GCCTGGCGGGAGTGGAGAAGCCCAGTCTGTCCTATGTAAGGGACAAAGCCAGGTCTAATG
GTACTGGGTAGGGGGCACTGCCAAGACAATAAGCTAGGCTACTGGGTCCAGCTACTACTT
TGGTGGGATTGAGGTGAGTCTCCATGCACTTCACATGTTACCCAGTGTCTTGTACTTTC
CAAGGAGAACCAAGAATGGCTCTGTCACTCGAAGCCAGGTTTGATCAATAAACACAAT
GGTATTCC

FIGURE 18

MWATGSLPDFPAAAKFLGFRQRCIPRSLCLSECPLEPPSLTRLCATLKDCPGPLELQLSC
EFLSDQSLETLLDCLPQLPQLSLLQLSQTGLSPKSPFLLANTLSLCPRVKKVDLRSLHHA
TLHFRSNEEEGVCCGLSANLLGDSGLRCLLECLPQVPISGLLDLSHNSISQESALYLLE
TLPSCPRVREASVNLGSEQSFRIHFSREDQAGKTLRLSECSFRPEHVSRLATGLSKSLQL
TELTLTQCCLGQKQLAILLSLVGRPAGLFSLRVQEPWADRARVLSLLEVCAQASGSVAEI
SISSETQQQLCVQLEFPQRQENPEAVALRLAHCDLGAHHSLLVGQLMETCARLQQLSLSQV
NLCEDDDASSLLLQSLLSLSELKTFRLTSSCVSTEGLAHLASGLGHCHHLEELDLSNNQ
FDEEGTKALMRALEGKWMLKRLDLSHLLNSSTLALLTHRLSQMTCLQSLRLNRNSIGDV
GCCHLSEALRAATSLEELDLSHNQIGDAGVQHLATILPGLPELRKIDLSGNSISSAGGVQ
LAESLVLCRRLEELMLGCNALGDPTALGLAQELPQHRLRVLHLPFSLHLPFGGALSQAQALD
GFPHLEEISLAENNLGGVLRFCMELPLLRLQIDLVCKIDNQTAKLLTSSFTSCPALEVI
LLSWNLGDEAAAEALAQVLPQMGRLLKRVDPKKNQITAGAWLLAEGLAQGSSIQVIRLWN
NPIPCDMAQHLLKSQEPRLDFAFFDNQPQAPWGT

Signal sequence
None

Transmembrane domain

654-674
694-714

N-glycosylation site.
450-453
644-644

Glycosaminoglycan attachment site.
403-406

N-myristoylation site.

132-137
136-141
196-201
233-238
335-340
404-409
530-535
538-543
590-595
706-711

Leucine zipper pattern.
84-105

Leucine Rich Repeat
80-107
239-262
410-434
438-462
466-493
494-521
522-546
550-578
604-627
628-655
656-680
712-732

FIGURE 19

ATAGGGTCAGTGGGCCGCTTGGCGGTGTCGTTGCGGTACCAGGTCCGCGTGAGGGGTTCG
GGGGTTCTGGGCAGGCACAATGGCGTCTCGAGCAGGCCCGCGAGCGGCCGGCACCGACGG
CAGCGACTTTCAGCACCGGGAGCGCGTCGCCATGCACTACCAGATGAGTGTGACTCTCAA
GTATGAAATCAAGAAGCTGATCTACGTACATCTGGTCATATGGCTGCTGCTGGTTGCTAA
GATGAGCGTGGGACACCTGAGGCTCTTGTCACATGATCAGGTGGCCATGCCCTATCAGTG
GGAATACCCGTATTTGCTGAGCATTTTGCCCTCTCTCTTGGGCCTTCTCTCCTTTCCCCG
CAACAACATTAGCTACCTGGTGCTCTCCATGATCAGCATGGGACTCTTTTCCATCGCTCC
ACTCATTTATGGCAGCATGGAGATGTTCCCTGCTGCACAGCAGCTCTACCGCCATGGCAA
GGCCTACCGTTTCTCTTTGGTTTTTCTGCCGTTTCCATCATGTACCTGGTGTGGTGTT
GGCAGTGCAAGTGCATGCCTGGCAGTTGTACTACAGCAAGAAGCTCCTAGACTCTTGGTT
CACCAGCACACAGGAGAAGAAGCATAAATGAAGCCTCTTTGGGGTGAAGCCTGGACATCC
CATCGAATGAAAGGACACTAGTACAGCGGTTCCAAAATCCCTTCTGGTGATTTTAGCAGC
TGTGATGTTGGTACCTGGTGCAGACCAGGCCAAAGTTCTGGAAAGCTCCTTTTGCCATCT
GCTGAGGTGGCAAACTATAATTTATTCCTGGTTGGCTAGAACTGGGTGACCAACAGCTA
TGAAACAAATTTAGCTGTTTGAAGTTGAACTTTGAGGTTTTTCTTTAAGAATGAGCTTC
GTCCTTGCCTCTACTCGGTCATTCTCCCCATTTCCATCCATTACCCCTTAGCCATTGAGA
CTAAAGGAAATAGGGAATAAATCAAATTACTTCATCTCTAGGTCACGGGTCAGGAAACAT
TTGGGCAGCTGCTCCCTTGGCAGGCTGTGGTCTCCTCTGCAAAGCATTTTAATTAAAAC
CTCAATAAAGA

FIGURE 20

MASRAGPRAAGTDGSDFOHRERVAMHYQMSVTLKYEIKKLIYVHLVIWLLLVAKMSVGHL
RLLSHDQVAMPYQWEYPYLLSILPSLLGLLSFPRNNISYLVLSMISMGLFSIAPLIYGSM
EMFPAAQQLYRHGKAYRFLFGFSAVSIMYLVVLAVQVHAWQLYYSKKLLDSWFTSTQEK
KHK

signal sequence
none

Transmembrane domain
38-58
77-97
99-119
138-158

N-glycosylation site.
96-99

N-myristoylation site.
11-16

FIGURE 21

GACGTGAACGGTCGTTGCAGAGATTGCGGGCGGCTGAGACGCCGCCTGCCTGGCACCTAG
GAGCGCAGCGGAGCCCCGACACCGCCGCGCCGCCATGGAGTCCGAGACCGAACCCGAGC
CCGTCACGCTCCTGGTGAAGAGCCCCAACCCAGCGCCACCGCGACTTGGAGCTGAGTGGCG
ACCGCGGCTGGAGTGTGGGCCACCTCAAGGCCACCTGAGCCGCGTCTACCCGAGCGTC
CGCGTCCAGAGGACCAGAGGTTAATTTATTCTGGGAAGCTGTTGTTGGATCACCAATGTC
TCAGGGACTTGCTTCCAAAGCAGGAAAAACGGCATGTTTTGCATCTGGTGTGCAATGTGA
AGAGTCCTTCAAAAATGCCAGAAATCAACGCCAAGGTGGCTGAATCCACAGAGGAGCCTG
CTGGTTCCTAATCGGGGACAGTATCCTGAGGATTCTCAAGTGATGGTTTAAGGCAAAGGG
AAGTTCTTCGGAACCTTTCTTCCCCTGGATGGGAAAACATCTCAAGGCCTGAAGCTGCCC
AGCAGGCATTCCAAGGCCTGGGTCTGTTTCTCCGGTTACACACCCTATGGGTGGCTTC
AGCTTTCCTGGTTCAGCAGATATATGCACGACAGTACTACATGCAATATTTAGCAGCCA
CTGCTGCATCAGGGGCTTTTGTTCACCAACCAAGTGCACAAGAGATACCTGTGGTCTCTG
CACCTGCTCCAGCCCCTATTCAACAACAGTTTCCAGCTGAAAACCAGCCTGCCAATCAGA
ATGCTGCTCCTCAAGTGGTTGTTAATCCTGGAGCCAATCAAAATTTGCGGATGAATGCAC
AAGGTGGCCCTATTGTGGAAGAAGATGATGAAATAAATCGAGATTGGTTGGATTGGACCT
ATTCAGCAGCTACATTTTCTGTTTTTCTCAGTATCCTCTACTTCTACTCCTCCCTGAGCA
GATTCCTCATGGTCATGGGGGCCACCGTTGTTATGTACCTGCATCACGTTGGGTGGTTTC
CATTTAGACCGAGGCCGGTTCAGAACTTCCCAAATGATGGTCCTCCTCCTGACGTTGTAA
ATCAGGACCCCAACAATAACTTACAGGAAGGCACTGATCCTGAACTGAAGACCCCAACC
ACCTCCCTCCAGACAGGGATGTACTAGATGGCGAGCAGACCAGCCCCTCCTTTATGAGCA
CAGCATGGCTTGTCTTCAAGACTTTCTTTGCCTCTCTTCTTCCAGAAGGCCCCCAGCCA
TCGCAAACCTGATGGTGTGTTGTGCTGTAGCTGTTGGAGGCTTTGACAGGAATGGACTGGAT
CACCTGACTCCAGCTAGATTGCCTCTCCTGGACATGGCAATGATGAGTTTTTAAAAACA
GTGTGGATGATGATATGCTTTTGTGAGCAAGCAAAAGCAGAAACGTGAAGCCGTGATACA
AATTGGTGAACAAAAAATGCCCAAGGCTTCTCATGTCTTTATTCTGAAGAGCTTTAATAT
ATACTCTATGTAGTTTAATAAGCACTGTACGTAGAAGGCCTTAGGTGTTGCATGTCTATG
CTTGAGGAACCTTTCCAAATGTGTGTGTCTGCATGTGTGTTTGTACATAGAAGTCATAGA
TGCAGAAGTGGTCTGCTGGTACGATTTGATTCTGTTGGAATGTTTAAATTACACTAAG
TGTACTACTTTATATAATCAATGAAATTGCTAGACATGTTTTAGCAGGACTTTTCTAGGA
AAGACTTATGTATAATTGCTTTTTTAAATGCAGTGCTTTACTTTAAACTAAGGGGAACCTT
TGCGGAGGTGAAAACCTTTGCTGGGTTTTCTGTTCAATAAAGTTTTACTATGAATGACCC
TGAAAAAAAAAAAAAAAAAAAAA

FIGURE 22

MESETEPEPVTLTVKSPNQRHRDLELSGDRGWSVGHLKAHLRSRVYPERPRPEDQRLLIYSG
KLLLDHQCLRDLLPKQEKRLHVLHLCNVKSPSKMPEINAKVAESTEPEAGSNRGQYPEDS
SSDGLRQREVLRLNLSSPGWENISRPEAAQQAQGLGPGFSGYTPYGWLQLSWFQQIYARQ
YYMQYLAATAASGAFVPPPSAQEIPVVSAPAPAPIHNQFPAENQPANQNAAPQVVVNPGA
NQNLRMNAQGGPIVEEDDEINRDWLDWTYSAATFSVFLSILYFYSSLSRFLMVMGATVVM
YLHHVGWFFRPRPVQNFNDGPPPDVVNQDPNNNLQEGTDPETEDPNHLPDPRDVLDE
QTSPSFMSTAWLVFKTFFASLLPEGPPAIAN

signal sequence

Transmembrane domain
278-298

N-glycosylation site.
133-136
141-144

Tyrosine kinase phosphorylation site.
262-269

N-myristoylation site.
110-115
154-159
239-244

Ubiquitin family
10-89

FIGURE 23

CGAGATGCGGGTCATGGCGCCCCGAACCCTCATCCTGCTGCTCTCGGGAGCCCTGGCCCT
GACCGAGACCTGGGCCTGCTCCCACTCCATGAGGTATTTGACACCGCCGTGTCCCGGCC
CGGCCGCGGAGAGCCCCGCTTCATCTCAGTGGGCTACGTGGACGACACGCAGTTCGTGCG
GTTTCGACAGCGACGCCGCGAGTCCGAGAGGGGAGCCCCGGGCGCCGTGGGTGGAGCAGGA
GGGGCCGGAGTATTGGGACCGGGAGACACAGAAGTACAAGCGCCAGGCACAGGCTGACCG
AGTGAACCTGCGGAAACTGCGCGGCTACTACAACCAGAGCGAGGACGGGTCTCACACCCT
CCAGTGGATGTATGGCTGCGACCTGGGGCCCGACGGGCGCCTCCTCCGCGGGTATGACCA
GTCCGCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGCGCTCCTGGACCGC
CGCGGACACGGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGAGGCGGAGCA
GTGGAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGG
GAAGGAGACGCTGCAGCGCGCGGAACACCCAAAGACACACGTGACCCACCATCCCGTCTC
TGACCATGAGGCCACCCTGAGGTGCTGGGTCCTGGGCTTCTACCCTGCGGAGATCACACT
GACCTGGCAGCGGGATGGCGAGGACCAAACCTCAGGACACCGAGCTTGTGGAGACCAGGCC
AGCAGGAGATGGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCA
GAGATACACGTGCCATGTGCAGCACGAGGGGCTGCCAGAGCCCCTCACCTGAGATGGGA
GCCATCTTCCCAGCCCACCATCCCCATCGTGGGCATCGTTGCTGGCCTGGCTGTCTGGC
TGTCTAGCTGTCCTAGGAGCTGTGATGGCTGTTGTGATGTGTAGGAGGAAGAGCTCAGG
TGGAAAAGGAGGAGCTGCTCTCAGGCTGCGTCCAGCAACAGTGCCAGGGCTCTGATGA
GTCTCTCATCGCTTGTAAGCCTGAGACAGCT

FIGURE 24

MRVMAPRTLILLLSGALALTETWACSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRF
DSDAASPRGEPRAPWVEQEGPEYWDRETQKYKROAQADRVNLRKLRGYYNQSEDGSHTLQ
WMYGCDLGPDGRLRLRGYDQSAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQW
RAYLEGTCEWLRRLRYLENGKETLQRAEHPKTHVTHHPVSDHEATLRCWALGFYPAEITLT
WQRDGEDQTQDTELVEVTRPAGDGTQKWAAVVPSGEEQRYTCHVQHEGLPEPLTLRWE
SSQPTIPIVGIVAGLAVLAVLAVLGAVMAVVMCRKSSGGKGGSCSQAASSNSAQGSDES
LIACKA

Signal sequence
1-24

Transmembrane domain
308-328

N-glycosylation site.
110-113

cAMP- and cGMP-dependent protein kinase phosphorylation site.
334-337
335-338

Tyrosine kinase phosphorylation site.
135-142

N-myristoylation site.
310-315
325-330
339-344
342-347
356-361

Microbodies C-terminal targeting signal.
364-367

Immunoglobulins and major histocompatibility complex proteins signature.
281-287

Class I Histocompatibility antigen
25-203

Immunoglobulin domain
220-285

FIGURE 25

ACTCCCAACGAGCGCCCAAGAAGAAAATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTT
TCATCATAGCTGTGCTGATGAGCGCTCAGGAATCATGGGCTATCAAAGAAGAACATGTGA
TCATCCAGGCCGAGTTCTATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTG
ATGGTGATGAGATTTTCCATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAAG
AATTTGGACGATTTGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACA
AAGCCAACCTGGAAATCATGACAAAGCGCTCCAATACTCCGATCACCAATGTACCTC
CAGAGGTAAGTGTGCTCACGAACAGCCCTGTGGAAGTGGAGAGCCCAACGTCCTCATCT
GTTTCATCGACAAGTTCACCCACAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAC
CTGTCACCACAGGAGTGTGAGAGACAGTCTTCTGCCCAGGGAAGACCACCTTTTCCGCA
AGTTCCACTATCTCCCCTTCTGCCCTCACTGAGGACGTTTACGACTGCAGGGTGGAGC
ACTGGGGCTTGGATGAGCCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAAGCCCTCTCC
CAGAGACTACAGAGAACGTGGTGTGTGCCCTGGGCCTGACTGTGGGTCTGGTGGGCATCA
TTATTGGGACCATCTTCATCATCAAGGGAGTGGCAGCAAGCAATGCAGCAGAACGCAGGG
GGCCTCTGTAAAGGCACATGGAGGTGATGATGTTTCTTAGAGAGAAGATCACTGAAGAAAC
TTCTGCTTTAATGACTTTACAAAGCTGGCAATATTACAATCCTTGACCTCAGTGAAAGCA
GTCATCTTCAGCGTTTCCAGCCCTATAGCCACCCCAAGTGTGGTTATGCCTCCTCGATT
GCTCCGTACTCTAACATCTAGCTGGCTTTCCCTGTCTATTGCCTTTTCCTGTATCTATTT
TCCTCTATTTCTATCATTTTATTATCACCATGCAATGCCTCTGGAATAAAACATACAGG
AGTCTGTCTCTGCTATGGAATGCCCCATGGGGCTCTCTTGTGTACTTATTGTTTAAGGTT
TCCTCAAACCTGTGATTTTTCTGAACACAATAAACTATTTTGATGATCTTGGGTGGAAA

FIGURE 26

MAISGVPVLGFFIIAVLMSAQESWAIKEEHVIIQAEFYLNPDQSGEFMFDFDGDGEIFHVD
MAKKETVWRLEEFGRFASFQAQALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNS
PVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTGVSFVFLPREDHLFRKFHYLPFLP
STEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENVVCALGLTVGLVGIIIGTIFI
GVRKSNAERRGPL

Signal sequence
1-25

Transmembrane domain
218-238

N-glycosylation site.
143-146

cAMP- and cGMP-dependent protein kinase phosphorylation site.
63-66

N-myristoylation site.
83-88
156-161
223-228
230-235
241-246

Immunoglobulins and major histocompatibility complex proteins signature.
186-192

Class II histocompatibility antigen
29-109

Immunoglobulin domain
125-190

FIGURE 27

ATGGCGCCCCGAAGCCTCCTCCTGCTGCTCTCAGGGGCCCTGGCCCTGACCGATACTTGG
GCGGGCTCCCACTCCTTGAGGTATTTAGCACCGCTGTGTGCGGGCCCGGCCGCGGGGAG
CCCCGCTACATCGCCGTGGAGTACGTAGACGACACGCAATTCCTGCGGTTTCGACAGCGAC
GCCGCGATTCCGAGGATGGAGCCGCGGGAGCCGTGGGTGGAGCAAGAGGGGCGCAGTAT
TGGGAGTGGACCACAGGGTACGCCAAGGCCAACGCACAGACTGACCGAGTGGCCCTGAGG
AACCTGCTCCGCCGCTACAACCAGAGCGAGGCTGGGTCTCACACCCTCCAGGGAATGAAT
GGCTGCGACATGGGGCCCGACGGACGCCTCCTCCGCGGGTATCACCAGCACGCGTACGAC
GGCAAGGATTACATCTCCCTGAACGAGGACCTGCGCTCCTGGACCGCGGCGGACACCGTG
GCTCAGATCACCCAGCGCTTCTATGAGGCAGAGGAATATGCAGAGGAGTTCAGGACCTAC
CTGGAGGGCGAGTGCCCTGGAGTTGCTCCGCAGATACTTGGAGAATGGGAAGGAGACGCTA
CAGCGCGCAGATCCTCCAAAGGCACACGTTGCCACCAACCCATCTCTGACCATGAGGCC
ACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACGCTGACCTGGCAGCGG
GATGGGGAGGAACAGACCCAGGACACAGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGA
ACCTTCCAGAAGTGGGCCGCTGTGGTGGTGCCTTCTGGAGAGGAACAGAGATACACATGC
CATGTGCAGCACGAGGGGCTGCCCCAGCCCTCATCCTGAGATGGGAGCAGTCTCCCCAG
CCCACCATCCCCATCGTGGGCATCGTTGCTGGCCTTGTGTGCTTGGAGCTGTGGTCACT
GGAGCTGTGGTCGCTGCTGTGATGTGGAGGAAGAAGAGCTCAGATAGAAACAGAGGGAGC
TACTCTCAGGCTGCAGTCACTGACAGTGCCAGGGCTCTGGGGTGTCTCTCACAGCTAAT
AAAGTGTGAGACAGCTTCCTTGTGTGGGACTGAGAAGCAAGATATCAATGTAGCAGAATT
GCACTTGTGCCTCACGAACATACATAAATTTTAAAAATAAAGAATAAA

FIGURE 28

MAPRSLLLLLSGALALTDTWAGSHSLRYFSTAVSRPGRGEPRIAVEYVDDTQFLRFDS
AAIPRMEPREPWVEQEGPQYWEWTTGYAKANAQTDRVALRNLLRRYNQSEAGSHTLQGMN
GCDMGPDGRLLRGYHQHAYDGKDYISLNEDLRSWTAADTVAQITQRFYEAEEYAEFRTY
LEGECELELLRRYLENGKETLQRADPPKAHVAAHHPISDHEATLRCWALGFYPAEITLTWQR
DGEEQTQDTELVEVTRPAGDGTQKWAAVVPSGEEQRYTCHVQHEGLPQPLILRWEQSPQ
PTIPIVGIVAGLVVLGAVVTGAVVAAMWRKKSSDRNRGSYSQAAVTDSAQSGVSLTAN
KV

signal sequence
1-17

Transmembrane domain
304-324

N-glycosylation site.
107-110

cAMP- and cGMP-dependent protein kinase phosphorylation site.
330-333
331-334

Tyrosine kinase phosphorylation site.
166-173

N-myristoylation site.
118-123
307-312
316-321
321-326
352-357
354-359

Microbodies C-terminal targeting signal.
360-363

Crystallins beta and gamma 'Greek key' motif signature.
131-146

Immunoglobulins and major histocompatibility complex proteins signature.
278-284

Class I Histocompatibility antigen, domains
22-200

Immunoglobulin domain
217-282

FIGURE 29

CAAGGATGGTGGTCATGGCGCCCCGAACCCTCTTCCTGCTGCTCTCGGGGGCCCTGACCC
TGACCGAGACCTGGGCGGGCTCCCACTCCATGAGGTATTTAGCGCGCCCGTGTCCCGGC
CCGGCCGCGGGGAGCCCCGCTTCATCGCCATGGGCTACGTGGACGACACGCAGTTCGTGC
GGTTCGACAGCGACTCGGCGTGTCCGAGGATGGAGCCGCGGGCGCCGTGGGTGGAGCAGG
AGGGGCGGAGTATTGGGAAGAGGAGACACGGAACACCAAGGCCACGCACAGACTGACA
GAATGAACCTGCAGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCAGTTCTCACACCC
TCCAGTGGATGATTGGCTGCGACCTGGGGTCCGACGGACGCCTCCTCCGCGGGTATGAAC
AGTATGCCTACGATGGCAAGGATTACCTCGCCCTGAACGAGGACCTGCGCTCCTGGACCG
CAGCGGACACTGCGGCTCAGATCTCCAAGCGCAAGTGTGAGGCGGCCAATGTGGCTGAAC
AAAGGAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCACAGATACCTGGAGAACG
GGAAGGAGATGCTGCAGCGCGCGGACCCCCCAAGACACACGTGACCCACCACCCTGTCT
TTGACTATGAGGCCACCCTGAGGTGCTGGGCCCCGGGCTTCTACCCTGCGGAGATCATA
TGACCTGGCAGCGGGATGGGGAGGACCAGACCCAGGACGTGGAGCTCGTGGAGACCAGGC
CTGCAGGGGATGGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAGGAGC
AGAGATACACGTGCCATGTGCAGCATGAGGGGCTGCCGGAGCCCCCTCATGCTGAGATGGA
AGCAGTCTTCCCTGCCACCATCCCCATCATGGGTATCGTTGCTGGCCTGGTTGTCCTTG
CAGCTGTAGTCACTGGAGCTGCGGTGCTGCTGTGCTGTGGAGAAAGAAGAGCTCAGATT
GAAAAGGAGGGAGCTACTCTCAGGCTGCAATGTGAAACAGCTGCCCTGTGTGGGACTGAG
TGGCAAGTCCCTTTGTGACTTCAAGAACCCTGACTTCTCTTTGTGCAGAGACCAGCCCAC
CCCTGTGCCCACCATGACCCTCTTCCTCATGCTGAACTGCATTCTTCCCCAATCACCTT
TCCTGTTCAGAAAAGGGGCTGGGATGTCTCCGTCTCTGTCTCAAATTTGTGGTCCACTG
AGCTATAACTTACTTCTGTATTAAATTAGAATCTGAGTAT

FIGURE 30

MVVMAPRTLFLLLSGALTTLTETWAGSHSMRYFSAAVSRPGRGEPRIAMGYVDDTQFVRF
DSDSACPRMEPRAPWVEQEGPEYWEETRNKHAQAQTDRLNLQTLRGYYNQSEASSHTLQ
WMIGCDLGS DGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEANVAEQR
RAYLEGT CVEWLHRYLENGKEMLRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIIIT
WQRDGEDQTQDVELVETRPA GDGTFQKWA AVVVP SGEEQRYTCHVQHEGLPEPLMLRWKQ
SSLPTIPIMGIVAGLVVLA AVVTGA AVAVLWRKKSSD

signal sequence
1-24

Transmembrane domain
306-326

N-glycosylation site.
110-113

cAMP- and cGMP-dependent protein kinase phosphorylation site.
333-336
334-337

Tyrosine kinase phosphorylation site.
135-142

N-myristoylation site.
124-129
310-315
324-239

Immunoglobulins and major histocompatibility complex proteins signature.
281-287

Class I Histocompatibility antigen
25-203

Immunoglobulin domain
220-285

FIGURE 31A

GTAAGAGTCGAGGCCTGAGTCGCAGTAGAAGCCGAAGTAGGGGGCGCAGCAAAGACCGGG
ATCCAAATAGGAATGTTGAGCACAGGGAAAGATCGAAGTTTAAGAGTGAAAGGAATGACC
TGGAGAGTTCCTATGTGCCTGTGTCTGCACCACCTCCAACTCTTCTGAGCAGTATTCCT
CTGGGGCACAGTCTATTCCCAGCACTGTTACTGTGATCGCACCTGCTCACCCTCTGAAA
ACACAACTGAGAGTTGGTCTAATTACTATAACAATCATAGCTCTTCCAATTCTTTTGGTC
GAAACCTACCACCAAAGAGGCGATGCAGAGATTATGATGAAAGAGGATTTTGTGTACTTG
GTGACCTTTGTGAGTTTGATCATGGAAATGATCCCCTAGTTGTTGATGAAGTTGCTCTGC
CAAGTATGATTTCCTTTCCCAACCCCTCCTCCTGGGCTTCCTCCTCCACCACCTCCTGGAA
TGTTAATGCCTCCAATGCCAGGTCCAGGCCAGGCCCGGGCCAGGTCCAGGCCAGGCC
CGGGCCAGGTCCAGGTCCCTGGCCATAGTATGAGACTTCCTGTTCCCAAGGACATGGTC
AGCCTCCACCATCCGTTGTGCTTCCCATACCAAGACCACCTATAACACAATCAAGCTTGA
TAAACAGCCGTGACCAGCCTGGGACAAGTGCAGTGCCCAATCTTGTCATCAGTGGGAACAA
GACTACCTCCTCCTTTACCCAGAACCTCCTTTACACAGTATCAGAACGACAGCCCATGT
ACTCTCGTGAAATGCTGCTGCTGCATCTGAGCGACTTCAGTTGGGGACACCGCCTCCTC
TGTTGGCAGCTCGTTTGGTGCCACCTCGAAACCTCATGGGATCCTCCATTGGATAACATA
CCTCAGTCTCCAGCCCTACCCCTCTGGTTCAGATACATATGAACCAGATGGTTACAACC
CAGAAGCTCCTAGTATTACTAGTTCTGGTAGATCTCAGTACAGACAGTTCTTTTCAAGAA
CTCAGACACAGCGTCCAATCTGATTGGCCTAACATCTGGAGATATGGATGTAAATCCAA
GAGCTGCTAACATTGTGATCCAGACTGAACCACCAGTTCCTGTTTTCGATTAATAGCAACA
TAACCAGAGTAGTTCTTGAACCAGATAGTCGAAAAAGAGCTATGAGTGGTTTGGAAAGGGC
CACTCACAAAGAAACCTTGGCTGGGAAAGCAAGGAAATAACAATCAAAATAAACAGGGT
TCTTACGAAAGAATCAGTATACAAACACCAAAATTAGAAGTCAAGAAAATCCCTCAGGAAT
TGAACAACATTACCAAGCTCAATGAACACTTCAGCAAATTTGGAAGTATTGTTAATATCC
AGGTTGCTTTTAAGGGTGACCCAGAAGCAGCCCTAATCCAATATCTTACCAATGAGGAGG
CCAGGAAAGCCATTTCTAGCACAGAAGCAGTTCTAAACAACCGATTCAATTCGAGTCTTGT
GGCATAGGGAAAATAATGAGCAACCGACACTACAGTCTCAGCACAGCTGCTCCTGCAAC
AACAGCAAACACTTAGTCACCTCTCACAGCAGCACCATCACCTGCCACAGCATCTACATC
AGCAGCAGGTGCTAGTGGCCAGTCTGCTCCTTCAACAGTGACGGAGGTATCCAGAAGA
TGATGAGCAAACCACAGACATCAGGTGCATATGTTCTTAACAAAGTTCCTGTTAAACATC
GTCTTGACATGCAGGTGGTAACCAGAGTGATGCATCACATTTGTTGAATCAGTCTGGTG
GTGCTGGAGAAGATTGCCAGATATTTTCAACTCCAGGCCATCCAAAAATGATTTACAGCT
CCTCAAACCTTAAAGACACCTTCAAAGCTCTGTTCAAGGTCTAAATCTCATGATGTTCAAG
AAGTGCTTAAAAAAAACAGGAAGCAATGAAGTTACAACAAGATATGAGGAAAAAAGAC
AGGAAGTGTTAGAAAAGCAAATAGAATGCCAAAAGATGTTAATATCCAAGTTAGAAAAAA
ACAAAAACATGAAACCAGAAGAAAGAGCAAATATAATGAAGACTTTGAAAGAGCTTGGAG
AGAAGATCTCACAATTAAAAGATGAATTAAAAACATCTTCTGCAGTCTCCACACCATCTA
AAGTGAAGACAAAAACGGAGGCCAGAAGGAGTTATTAGATACTGAACTGGACCTCCACA
AGAGGCTGTCCTCAGGAGAAGACACCACAGAATTACGGAAAAAACTCAGTCAGTTACAGG
TTGAGGCTGCACGGTTAGGTATTTTACCTGTGGGTGCGAGGAAAGACCATGTCTCTCAAG
GTCGAGGAAGAGGCCGAGGGCGTGAGGAAGAGGAAGGGGCTCACTAAATCACATGGTGG
TGGACCATCGTCCCAAAGCACTAACAGTTGGAGGATTCATTGAGGAAGAAAAAGAAGACT
TGCTTCAGCATTTCTCAACCGCAAACCAAGGGCCAAAATTTAAAGACCGTCGGCTACAGA
TATCATGGCACAAGCCCAAGGTACCATCTATATCCACTGAGACTGAAGAAGAAGAAGTCA
AGGAGGAGGAAACAGAAACCTCAGATTTGTTTTTGCCTGATGATGACGATGAAGATGAAG
ATGAATATGAGTCTCGCTCATGGCGAAGATGAATCTGATGCTAGCTGTATAATTTTTAG
GAATATTGTTTAGAAGAACAACCTTTTAAAAATTATTTAAAAGAAGTCAATGAGCCAAAAA
AAATTTTTTTATTTTTCTTTTCAACACAGTAGGTTCAAGAACAGCAAGTTTGCTATTTAA
ACACATCTCATAACTGTACATGATATTAAAGCACCAAGGCCTAGTGACTTTTACACAGT
TGTGAAGATCCACAGCAATGACATGGATAATCTCTAGAGCCTTATTTTCCACACCACCTT
TTTTTTGTGCTGTTGGTGTGGATTATGATGTAAATGACAGGGTGTTTCAAGAAATTTTAT
TTTGGATTATAATCTACTGATAAAATTTAATTAATGTCAAATCACCTGTAATCTTTTA
ACTCTCAGTTGTTATGGATGGGTTCATCAGACAGTAGGAAATATTTGTAATTTAAATACCC
TTTTGCTTTCAAGAGTGGTCTTGGAGAAAAATATGTTTATTTTAAATTTTATTTTTTT
TTTTTTTACTTTGGAGGAGCCCAATTTGTATTCAGTCTAAATTTGTTTTTCATGGTTTTT
ATGTGTGGTAGTACTAGTTTCAGTGAAATCACAACTGTGTGTTCTTAAATGCTACA
GCAATGGTAGCTAGCTCTATAGTATTTCCATTCTCTTGTGTCATATGAACTCCTGGACTTTT

FIGURE 31B

CCTGCTACTGATTCTTAGTTTGCTTTGATATTTAGTGAGCGCTGGTTCGGCTGGTCTTTT
TAAAAATTTTATAACTCAGAATGTAAAAGGCTTTCACCTATTGCCCTTTCTCGTCCCC
CTTTTCTTCTCTTGCCTTTCTATTAATAGGCCTGACTTAGTCATCATTGATATAAGTGG
TTCATTTGGGCAACCGCAGGCAGTCTCCAATAAAAGGTTCAAACCAGCACCTGGATAAAT
AAGTGATGTTTTGATGAGAATGATGGAAGGATTTTGGGGAGAAGAGAATCACCAGCTTTA
TTTTTCCCTCTTTTGAAGCTTCAGTTCAGTATAGTTACACAGAAGGGTTTAAAAATGTC
TGAAATTCCTTTTCTAAATTTAAACCATGATGGTGAGGTGACTGGGGGGTGGGGGGTGGG
GGTGGGAGGGGGTGGAGGGCTGAGTATGCTAGTAATAAATGGGAGTCATATATGACTTTG
TTCAGATGACCTTATTTTTTCATAATTTTGTAGCTTGTGCTATCCATGAACATACGCAT
CCCTCAGTAGACAGTTTCCTTTTACTGTGTGCATTTTACTGTACACTGTATAGAGTAGAG
TATCTGTTAAGTAAAATATATATGTAAATTTATGTCTTCGTGTTCTGAATGTTAGATGGA
AAAGCAGAGGAGCAACACTACACTGTACTGACCCCTGGGAAAATAAAATGATTAATGTAC
CTAGGCTGTCACTTTTTCAAGGATATACACATCTGTGTTTTTATATATGTGTGGTATGAA
AATTTGAAACCTCCTGTTGTCTCCAAAAGGGTCTTGGTGACCACTATATCAAGGATTTTG
TTTGCTGAGGTAAAGACAATTTCTCAATATAGAACTATTCACTAAGAACTTAAAACCAT
CAGGATTCTAGATTTACTTAGCTATAAGAAGTTAAATCCCACGTTCTGATAATCTTTATT
CTTCTACATGTTTTCTGGAATGATGTGTCAAACCAGGGTCATTTTTAAGTTCATATAAT
TTTCTTTCATAATAATGAGGACTTCCTTTTTCTAGGTTATTGTTATATTTCTAGTAACAC
TGAAGGTAAAATAAGCTTATAAAAGAAGGAAAACATCAGAATGGTGTATCTAGAATACAC
AATCTTGCTCCTTACTCCTCCATCATCTCTAATGAAATTTTTCTTGATGTCTGTGGCTCA
GTCAGTATATATTTTGAAAGATTCATTGTGGTGAATATTTTGAGTCCTGACAGTTTAAAC
GTGATAGAGGGAACAAAGGATTTATATATTTTTTGTACAAAGTTTTTTCTTAAACTGTAT
AATTTTGTAATAATTTGTTTGGGTTTTTTTTTTGTGTACTAAACTACCAGCGTATAGA
TTTCAATAAGAATTGTTGTATTTTGTATTTGGAACTGAAAATTACAGTAAATAAATGG
AACTCTAAGAAAAATTTCAGTAGACAGTTCAACAGAATGAGATTCCTTTTCATATGATTT
TTTTGACCTCAAAATGGACATCTTATTTCACTCTCAGTAAAAAGTTGAAAATTTGACTTT
TTAGTATTGGGGGCAGAAGATAGAAGTGTGTTAAAGTGAAAAACAGTTTTTTTCAGTAAGG
TTTGAGGCCCTTTCTATAAGTTTTTCAGTACACCTTAAACAGGACTAAAAATACTTTAAAA
GTGTGCTTTCAAAGAATTTTAAACATGTTTGACTCAAAGATGAATTTGAAGTGAGTTAA
TTATAATACTGGAAACTTCAGGTTAGCATAAAATAGTTTATATATATCCCCTGCCCTT
TTGGGATTTACTTCCACCATCAAATCTTCAACTGTTAGAATTTCACTTAAAAGTGAATAA
CTGCCATACATGTTTTCTTGGCATCTTCATTTACAGAAATAACATACAGCATCTAAAGCA
AGTTCTGTCCCTCTTAATGTGTATGACATCTTTTTTAAGTAGCTGATCAGCAATAATAGCC
ACCAGTTGACTAGGTCAGCCTGATATACTAGTGGATCACTGTCCAAGATAAAAAGGTAAC
CCCAAGTATTGCAAAATTTCCCTCAATTTCTTTATGTAACATTGAAGAAATGTTGTTACC
AGCTAAGATGATAAATTGGAAAACAGTCTTGTTAAGGTGAAAGGGTCCTTGGTGATGGA
TCATTATTTCAAAAAAGAAAAAATCATGTGAAAAGGAATAGTGGTTCCTCTTGATGTAT
AGTATGCCTGTATTATAGTTTTTACAAAATTGTGAACCTGTGTAAATAGTATAATAGGAGA
TATTGTTGAATTTCTAACTGTTTATACATTTAAATTCATATATGTAATGTTTGTATC
AATTACAATCTGAATTTCTAAGAAGCATGTTGACTTTTGCAATAAAGATGCAATATGGAA
TGGTTCACAATTGG

FIGURE 32

MIPFPPPPGLPPPPPPGMLMPPMPGPGPGPGPGPGPGPGPGPGHSMRLPVPQGHGQP
PPSVVLPIPRPPITQSSLINSRDQPGTSAVPNLASVGTRLPPPLPQNLLYTVSERQPMYS
REHGAAASERLQLGTPPPLLAARLVPPRNLMGSSIGYHTSVSSPTPLVPDITYEPDGYNPE
APSITSSGRSQYRQFFSRTQTQRPNLIGLTSGDMDVNPRAANIVIQTEPPVPVSINSNIT
RVVLEPDSRKRAMSGLEGPLTKKPWLKGQGNNNQNKPGFLRKNQYTNKLEVKKIPQELN
NITKLNEHFSKFGTIVNIQVAFKGDPEAALIQYLTNEEARKAISSTEAVLNNRFRIRVLWH
RENNEQPTLQSSAQLLLQQQQTLSHLSQQHHHLPQHLHQQQVLVAQSAPSTVHGGIQKMM
SKPQTS GAYVLNKVPVKHRLGHAGGNQSDASHLLNQSGGAGEDCQIFSTPGHPKMIYSSS
NLKTPSKLCSGSKSHDVQEV LKKKQEAMKLQQDMRKKRQEVLEKQIECQKMLISKLEKNK
NMKPEERANIMKTLKELGEKISQLKDELKTSSAVSTPSKVTKTEAQKELDTLHHR
LSSGEDTTELKRLKLSQLQVEAARLGILPVGRGKTMSSQGRGRGRGRGRGRGSLNHMVVD
HRPKALTVGGFIEEEKEDLLQHFSTANQGP KFKDRRLQISWHKPKVPSISTETEL EEVKE
EETETSDLFLPDDDDDEDEDEYESRSWRR

Signal sequence

none

Transmembrane domain

none

N-glycosylation site.

238-241

301-304

446-449

455-458

cAMP- and cGMP-dependent protein kinase phosphorylation site.

599-602

612-615

N-myristoylation site.

124-129

152-157

208-213

313-318

444-449

FIGURE 33

AAACACTCTGTGTGGCTCCTCGGCTTTGGGACAGAGTGCAAGACGATGACTTGCAAAATG
TCGCAGCTGGAACGCAACATAGAGACCATCATCAACACCTTCCACCAATACTCTGTGAAG
CTGGGGCACCCAGACACCCTGAACCAGGGGGAATTCAAAGAGCTGGTGCGAAAAGATCTG
CAAAATTTTCTCAAGAAGGAGAATAAGAATGAAAAGGTCATAGAACACATCATGGAGGAC
CTGGACACAAATGCAGACAAGCAGCTGAGCTTCGAGGAGTTCATCATGCTGATGGCGAGG
CTAACCTGGGCCTCCACGAGAAGATGCACGAGGGTGACGAGGGCCCTGGCCACCACCAT
AAGCCAGGCCTCGGGGAGGGCACCCCTAAGACCACAGTGGCCAAGATCACAGTGGCCAC
GGCCATGGCCACAGTCATGGTGGCCACGGCCACAGGCCACTAATCAGGAGGCCAGGCCAC
CCTGCCTCTACCCAACCAGGGCCCCGGGGCCTGTTATGTCAAAGTGTCTTGGCTGTGGGG
CTAGGGGCTGGGGCCAAATAAAGTCTCTTCCTCCAA

FIGURE 34

MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLKKENKNEKVIE
HIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLGEGTP

signal sequence
none

Transmembrane domain
none

N-myristoylation site.
108-113

S-100/ICaBP type calcium binding domain
8-51

EF hand
58-86

FIGURE 35

AAGAGGAAGCGCTGGCAGACAATGCGACCCGACCGCGCTGAGGCTCCAGGACCGCCCGCC
ATGGCTGCAGGAGGTCCCGGCGCGGGGTCTGCGGCCCCGGTCTCCTCCACATCCTCCCTT
CCCCTGGCTGCTCTCAACATGCGAGTGCGGCGCCGCTGTCTCTGTTCTTGAACGTGCGG
ACACAGGTGGCGGCCGACTGGACCGCGCTGGCGGAGGAGATGGACTTTGAGTACTTGGAG
ATCCGGCAACTGGAGACACAAGCGGACCCCACTGGCAGGCTGCTGGACGCCTGGCAGGGA
CGCCCTGGCGCCTCTGTAGGCCGACTGCTCGAGCTGCTTACCAAGCTGGGCCGCGACGAC
GTGCTGCTGGAGCTGGGACCCAGCATTTGAGGAGGATTGCCAAAAGTATATCTTGAAGCAG
CAGCAGGAGGAGGCTGAGAAGCCTTTACAGGTGGCCGCTGTAGACAGCAGTGTCACCGG
ACAGCAGAGCTGGCGGGCATCACCACACTTGATGACCCCCTGGGGCATATGCCTGAGCGT
TTCGATGCCTTCATCTGCTATTGCCCCAGCGACATCCAGTTTGTGCAGGAGATGATCCGG
CAACTGGAACAGACAACTATCGACTGAAGTTGTGTGTGTCTGACCGCGATGTCCTGCCT
GGCACCTGTGTCTGGTCTATTGCTAGTGAGCTCATCGAAAAGAGGTGCCGCCGGATGGTG
GTGGTTGTCTCTGATGATTACCTGCAGAGCAAGGAATGTGACTTCCAGACCAAATTTGCA
CTCAGCCTCTCTCCAGGTGCCCATCAGAAGCGACTGATCCCCATCAAGTACAAGGCAATG
AAGAAAGAGTTCCCCAGCATCCTGAGGTTCACTGTCTGCGACTACACCAACCCCTGC
ACCAAATCTTGGTTCTGGACTCGCCTTGCCAAGGCCTTGTCCCTGCCCTGA

FIGURE 36

MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLE
IRQLETQADPTGRLLDAWQGRPGASVGRLLLELLTKLGRDDVLLELGPSIEEDCQKYILKQ
QQEEAEKPLQVAADVSSVPRTAELAGITTLDPLGHMPERFDAFICYCPSDIQFVQEMIR
QLEQTNRYRLKLCVSDRDVLPGTCVWSIASELIEKRCRMRVVVSDDYLOSKECDFQTKFA
LSLSPGAHQKRLIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP

signal sequence
1-45

Transmembrane domain
none

cAMP- and cGMP-dependent protein kinase phosphorylation site.
31-34

Tyrosine kinase phosphorylation site.
180-187

N-myristoylation site.
4-9
7-12
83-88

Growth factor and cytokines receptors family signature 1.
192-205

TIR domain
163-292

Death domain
33-109

FIGURE 37

GAATTCGGCACGAGTGCCCAGCTCCTGCTGTAATTAGCTCCACGTGTACCCCCTTCATTC
CCTCCCTCCCACCGAGCCATCCCTGACCCAGGAACTTTCCGCAGACTCGCCGCCATCTGG
GAGTGAAGCAACATGGATGCAGTCAGCCAAGTCCCCATGGAAGTCGTGCTTCCCAAGCAC
ATCCTGGATATCTGGGTATTGTCTCATCATCCTGGCCACCATTTGTCATCATGACCTCG
TTGTTGCTGTGCCCAGCCACTGCAGTAATCATCTATCGCATGCGGACTCATCCGATCCTT
AGTGGGGCTGTTGAGAGAGCCTCCCAAGAGGGCCGGGTGAGGGATGAGGACAGGCATCCTA
TCCCCAGCCTCTTCTGTCTTCAGAAAAGCAGCAGGAGGGACTTTGGGGCATGGACCTGA
GTTCTGGTTTTGATTCTGCCACGAGCCAGCTGTGTGAATTTGGTCAAGGGACCTAACTCT
CTGAGTTCCAGGTTCCCTTATCTTTCAAATGGGGATGGTGATCCCTGCCCTTTCTACCTCA
TAGGGATGTGAGAACCACCTGACTTAGTGGATGTGAAAGCTGTTTGTGATCAGTAAAGCT
ACCACAGATATAAGGGTGTATGCTGAACTCTGAGAAGCTTTCAAGAACCAGAGAACCTG
ATTGCTGATGATGGCCTTAAAGGTGGTGAGGGAGATACTGGGGGCAGAGCAGACTTTGCC
AGTGCCCCCTCAGGTCAAACCAAGCCAAGAGCACCTGTCCCCATTTCAAGGGGCCAGCAG
CACTTTGGCCCAAAGTATTTTCTTTAAGGTGCCATTCCTTCATGTTTTCTCAGTTTGAG
GGTGATGGGTAGAGCTTTCCAGAACCTTCTCCATTCCAGAATCTCTGCCCCTGTGTAATC
TGAAGGAAGGCTGTGCCATCTTTGGGCACTGCCAAGGGAGTTGGGGTGATGGGCTTCTTT
CTGCACTGGAGTCTCACATCTGTTAGCTTTGACACTCAAGCAATGTTGGAAAATGCAGGG
TGACTGAGTTCCCTGCCAGCTTTCGGGATCTCTGGCCCCCATCCCCTTGTGTGTGTCCC
TCTGCCAGCTCCTGCTGTAATTAGCTCCACGTGTACCCCCTTCACTCCCTCCCACCAGC
TCTGCAGCCAGCCTATGGCAATTATATTTTAAGAGGTGTTCCCAGGACTTTTGGGACCTA
CTAAAACAATGATGGTTATTTTAGATGTGATGATTATATTTATGTAGAGATATTTCTGG
ACCACTCAAGCTCTTCGATACCAAAATCAGGAGCATCTTGGGATTTATTAATTTATGTAA
GAAGATAGCACAGATATCGGGATATTATTGTGTGAAAATGCTGCTTTTACTTTGATGTGA
TCTCATTGATGTACACAACCAAGTTCCAATAAAGTGCTAGAATGTGAAAAAAAAAAAAAA
AAAAGTGCAGAGGGGGGGACCCGTAACCCTAATCGACCTTAATGAGTGTA

FIGURE 38

MDAVSQVPMEVVLPKHILDIWVIVLIILATIVIMTSLLLCPATAVIIYRMRTHPILSGAV

Signal sequence
1-44

Transmembrane domain
None

FIGURE 39A

CTGGAGCAGCTGAAACCGGTTTGAGCGTGGCTGCTTCCTGCCGCTCGACGCCGCGGCAGG
CCGCCTGGGGGAGCGCTGGCGAGGCACGGACGGCGGGCGCCCGGTACCTCTGCCCGCGGT
CCTCGCTCTCGGGCGGGGCGGCGGCGACGCGGACCTGCGGACTAGCGAACCCGGAGCACG
ACATCATAAAATAAATCCATCAGAATGACACCTTCTCAGGTTGCCTTTGAAATAAGAGGA
ACTCTTTTACCAGGAGAAGTTTTTGGGATATGTGGAAGCTGTGATGCTTTGGGAAACTGG
AATCCTCAAAATGCTGTGGCTCTTCTTCCAGAGAATGACACAGGTGAAAGCATGCTATGG
AAAGCAACCATTGTACTCAGTAGAGGAGTATCAGTTCAGTATCGCTACTTCAAAGGGTAC
TTTTTAGAACCAGACTATCGGTGGTCCATGTCAAGTGATAGTTTCAAAGTGGGAGACT
CATCTACAACCACGATCAATAACCCCTTTAGAAAGCGAAATTATTATTGACGATGGACAA
TTTGGAATCCACAATGGTGTGAAACTCTGGATTCTGGATGGCTGACATGTCAGACTGAA
ATAAGATTACGTTTGCATTATTCTGAAAAACCTCCTGTGTCAATAACCAAGAAAAAATTA
AAAAATCTAGATTTAGGGTGAAGCTGACACTAGAAGGCCTGGAGGAAGATGACGATGAT
AGGGTATCTCCCACTGTACTCCACAAAATGTCCAATAGCTTGGAGATATCCTTAATAAGC
GACAATGAGTTCAAGTGCAGGCATTACAGCCGGAGTGTGGTTATGGCTTGCAGCCTGAT
CGTTGGACAGAGTACAGCATACAGACGATGGAACCAGATAACCTGGAACATACTTTTGAT
TTTTTCGAAGAAGATCTCAGTGAGCACGTAGTTTCAAGGTGATGCCCTTCTTGACATGTG
GGTACAGCTTGTCTCTTATCATCCACCATTGCTGAGAGTGGAAAGAGTGCTGGAATTCTT
ACTCTTCCCATCATGAGCAGAAATTCCCGGAAAACAATAGGCAAAGTGAGAGTTGACTAT
ATAATTATTAAGCCATTACCAGGATACAGTTGTGACATGAAATCTTCATTTTCCAAGTAT
TGGAAGCCAAGAATACCATTGGATGTTGGCCATCGAGGTGCAGGAAACTCTACAACAAC
GCCCAGCTGGCTAAAGTTCAAGAAAATACTATTGCTTCTTTAAGAAATGCTGCTAGTCAT
GGTGCAGCCTTTGTAGAATTTGACGTACACCTTTCAAAGGACTTTGTGCCCGTGGTATAT
CATGATCTTACCTGTTGTTTGACTATGAAAAAGAAATTTGATGCTGATCCAGTTGAATTA
TTTGAAATTCAGTAAAGAATTAACATTTGACCAACTCCAGTTGTTAAAGCTCACTCAT
GTGACTGCACTGAAATCTAAGGATCGGAAAGAATCTGTGGTTCAGGAGGAAATTCCTTT
TCAGAAAATCAGCCATTTCTTCTCTTAAGATGGTTTTAGAGTCTTTGCCAGAAGATGTA
GGGTTTAACATTGAAATAAAATGGATCTGCCAGCAAAGGGATGGAATGTGGGATGGTAAC
TTATCAACATATTTTGACATGAATCTGTTTTTGGATATAATTTTAAAACTGTTTTAGAA
AATCTGGGAAGAGGAGAATAGTGTCTTCTTCAATTTGATGCAGATATTTGCACAATGGTT
CGGCAAAAGCAGAACAAATATCCGATACTATTTTAACTCAAGGAAAATCTGAGATTTAT
CCTGAACTCATGGACCTCAGATCTCGGACAACCCCCATTGCAATGAGCTTTGCACAGTTT
GAAAATCTACTGGGGATAAATGTACATACTGAAGACTTGCTCAGAAACCCATCCTATATT
CAAGAGGCAAAAGCTAAGGGACTAGTCATATTTCTGCTGGGGTGATGATACCAATGATCCT
GAAAACAGAAGGAAATTTGAAGGAACTTGGAGTTAATGGTCTAATTTATGATAGGATATAT
GATTGGATGCCTGAACAACCAATATATTCCAAGTGGAGCAATTGGAACGCCTGAAGCAG
GAATTGCCAGAGCTTAAGAGCTGTTTGTGTCCCACTGTTAGCCGCTTTGTTCCCTCATCT
TTGTGTGGGGAGTCTGATATCCATGTGGATGCCAACGGCATTGATAACGTGGAGAATGCT
TAGTTTTTATTGCACAGAGGTCATTTTGGGGGCGTGACCGCTGTTCTGGGTATTCAATTT
TTCATCACTGAGCATTGTTGATCTATGCCCTTTTGGGCTTCTCAGTTCAATGAAGCAATAA
TGAAGTATTTAACTCTTTCCTACAGTTCTTGCAAGTATGCTATTTAAATTACTTGGCCA
GGTATAATTGCCAGTCAGTCTCTTTATAGTGAGAAAATTTATTGGTTAGTAATATAAATA
TTTTAACTAAATATATAAATCTATAATGTTAAACATATGTTCAATTAAGCATAGCACT
TTGAAATTAATATATAAATAGCTCATATTTACACTTACAGCTTTTCATTTGATCAGGTC
TGAAATCTTTAGCACTTAAGGAAAATGACTATGCATAATTATACCTGACCATGAAAAAA
TAAGTACCTCAAATGCATGCATTTGCACTGGTGATTCCAAGTGCACAAATCTTTGTGCCA
TCTTGTATATAGGTATTTTTTACATGGGTTGACATGCACACAACACCATTTTCATTCAGT
ATGAACCTTGAGGCTGCTGCCATTTTTTCCACTTAACCAACAGCCTGAAGGTGAACCTC
GAACTTGTTTCATAAATCTTTCAAAGTTGTTTTACATCAATGTTAAATTTCAAATG
CTGCAGGGTAATTTAATGTATAAAATATTAGTAAGAAAAAGTATGTATTGCATACTTAGT
AGAATAGATCACAAACATACAAATTCATTCAGTGCATGCTTTAGGTGTTAAGCATGAGAT
TGTACATGTTTACTGTTAGGTCCTTGCATCTGTGGTGCTAGGTGAGTATGAGAAGATGTC
AAGGACTGGACGTATTTTGTGCTAAAAAAAAGGCTGTTTGTAGGCGTTTTAAATAT
GCTTATTTTGTGTGTCTCTCACTACCTATTACACACTGTTGCTTTGTGGGTTTTGTTTTGT
ATGTGCGTGTGTTATACAGTAGTTAAATTTCCATGCAGAAAAATAAATGTCCTGAATTC
CATATTAGTATTCTTTATTGTATATCATGCATGTAATTTATTAGAAATGTAGGTCTTAC
TAAATGTATATGCATGTATTTAGATTATACTAGGATTTCTTGGATTAGAAGCTGATTGT
GTTAACTGTAACCTAAAGAATGAATGTTAAATAAAATGATACAGATTTATTTTCTTCATT

FIGURE 39B

ACAAAATGAAATTTCAAGAAGGTGTTACTTTTGTAGAATGGTTTTATAATATGACAAGAA
ATTTTAATATAGTGTCTACCCTAAAGGGATGGCTTATTTGCATCTACCTTTTACTGCATG
TTTTTCACAAGGCAGTTTATTCATATATTGACATATTTTGGTAGTAGCTGAGAACCCTAAG
ACTTGAAATTATACATTGTGTAGTATTTTTTAAGCTAAGCAATGCAATTTTGGTCAGATC
TTATTTGTGTGAAGATAGGCTCTGAAATCCTATGGTATTGCGTTTGTAACGTTGATATTA
ATGCAAAATAGTTTAGGAAATGGAGTCTTCTGCAAGGGTCTGTATACTTTTCCACATT
GTATGAGATTTTCCAAAATTTTGGTGTGAATTGGGCACTTTTGGAAAACCTCCTGAAAAG
AATTAGTTTCCTTCATCTGCAGACCTTTGTCCAATACGGTTACCATTTCCTTATAGTAAC
TCGATTAGCCATATATGTTTGTCTTAGTCCTGCTCCTTTGCTCCTCTCCTATGCCTTCC
CAGTGCTGGCTCCATTTTGAAGACTCAAGGACAGAGGGGAAGCAGATCATAAAGAGAAAA
AGGAGACAGAAGAAAGGATGAAGGAAGGAGGTGATGGGGAGTGTGGCTTCTGAGCAGTTT
AGTTGCTGGGGAGAGCAGACAGTCACTGCCTACAATACAGACAGAACCTTCCTGCTCACT
TTCTGTCTATCTCTTCCTGACCTTATGAACCAGTGTAGTAGATGATTAACATGACA
AGCAATGGCTCCTTATTTTACAGGACTAAGTCCGGGCCTTCGTATCACTAGCTGTTGCC
TTTTACACCCTGCTTCAGCCACCCTGTCCCTGTCAATTGGCCCTGGACTTCCTCTCTGTGC
CCGTGTGCTCTGCTGGGAGCCCTCTCCTCCCATAGTCACTTTCTCTCTGCCAACTC
ATTTCTTCTTGTGCCCAAGACCTCTCTCCTGAGCCCCTGTGGAACTTCAGGAAGGATGA
ATCCGTCTTTGTGCTCCACGGCTCGTACCTTGATCAGGCTGTGCATCACAGTAATTCCGT
TCTAGGTAGGCAGAGTTGATCTTTGTCTCATCTGCCAGGCTGCGGGCTCTTCAAGGGCAG
GGACCTTGTCATAGTCATTTTTATTTTACAGTGCTTGGAACATGGTGGAAAATGAATGT
TGGAATTATTGGAGTAATATAATTTGTATCAAAATGTCCTTTTGAATTAAGAGATTTAGTT
ATGTTTACTAAGAATGTAACTTTGAATTGGTTTGCATTTTAACAATTAGGATGGTTTAT
TGATGTGAATTTTGAATGTAGAGGTATAATGTTAAATTATTTTATACTTTATGGAAATC
AAGTGAAATGTTTGAATAATGCCGCCATTATCCTCTGGTATTTTCTACTCTCTGGAATT
ATGTGCTGTAAATGATCGGCTGTAAATGTGAGGCACACCACCCACCCCTGTGTGGAAAGT
GTTGTGGCGCTTCCTGCCACCCACCCACCTCTCTGCCGTTGCTCCTTGTGACACTTGTCT
GTCGTCTCCCATCCAACTCCAAGCTTACAGCTACCTCAGTACTGCTTTGCTTGTCTGAA
ACACCTCCTTTGCCTTCCTTCAGTGTCCCGCTCAGGTGCAGCCTCCTCCCTAAAGCTCAT
CTCAGCTTTTGATCTGAATGATGATGGAAACATGCAGACAGCCTCTCAGTCTTACTATTT
AATGTTGTAGCTGGGAAAAAACCCAGAGAGGTTAACTGATATACTGGGTTGGGACTAGGA
TGTGGGTTTTGTGACTCTGAATCCCATGTTCTCAAACTACGCTGCCTTCCGAAGTCTGGC
ATTTGTTAGCTCATGCTTCCTTGTAGTCCAGCTTCTTATGTGCCTGTTATATTCTCCAGT
AAGATTGTAAGCCCCCTAAGGGCAGGGACGTCTTTGCATCTCTAGCACTGCTATAGTGTT
CTATCCTTAGTTATGAACTAGATAAATAAATGGTGGTGGCAAC

FIGURE 40

NKSIRMTPSQVAFEIRGTLTPGEVFAICGSCDALGNWNPQNAVALLPENDTGESMLWKAT
IVLSRGVSVQYRYFKGYFLEPKTIGGPCQVIVHKWETHLQPRSITPLESEIIIDDGQFGI
HNGVETLD SGWLT CQTEIRLRLHYSEKPPVSITKKLKKSRFRVKLTLEGLEEDDDDRVS
PTVLHKMSNSLEISLISDNEFKCRHSQPECGYGLQPDWTEYSIQTMEDPNLELIFDFFE
EDLSEHVVG DALP GHVGTACLLSSTIAESGKSAGILTLPIMSRNSRKTIGKVRVDYIII
KPLPGYSCDMKSSFSKYWKPRIPLDVGHRGAGNSTTTAQLAKVQENTIASLRNAASHGAA
FVEFDVHLSKDFVPVYHDLTCCLTMKKKFDADPVELFEIPVKELTFDQLQLLKLTHVTA
LKSKDRKESVQEENSFSSENQPFPSLKMVLESLPEDVGFNIEIKWICQQRDGMWDGNLST
YFDMNLF LD IILKTVLENSGKRRIVFSSFDADICTMVRQKQNKYPILFLTQKSEIYPEL
MDLRSRTTPIAMSFAQFENLLGINVHTEDLLRNPSYIQEAKAKGLVIFCWGDDTNDPENR
RKLKELGVNGLIYDRIYDWMPEQPNIFQVEQLERLKQELPELKSCLCPTVSRFVPSSLCG
ESDIHVDANGIDNVENA

Signal sequence
none

Transmembrane domain
none

N-glycosylation site.
1-4
49-52
333-336
477-480

cAMP- and cGMP-dependent protein kinase phosphorylation site.
426-429

N-myristoylation site.
29-34
119-124
330-335
332-337
472-477
476-481

Amidation site.
499-502

Glycerophosphoryl diester phosphodiesterase
328-620

Starch binding domain
8-115

FIGURE 41A

GTACTCTCGCGGTATTTGTCCCGACTCTCGCGGGGTTTAGCGTGGCATTGGGAGGCCCGG
CCTGGGGGAGGAGACGGCGTTCCGTTAGCGGCGTTGGGGTTTGGCTGCAGTGGCAGTGCT
TTCTCTTCTGCTCACGGGGACCCGCTCAGGCTGGAGGCCAGCCAGCTCTTGCCGCCACCT
CGGTCGCGATGGGGGCGCAGGACCGGCCGAGTGCCACTTCGACATCGAGATCAACCGGG
AGCCGGTTGGTTCGATTATGTTTCAGCTCTTCTCAGACATATGTCCAAAAACATGCAAAA
ACTTCCTTTGCTTGTGCTCAGGAGAGAAAGGCCTTGGGAAAACAACCTGGGAAGAAGTTAT
GTTATAAAGGTTCTACGTTCCATCGTGTGGTTAAAACTTTATGATTGAGGGTGGGGACT
TCAGTGAAGGTAATGGAAAAGGTGGAGAATCAATTTATGGTGGATATTTTAAAGATGAAA
ACTTTATTCTCAAACATGACAGAGCGTTCCTTTTATCAATGGCAAATCGAGGGAAACATA
CCAATGGTTCAGTTTTTTCATTACCACAAAGCCTGCTCCACACCTGGATGGGGTGCATG
TAGTCTTTGGACTGGTTATTTCTGGTTTTGAAGTAATCGAACAAATTGAAAATCTGAAGA
CCGATGCTGCAAGCAGACCATATGCAGATGTGCGAGTTATTGACTGTGGAGTACTTGCCA
CAAAATCAATAAAAGATGTTTTTGAGAAAAAAAGGAAGAAACCAACTCAATCAGAAGGCT
CGGATTCTCTTCCAATTCCTCCTCTTCTTCAGAATCATCTTCAGAAAGTGAACCTTGAAC
ATGAGAGAAGCAGAAGGAGGAAACATAAGAGGAGGCCAAAAGTTAAACGTTCTAAAAAGA
GGCGAAAGGAAGCAAGCAGTTCAGAAGAGCCAAGGAATAAACATGCAATGAACCCAAAAG
GTCACTCTGAGAGGAGTGATACCAATGAAAAAGGTCAGTTGATTCCAGTGCTAAAAGGG
AAAAACCTGTGGTCCGCCCAGAAGAGATTCTCCAGTGCCTGAGAACCGATTTTACTGA
GAAGAGATATGCCTGTTGTTACTGCAGAACCTGAACCGAAGATTCCTGATGTTGCACCCA
TTGTAAGTGATCAGAAACCATCTGTATCAAAGTCTGGACGGAAGATTAAAGGAAGGGGCA
CAATTCGCTATCACACACCTCCAAGATCAAGATCCTGTTCTGAGTCAGATGATGATGACA
GCAGTGAAACTCCTCCTCACTGGAAAGAGGAAATGCAGAGATTAAGAGCATATAGACCAC
CTAGTGGAGAAAAATGGAGTAAAGGAGATAAGTTAAGTGACCCCTGTTCAAGCCGATGGG
ATGAAAGAAGCTTGTCTCAGAGATCCAGATCATGGTCTTATAATGGATATTATTGAGACC
TTAGTACAGCAAGACACTCTGGCCACCATAAAAAACGCAGAAAAAGAAAAAAGGTTAAGC
ATAAAAAAGAAAGGGAAAAAGCAGAAACACTGCAGAAGACACAAACAAACAAAGAGAGAA
GGATTCTTATACCGTCTGACATAGAATCCTCAAAATCTTCCACTCGAAGAATGAAATCCT
CTTGTGATAGAGAAAGGAGTTCTCGTTCTTCTCATTGTCTCATCTCACTCATCAAAGA
GAGACTGGTCTAAATCTGATAAGGATGTCCAGAGCTCTTTAACCCATTCCAGCAGAGACT
CATACAGATCAAAATCTCACTCACAGTCTTATTCTAGAGGAAGCTCAAGATCAAGGACTG
CGTCAAAGTCCTCATCACATTCTCGAAGTAGATCAAAGTCCAGATCTAGTTCCAAGTCTG
GGCACCAGAAAGAGAGCATCAAAATCACCAAGAAAAACAGCTTCTCAGTTAAGTGAAAATA
AACCAGTTAAACAGAACCTTTAAGAGCAACCATGGCACAAAATGAAAATGTAGTAGTAC
AACCAGTTGTAGCAGAAAATATTCTGTAAATACCACTGAGTGACAGTCCCCCCCCCTTCAA
GATGGAAGCCTGGACAGAAACCTTGAAGCCCTCTTATGAGCGAATTCAGGAAATGAAAG
CTAAACAACCCATTTGCTACCCATCCAAGCACTTACAGTTTAGCAAATATTAAAGAGA
CTGGTAGCTCATCATCCTACCATAAAAGAGAAAAAATTCGGAAAGTGATCAGAGCACTT
ATTCAAAATACAGTGATAGAAGTTTCAGAAAGCTCACCAAGGTCAAGGAGCAGATCTTCTA
GGAGTAGATCTTATTCCAGATCATATACAAGATCACGTAGTCTAGCTAGTTCACATTCAA
GGTCTAGGTCTCCATCATCTAGATCTCATTACGAAATAAATACAGTGATCATTCACAGT
GTAGTAGATCATCTTCATATACTTCTATTAGCAGTGATGATGGAAGGCGAGCTAAGAGGA
GACTTAGATCCAGTGGGAAAAAAATAGCGTTTTACATAAAAAGCATAGCAGCAGCTCTG
AAAAGACACTTCACAGTAAATATGTCAAAGGTAGAGACAGGTCTTCATGTGTGAGAAAGT
ATAGCGAGAGCAGATCATCTTTAGATTATTCTTCAGACAGTGAGCAGTCAAGTGTTTCAGG
CCACACAGTCAGCCCAGGAAAAAGAGAAGCAGGGCCAAATGGAAAGAACACATAATAAAC
AAGAAAAAACAGAGGTGAAGAAAAATCCAAGTCTGAACGGGAATGCCCTCATTCAAAAA
AAAGAACTTTGAAAGAGAATCTTTCTGATCACCTTAGAAATGGCAGTAAGCCCAAAAGGA
AGAATTATGCTGGTAGTAAATGGGACTCTGAGTCAAATTCAGAACGAGATGTCACTAAAA
ACAGTAAAAATGACTCCCATCCATCCTCTGACAAGGAAGAAGGTGAGGCCACATCCGATT
CTGAATCAGAGGTTAGTGAAATTCACATCAAAGTCAAACCCACAACCAAGTCGTCCACAA
ATACTTCACTGCCTGATGATAATGGTGTCTGGAAATCAAGCAAACAGCGCACATCAACTT
CTGACTCTGAGGGGTCTGTTCCAATTCGGAAAAACAATAGGGGAAAGCCACAAAAGCACA
AACATGGGTCAAAGGAAATCTTAAAGAGAACACACCAAAAAAGTGAAAGAGAAATTGA
AAGGGAAAAAGACAAAAGCATAAGGCTCCAAAACGAAAGCAAGCATTTCCTGAGCAGC
CTCCACTAGAATTTGGTGAAGAGGAGGAGGAGGAGATTGATGACAAGCAAGTTACTCAGG
AATCAAAAGAGAAAAAAGTTTCTGAAAACAATGAAACCATAAAAGATAATATTCTAAAAA
CTGAGAAATCCAGTGAAGAGGACCTTTCAGGTAAACATGATACAGTGACTGTTTCATCAG

FIGURE 41B

ATCTTGATCAGTTTACTAAAGATGATAGTAAACTCAGTATTTCTCCCACAGCTTTAAATA
CTGAGGAAAATGTGGCCTGTTTACAAAACATTTCAGCACGTTGAAGAAAGTGTTCCTCAATG
GAGTGGAAAGATGTGCTTCAAACAGATGACAACATGGAGATCTGCACTCCTGATAGGAGTT
CCCCAGCAAAAGTAGAGGAGACTTCCCCTCTAGGAAATGCACGGCTTGATACCCACAGATA
TAAACATTGTTTTGAAGCAGGATATGGCAACGGAACATCCTCAAGCAGAGGTTAGTAAAC
AGGAAAGCAGCATGTCCGAAAGTAAAGTGTGGGTGAAGTGGGGAAACAGGACAGCAGCT
CTGCTAGCTTGGCTAGTGTGGAGAAAGTACCGGGAAGAAGGAGGTGGCTGAGAAGAGCC
AGATCAACCTCATTGATAAGAAATGGAAGCCCCCTGCAAGGTGTGGGGAACCTGGCAGCAC
CTAATGCTGCCACATCCAGTGCTGTGGAAGTTAAGGTGTTGACCACTGTGCCTGAAATGA
AACCACAAGGCTTGAGAATAGAAATTAAGCAAAAATAAAGTTCGGCCTGGGTCTCTCT
TTGATGAAGTAAGAAAGACAGCACGCTTAAACCGTAGACCAAGAAATCAGGAGAGTTCAA
GTGATGAGCAGACGCCCTAGTCGGGATGATGATAGCCAGTCCAGGAGTCCAAGTAGATCTC
GAAGTAAATCTGAAACCAAATCAAGACACAGAACAAGGTCTGTCTCTATAGTCACTCAA
GAAGTCGATCGAGAAGTTCCACATCATCTTATCGATCAAGAAGCTACTCTAGAAGTCGGA
GCAGAGGATGGTACAGCAGAGGCCGAACCAGAAGCCGGAGCAGTTCTACCGGAGTTACA
AAAGTCACAGGACGTCCAGCAGGAGCAGATCCAGGAGCAGCTCATATGATCCCCACAGTC
GATCCAGGTCTACACCTACGATAGCTACTATAGCAGGAGTCGGAGTCGAAGTAGAAGCC
AGAGAAGTGACAGTTACCACCGAGGCAGAAGTTATAATCGGCGGTCCAGGAGTTGTAGAT
CTTATGGCTCTGACAGTGAAAGTGACCGAAGTTACTCTCATCACCGGAGCCCCAGTGAGA
GCAGCAGATACAGTTGAAAACGTCCGGATACAAATTATATCTTATTTGTAAATATCTGGC
AACTTAGCTTAAGAAATGTAATGACAGTCTGTTGTTCTATTTCAATATCAGAGGTGAATT
TCAAAAATAGACACTTCTTAATTGTTACTGGTTCATTTACATGTGGGGAGAAGAATTTAA
AATACAGATATGTCTCCTAAAAATATTTTATGCCACATTTTACAGTAGCCAACTATGGA
AATGAATTTTCAATTTCTTGAATCAAGAAATCGTGAAATTTATCTATGTATAATTTGCAAT
ATTATTTTAAAGTCTATTTCACTCTATCTTACGTATCCCTTAGAATACAGATTCTTTTTGC
CTGTTTTTCCAGTTTTAGCATATATGCTGCCAAGCATAGAACTGTGAAGGAGAACTGTTA
AAGGCGGCCAAATATTTATATACTGATTACATAGAGTCTTGATACATATGTGCTCTAAAA
CAAACCAACCCAGAATTGATACTGTTGGTAACCAGGAGTATAAGGCAGTGGCTCTGGGGTT
CTTAATTCATTCCTAACTTCTTTGATACTTCACAGGATTAGGAAAGTGGTCATCATACT
CCCACACAGTCTGTATTACTTCAGGCTTGTGGGCAAGGTTAGGAAGAATCAATCAGCCTT
AACTATAAATACCTGCACTGTCTCTGAGGACTTACTATTTTATGTTCTTTTTAATCAATA
CCGATCAGAAGTTTAGGTTATAAAAACAATTCCTACTTCATGCTTTGGTGCTTGGTAATTT
TTGGTGCGTCTTTAAGCATTACTCTTATATATCATATATTAATAATACCATAAAAAATGAAA
TTCAGACAAAATCACTGGCACCAAAAATGGTTTATTCTGAGCTGTCTTCACTTTGACTAT
TTGGGGGGCTTCTCTCAAGTACAGATGTGGGTGGGGTCCCCCTGGAGCAGGCAGGATTGG
CAGTAAGAGATATTGGCCACTCAAGTCTACTGTGTGTGTGTGCCTCTGGAAGAGTGAAGA
ATGGACTTCAAAGTAACATCAAAAATCTAACTGCCACCATCCTGGAGACATTTTGCAGG
GCTTTCCTTTCAAGTCTTTCAAGTACAGGATATTACCACAACAGCAGCTGAACTGTTGTA
ACCAGCATGTTTTCTTATTTCCACTGTGACCTGCAGCTGACTCAAAGCCTTGCGTGACC
TGACCCAGGTGCAAGAGACAGGGGAAGAGGGATAGAGGGTATAGCATAAATTACATATTT
TCATGGCTTTGGGTGGTTCCTCCAAAATAATTGGACCTGTAAAACTAGTGTGTGTGTG
TGT
CAAGTGTACTTAATCACCTTAGTGCCAGTTTAAATCCAGTTATGCAGAAGAAATTCATATT
GGTTGCCTGATGTAGAGCTCAGCACCAACCCCTACCACAGGCCTTGTCTGGTGTATTGGGA
AGTGGAAGAGAGCCCTCAGTTGGAGGGAGCTGACAACCCCTGGTGGAGGGAGGGTGCCCT
TGAATGTATTAAACTATCACCCAAAGAAGGTATGAAAACAGGGTAAGGTGGTCAGTTGT
TTGCCAGGTCAATAGACAGAAAGTACATTAGAAAACAGGACTTAGGCCAAACAAACAATA
CTGGATACTGAATACAAAACAGTATGATTTATATTAAAGGTTTCAAAGGTTGCCTGCAA
AGGAGAATATTACTACTAGTCAGCAGGAAAAAATGCATTCAGAACCAAGCAGAACTG
CCAAATGTAAATTAGGTTAAGAAAAGTTACCCTTGGGCAGTGTATTAGTTTTCTATTGCTG
TGTGACAAATTACCCCAAATTTAGCAGTTTAAAAACAATAACCATAGCAGTTCTGTAGC
TCATGAGTCTGGCACAGTGTGGCTGGATTCTCTGCTCAGGGTCTTAAAGGCTGAAATAAG
GGTTGGCAGGACAACATTCCTTCATGGAGGCTCTGGGGAAGAATCTGCTTCTAAGTTCAT
TCAGGTTGTTGGCGGAATTCAGTTCTTTGCTGGCTCTCAGCTGGAGGCCCTCTCTCACC
TCAAGGCTGCCTGCATTCTTCTTATGTGGTCCCCCTCCAGCTTCAAACCAGCCTTCCTGC
TCTTCTCATGCTTCATATCTCTCTCCCGTCTCTCTGTTTTAGGGGCATATGATTAGCTC

FIGURE 41C

AAGCCACAGATATATTTTAAGGTTGATTGTGCGATAGAACATAATTGCAGGAGTACTGT
CTCATCTCATCATATTCACGGGTTCTGGAGATTAGCTCATTGAAAGTGGGAGGGGCATTT
TCAAATTCTGCCTACCACAGGCAATAACTGCCCATCTCAGCTGTAGGTGGAATTTTACC
CAGAAAAGATAGGCCCTAGAAGCCTCATTTCTTTTCTCCATGGAAAAGGACAGCCCTCTG
CTGCAGCGTTCAACTTGTGTGTTTACTGACAGAGTGAACACAGAAATAGCTTTTCTTCC
TAAAGGGGATTGTTCTACATTTTGAAGTTATTTTAAATAAAATTGAATTATGTTGT

FIGURE 42A

MGAQDRPQCHFDIEINREPVGRIMFQLFSDICPKTCKNFLCLCSGEKGLGKTTGKKLCYK
GSTFHRVVKNFMIQGGDFSEGNGKGGESIYGGYFKDENFILKHDRAFLLSMANRGKHTNG
SQFFITTKPAPHLDGHVHVFLVISGFEVIEQIENLKTDAASRPYADVVIDCGVLATKS
IKDVFEKKRKKPTHSEGSDDSSNSSSSSSSSSESESELEHERSRRRKHKRRPKVKRSKKRRK
EASSSEEP RNKHAMNPKGHSERSDTNEKRSVDSSAKREKPVVRPEEIPV PENRFLLRD
MPVVTAEPEPKIPDVAPIVSDQKPSVSKSGRKIKGRGTIRYHTPPRSRSCSESDDDDSSE
TPPHWKEEMQRLRAYRPPSGEKWSKGDKLSDPCSSRWDERSLSQRSRSWSYNGYYSDLST
ARHSGHHKKRRKEKKVKHKKKGKKQKHCRRHKQTKRRILIPSDIESSKSSTRMKSSCD
RERSSRSSSLSSHSSKRDWSKSDKDVQSSLTHSSRDSYRSKSHSQSYSRGSSRSRTASK
SSSHSRSRSKSRSSSKSGHRKRASKSPRKASQLSENKPVKTEPLRATMAQNENVVQPV
VAENIPVIPLSDSPPPSRWKPGQKPKPSYERIQEMKAKTTHLLPIQSTYSLANIKETGS
SSSYHKREKNSESDQSTYSKYSDRSSESSPRSRSRSSRSRSYSYTRSRSLASSHSR
SPSSRSHSRNKYS DHSQCSRSSSYTSISSDDGRRAKRRLRSSGKNSVSHKKHSSSSEKT
LH SKYVKGRDRSSCVRKYSESRSSLDYSSDSEQSSVQATQSAQEKEKQGMERTHNKQEK
NRGEEKSKSERECPHSKKRTLKENLSDHLRNGSKPKRK NYAGSKWDSESNSE RDVTKNSK
NDSHPSSDKEEGEATSDSESEVSEIHIKVKPTTKSSTNTSLPDDNGAWKSSKQRTSTSDS
EGSCSNSENNRGKPQKHKGSKENLKREHTKKVKEKLKGKKDKKHKAPKRKQAFHWQPPL
EFGE EEEEEIDDKQVTQESKEKKVSENNETIKDNILKTEKSSEEDLSGKHDTVTVSSDL
QFTKDDSKLSISPTALNTEENVACLQNIQHVEESVPNGVEDVLQTDNMEICTPDRSSPA
KVEETSPLGNARLDTPDINIVLKQDMATEHPQAEVVKQESSMSSESKVLGEVVKQDSSSAS
LASAGESTGKKEVAEKSQINLIDKKWKPLQGVGNLAAPNAATSSAVEVKVLTTPPEMKPQ
GLRIEIKSKNKVRPGSLFDEVKRTARLNRRPRNQESSSDEQTPSRDDDSQSRSPSRSRK
SETKSRHRTRSVSYSHSRSRSRSTSSYRSRSYRSRSGWYSRGRTRSRSSSYRSYKSH
RTSSRSRSRSSSYDPHSRSRSYTYDSYYSRSRSRSRSQRSDSYHRGRSYNRRSRSCR SYG
SDSESDRSYSHHRSPSESSRY

signal sequence
none

Transmembrane domain
none

N-glycosylation site.
119-122
203-206
864-867
871-874
901-904
938-941
1048-1051

cAMP- and cGMP-dependent protein kinase phosphorylation site.
190-193
561-564
764-767
771-774
796-799
857-860
1042-1045

Tyrosine kinase phosphorylation site.
84-90
1453-1461

FIGURE 42B

N-myristoylation site.

48-53
75-80
81-86
141-146
174-179
197-202
531-536
659-664
946-951
962-967
980-985

Amidation site.

53-56
329-332
441-444
751-754
762-765
998-1001
1208-1211

ATP/GTP-binding site motif A (P-loop).
45-52

Cyclophilin-type peptidyl-prolyl cis-trans isomerase signature.
59-76

Cyclophilin type peptidyl-prolyl cis-trans isomerase
8-177

FIGURE 43

ATGAAAGATCCAAGTCGCAGCAGTACTAGCCCAAGCATCATCAATGAAGATGTGATTATT
AACGGTCATTCTCATGAAGATGACAATCCATTTGCAGAGTACATGTGGATGGAAAATGAA
GAAGAATTCAACAGACAAATAGAAGAGGAGTTATGGGAAGAAGAATTTATTGAACGCTGT
TTCCAAGAAATGCTGGAAGAGGAAGAAGAGCATGAATGGTTTATTCCAGCTCGAGATCTC
CCACAAACTATGGACCAAATCCAAGACCAGTTAATGACCTTGTTATCAGTGATGGCTCT
TCTCTGGAAGATCTTGTGGTCAAGAGCAATCTGAATCAAATGCAACGGAGTTTGTTCCCT
GGGGTGAAGTACGGAAATATTTGA

FIGURE 44

MKDPSRSSTSPSIINEDVIINGHSHEDDNPFAEYMWMEENEEFNQRQIEEELWEEEFIERC
FQEMLEEEEEEHEWFIPARDLPQTMDOIQDQFNDLVISDGSSLEDLVVKSNNLPNATEFVP
GVKYGNI

signal sequence
none

transmembrane domain
none

N-glycosylation site.
114-117

N-myristoylation site.
121-126

FIGURE 45

AAGTCAGCACCGACCCAAACAAGCAGGAAACAGGAAATGTTTACGTTTCAGAGAGGCTGC
AGCCCGGCGCAGCATCCTGAGCGCGCCTCTGCCGAGGCGAGCGGACATGCGAGGCTCCCCG
CGCAGCCCTAGTCTTCGCCCTGGTGATCGCGCTCGTTCCCGTCGGCCGGGGTAATTATGA
GGAATTAGAAAACCTCAGGAGATACAACCTGTGGAATCTGAAAGACCAAATAAAGTGACTAT
TCCAAGCACATTTGCTGCAGTGACCATCAAAGAAACATTAAATGCAAATATAAATTCTAC
CAACTTTGCTCCGGATGAAAATCAGTTAGAGTTTATACTGATGGTGTTAATCCCATTGAT
TTTATTGGTCCTCTTACTTTTATCCGTGGTATTCTTGCAACATACTATAAAAGAAAAAG
AACTAAACAAGAACCTTCTAGCCAAGGATCTCAGAGTGCTTTACAGACATATGAACTGGG
AAGTGAAAACGTGAAAGTCCCTATTTTTGAGGAAGATACACCCTCTGTTATGGAAATTGA
AATGGAAGAGCTTGATAAATGGATGAACAGCATGAATAGAAATGCCGACTTTGAATGTTT
ACCTACCTTGAAGGAAGAGAAGGAATCAAATCACAAACCAAGTGACAGTGAAATCCTAAAC
CTGAATGGCGCTCATGTTTTCCAAGAGAAGCAGCCCCTGAGGGAGTCTGCTGAGGCTGCC
AACAGAGGATGAAGAGGATACAAATTTAATTAATTTCAAATCAACATAGACACAAGAACC
TTTTGCTGTTTTCTTCCAACGCCCCTCTTCTTAATGATGGCATCACTTGCACTTGGAAGA
ATGTGCAATTGAGAAGTACTAGGAAAAGGCCTGGCTGCCATCCATCGCTGCCTCTGAGGG
TGGAGAAGGAGGCGGGTGATGTGCTCACTTCTGATCAACATGTGTTGCCTCCTCTCAGCC
AACTTCTAGCTCACTGCACTCACTCTGGTCATGATAAATGTTTCGTACCTTTCTGCTTCA
TTCCTTAGGGCCTAAATCAGGAAGCTGTTTTATCGATGGTTTTCTTTTGGGTCAGTAACC
AGCTTTTGATAATTTCTCTGATTATTCAAGTCGTGGGACAGGTAAACTACATTTCAGCAG
GAACTTTTCTCGAGGAGTGTTATGTGATGGAAGACACCAAACACAGCAAGTATTTTAA
TGAATACACCATCCCAGGGGGTCAGTAAGCTCTGCCTGCCAAGAAGACACAGTGAGAGGG
GTCCACAGTCCTGATGAGGTGGCGTTTTGGTAACCTTGTAAGACCTAGCATGGCCAGGTCTG
GTCACCCTTAAGAACTTCTCAGAGAACTAGGAATCTTCAGTGAAAGAACTAATGTTCTC
CTCAGCTGAAATTCCTTGCTTGCTGTCAGCATTTCTGCAAGCTCACACTTGTTTCACCATA
CCTCCCTTGATGTGACATGTAGGTAGGAAGTATGTGCAGGTGGGAGTCATCTGTCAGCC
TTCTATGTTTCAGAGATCCTGAAGGTGGTTTTGAAACAAACAGAAGAGGAGCAGGAAATAT
CCGTGCCTGTGGCAGATCTCACTCATCATGCTTAGCATTTCTCTCCCGCCAAGCTGGGATA
AGCCTCATGTCTAACACAGCACAAACAGGAGGTCTCTGTGAGTCCATCAGAGATGACATT
CTATGTGATATTTTTGACATCCTTGTGCTAAAAGCAATGGCACAAAATGGAAAAGGCCT
ATTGACCACACCTACTCCAGTAAAATTTGTTCTTCAATTTATTCCTTAATTTTCTAAATCTG
ACCCCTTTAAAGCAATCTAGCAAATTTGAGAATCCTCAGCTCTCCTTGATACCTGATATT
TTATTTCAAGAAAGAGACAAAGAAGGAAAATTTTATTTATTTTACTACCCACATATAAAC
CGAAGGGAGATGGGACTACCCAAACATTTGCTGCTCAATTTTGTGTCTTGTGCTTGAAAG
TCTGCCCTAATGCATAACAAAACTACTTGTCTCCTACCTTTTGGGATCCCTTTAACAAG
TATTTGCCTTCTGAACTACGTGGATAATTTCAAAGGCAGAGTTCAGACCAGAGAGGTCT
TTCCATACAATGAAAGCTATAACTAGCTGGTTGTGTTTAACTGCTATCACGCTATCC
TGGGACTGCATAGAACTTTGACAAAAGACAGACTTCATGGTACACAACTTCAACAGATTT
TCTGTCATATTCTCACCAGCACATCTGAATGAGGCTTTGTGTTTTCTTGCTCTCTTGCA
TGTTCCCTTTTCAACTCATGGCCACAGTGACTCTCAGAGATTTATGCCAAAATTGCATAC
AATTGTTTTCTGAATCATAACTTGTCTATTTTTCTGCCTATGTGTGCTACTTTCAGTTTG
TTTCTCATCAACATTTTGACTCTCAGAAGAGCCTCCATTTGCCCTTTCTCTCTTTAGGT
ATCTAAGATCTTTGAACACCTGGACCTTTACATTTGATCCAACCCTATCAAATAATGAAC
TTCTCAGAGAGGCATCTGGGGTCTGGAACCTCATGTTGATGAAGTCATATTATATAATA
TGATAAAAATATTCTCATGCAGTATTTTAAATAATTTCAAATCTAGAAGAAGCAAATTT
CAGCGACATGTCATTGAGTTTTTATTTGGTAAAGCTATAATTGTGCAGTGTAACAAGCAC
TTTTTAAAAAGATAGTTTATTTCTGTCAGGGTATATGAAGTTAGTATACAGCCAGAACAGC
CAAGCCTCAATTCTTGACCTTGTGTCTTTTTTATTACTGTTTAATCAATAGATATCATAT
GTTTATGACAGTTTCAAGAATTGTTTTTAAACCCAACTTAATTTTATGTTTCAGACTAT
TGTTAGAAAAACAAAACAAAAACAAAAACCCCTCACTAATTTGCCCTAATTGGATAGG
GCAATCAGGACAAAATCTGACTTTTGAATATTTAAAAGATATGTAAGTTTGATTGCATTT
TCGTACATTTTAAAGCAAACCTAGGTTAACAACAACATAGCCTAGTCAAACCTTCTCAGGAAA
CTTGTTTTAATAAATATGTAAAAAT

FIGURE 46

MQAPRAALVFALVIALVPVGRGNYEELENSGDTTVESERPKNKVTIPSTFAAVTIKETLNA
NINSTNFAPDENQLEFILMVLIPLILLVLLLLSVVFLATYYKRKRTKQEPSSQGSQSALQ
TYELGSENVKVPIFEEDTPSVMEIEMEELDKWMNSMNRNADFECLPTLKEEKESNHNPSD
SES

signal sequence
1-22

Transmembrane domain
76-96

N-glycosylation site.

63-66

cAMP- and cGMP-dependent protein kinase phosphorylation site.

103-106

N-myristoylation site.

114-119

FIGURE 47

CTCCGCCCTCTCCCACTCTCTCTTTCCGGTGTGGAGTCTGGAGACGACGTGCAGAAATGG
CACCTCGAAAGGGGAAGGAAAAGAAGGAAGAACAGGTCATCAGCCTCGGACCTCAGGTGG
CTGAAGGAGAGAATGTATTTGGTGTCTGCCATATCTTTGCATCCTTCAATGACACTTTTG
TCCATGTCACTGATCTTTCTGGCAAGGAAACCATCTGCCGTGTGACTGGTGGGATGAAGG
TAAAGGCAGACCGAGATGAATCCTCACCATATGCTGCTATGTTGGCTGCCCAGGATGTGG
CCCAGAGGTGCAAGGAGCTGGGTATCACCGCCCTACACATCAAACCTCCGGGCCACAGGAG
GAAATAGGACCAAGACCCCTGGACCTGGGGCCCAGTCGGCCCTCAGAGCCCTTGCCCGCT
CGGGTATGAAGATCGGGCGGATTGAGGATGTCACCCCCATCCCCTCTGACAGCACTCGCA
GGAAGGGGGTTCGCCGTGGTCGCCGTCTGTGAACAAGATTCTCAAATATTTTCTGTTA
ATAAATTGCCTTCATGTAAAAA

FIGURE 48

MAPRKGKEKKEEQVISLGPQVAEGENVFGVCHIFASFNDTFVHVTDLSGKETICRVTGGM
KVKADRDESSPYAAMLAAQDVAQRCKELGITALHIKLRATGGNRTKTPGPGAQSALRALA
RSGMKIGRIEDVTPIPSDSTRRKGGRRGRRL

Signal sequence
none

transmembrane domain
none

N-glycosylation site.
38-41
103-106

N-myristoylation site.
101-106
111-116
123-128
144-149

Amidation site.
144-147
147-150

Ribosomal protein S11 signature.
131-138

Ribosomal protein S11
29-147

FIGURE 49

ACCACTGCTGGCTTTTTGCTGTAGCTCCACATTCCTGTGCATTGAGGGGTAAACATTAGG
CTGGGAAGATGACAAAACCTTGAAGAGCATCTGGAGGGAATTGTCAATATCTTCCACCAAT
ACTCAGTTCCGAAGGGGCATTTTGACACCCTCTCTAAGGGTGAGCTGAAGCAGCTGCTTA
CAAAGGAGCTTGCAAACACCATCAAGAATATCAAAGATAAAGCTGTCATTGATGAAATAT
TCCAAGGCCTGGATGCTAATCAAGATGAACAGGTCGACTTTCAAGAATTCATATCCCTGG
TAGCCATTGCGCTGAAGGCTGCCCATTACCACACCCACAAAGAGTAGGTAGCTCTCTGAA
GGCTTTTACCCAGCAATGTCCTCAATGAGGGTCTTTTCTTCCCTCACCAAACCCAGC
CTTGCCCGTGGGGAGTAAGAGTTAATAAACACACTCACGAAAAGTT

FIGURE 50

MTKLEEHLEGIVNIFHQYSVRKGHFDTLKSGELKQLLTKEANTIKNIKDKAVIDEIFQG
LDANQDEQVDFQEFISLVAIALKAAHYHTHKE

Signal sequence
None

Transmembrane domain
None

N-myristoylation site.
60-65

S-100/ICaBP type calcium binding domain
4-47

FIGURE 51

CTCTTGTCAGCTGTCTTTCAGAAGACCTGGTGGGGXAAGTCCGTGGGCATCATGTTGACC
GAGCTGGAGAAAGCCTTGAAGTCTATCATCGACGTCTACCACAAGTACTCCCTGATAAAG
GGGAATTTCCATGCCGTCTACAGGGATGACCTGAAGAAATTGCTAGAGACCGAGTGTCTT
CAGTATATCAGGAAAAAGGGTGCAGACGTCTGGTTCAAAGAGTTGGATATCAACACTGAT
GGTGCAGTTAACTTCCAGGAGTTCCTCATTCCTGGTGATAAAGATGGGCTGGCAGCCCACA
AAAAAAGCCATGAAGAAAGCCACAAAGAGTAGCTGAGTTACTGCCCAGAGGCTGGGCCCC
TGACATGTACCTGCAGAATAATAAAGTCATCAATACCTCAAAAAAAAAAAAAAAAAAAAAA

FIGURE 52

MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLLKLLTECPQYIRKKGADVWFKELDI
NTDGAVNFQEFLLILVIKMGWQPTKKAMKKATKSS

signal sequence
none

Transmembrane domain
None

cAMP- and cGMP-dependent protein kinase phosphorylation site.
88-91

N-myristoylation site.
24-29

S-100/ICaBP type calcium binding domain
5-48

EF hand
50-78

FIGURE 53

TTTCTTTGCGTAACCAATACTGGAAGGCATTTAAAGGACCTCTGCCGCCTCAGACCTTGC
AGTTAACTCCGCCCTGACCCACCCCTTCCCGATGCGAGTCCCTGATGCAGGCTCCCTCCTG
ATCGCCCTGGGCTTGCTTCTCGCGACCCCTGCGCAAGCCCACCTGAAAAAGCCATCCCAG
CTCAGTAGCTTTTCCTGGGATAACTGTGATGAAGGGAAGGACCCTGCGGTGATCAGAAGC
CTGACTCTGGAGCCTGACCCCATCGTCGTTCTGGAATGTGACCCTCAGTGTCTGTGGGC
AGCACCAGTGTCCCCCTGAGTTCTCCTCTGAAGGTGGATTTAGTTTTGGAGAAGGAGGTG
GCTGGCCTCTGGATCAAGATCCCATGCACAGACTACATTGGCAGCTGTACCTTTGAACAC
TTCTGTGATGTGCTTGACATGTTAATTCTACTGGGGAGCCCTGCCAGAGCCCCTGCGT
ACCTATGGGCTTCCTTGCCACTGTCCCTTCAAAGAAGGAACCTACTCACTGCCCAAGAGC
GAATTCGTTGTGCCTGACCTGGAGCTGCCAGTTGGCTCACCACCGGGAACCTACCGCATA
GAGAGCGTCCTGAGCAGCAGTGGGAAGCGTCTGGGCTGCATCAAGATCGCTGCCTCTCTA
AAGGGCATATAGCATGGCATCTGCCACAGCAGAATGGAGCGGTGTGAGGAAGGTCCCTTT
TCCTCTGTTTTGTGTTTGCCAAGGCCAACTCCCACTCTCTGCCCCCCTTTAATCCCCTT
TCTACAGTGAGTCCACTACCCTCACTGAAAATCATTTTGTACCATTACATTTTAGGCTG
GGGCAAGCAGCCCTGACCTAAGGGAGAATGAGTTGGACAGTTCTTGATAGCCCAGGGCAT
CTGCTGGGCTGACCACGTTACTCATCCCCGTTAACATTCTCTCTAAAGAGCCTCGTTTCAT
TTCCAAAGCAGTTAAGGAATGGGAACAGAGTGTTTTAGGACCTGAAGAATCTTTATGACT
CTCTCTCTTCTCTCTTTTTTTT

FIGURE 54

MQSLMQAPLLIALGLLLATPAQAHLKKPSQLSSFSWDNCDEGKDPVIRSLTLEPDPIVV
PGNVTLSVVGSTSVPLSSPLKVDLVLEKEVAGLWIKIPCTDYIGSCTFEHFCDVLDMLIP
TGEPCPEPLRITYGLPCHCPFKEGTYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKR
LGCICKIAASLKGI

Signal sequence
1-23

Transmembrane domain
none

N-glycosylation site.
63-66

cAMP- and cGMP-dependent protein kinase phosphorylation site.
26-29

N-myristoylation site.
14-19

Amidation site.
177-180

FIGURE 55

ATGACGGTGGGCAAGAGCAGCAAGATGCTGCAGCATATTGATTACAGGATGAGGTGCATC
CTGCAGGACGGCCGGATCTTCATTGGCACCTTCAAGGCTTTTGACAAGCACATGAATTTG
ATCCTCTGTGACTGTGATGAGTTCAGAAAGATCAAGCCAAAGAATCCAAACAAGCAGAA
AGGGAAGAGAAGCGAGTCCTCGGTCTGGTGCTGCTGCGAGGGGAGAATCTGGTCTCAATG
ACAGTAGAGGGACCTCCTCCCAAAGATACTGGTATTGCTCGAGTTCCACTTGCTGGAGCT
GCCGGGGGGCCAGGGATCGGCAGGGCTGCTGGCAGAGGAATCCCAGCTGGGGTTCCCATG
CCCCAGGCTCCTGCAGGACTTGCTGGGCCAGTCCGTGGGGTTGGCGGGCCATCCCAACAG
GTGATGACCCACAAGGAAGAGGTACTGTTGCAGCCGCTGCACTGCTGCCACAGCCAGT
ATTGCCGGGGCTCCAACCCAGTACCCACCTGGCCGTGGGGGTCTCCCCACCTATGGGC
CGAGGAGCACCCCCTCCAGGCATGATGGGCCACCTCCTGGTATGAGACCTCCTATGGGT
CCCCAATGGGGATCCCCCTGGAAGAGGGACTCCAATGGGCATGCCCCCTCCGGGAATG
CGGCCTCCTCCCCCTGGGATGCGAGGCCTTCTTTGA

FIGURE 56

MTVGKSSKMLQHIDYRMRCILQDGRIFIGTFKAFDKHMNLILCDCDEFKIKPKNSKQAE
REEKRVLGVLRLRGENLVSMTEGPPPKDTGIARVPLAGAAGGPGIGRAAGRGI PAGVPM
PQAPAGLAGPVRGVGGPSQQVMTPOGRGTVAATAAATAIAGAPTQYPPGRGGPPPPMG
RGAPPPGMMGPPPGMRPPMGPPMGIPPGRGTPMGMPPPGMRPPPPGMRGLL

signal sequence
none

Transmembrane domain
none

N-myristoylation site.

29-34
105-110
113-118
148-153
204-209
210-215

Sm protein
7-82

FIGURE 57

TCCTTTGGTGCCTTGTGACCAGGGCCCTGATGGTTCATTAGATGGAGCCTTCGAGTCTTA
GGGAGTTGCCGCAGGGTCCCCACAGCGGCTCCCGACGGTTGTGAACCAGCATCCATCCTC
CACGGATTCCGGCAACCCGCCTGGCCCTGGACGTGTCTCAACTGGCCCGCGTGAGGGGCC
GCCCCGAAATGACGCGCTGCCCCGCTGGCCAAGCGGAAGTGGAGATGGCGGAGCTGTAC
GTGAAGCCGGGCAACAAGGAACGCGGCTGGAACGACCCGCCGCAGTTCTCATACGGGCTG
CAGACCCAGGCCGGCGGACCCAGGCGCTCGCTGCTTACCAAGAGGGTAGCCGCACCCAG
GATGGATCCCCCAGAGTCCCCGCATCAGAGACTTCTCCTGGGCCTCCCCCAATGGGGCCT
CCACCTCCTTCAAGTAAGGCTCCCAGGTCCCCACCTGTGGGGAGTGGTCCTGCCTCTGGC
GTGGAGCCCAAGTTTCCCAGTCGAGTCTGAGGCTCGACTGATGGAGGATGTGCTGAGA
CCTTTGGAACAGGCATTGGAAGACTGCCGTGGCCACACAAGGAAGCAGGTATGTGATGAC
ATCAGCCGACGCCTGGCACTGCTGCAGGAACAGTGGGCTGGAGGAAAGTTGTCAATACCT
GTAAAGAAGAGAATGGCTCTACTGGTGCAAGAGCTTTCAAGCCACCGGTGGGACGCAGCA
GATGACATCCACCGCTCCCTCATGGTTGACCATGTGACTGAGGTCAGTCAGTGGATGGTA
GGAGTTAAAAGATTAAATTGCAGAAAAGAGGAGTCTGTTTTTCAGAGGAGGCAGCCAATGAA
GAGAAATCTGCAGCCACAGCTGAGAAGAACCATAACCATAACCAGGCTTCCAGCAGGCTTCA
TAATCCTCGGTTCCCCAGACT

FIGURE 58

MTRCPAGQAEVEMAELYVKPGNKERGWNPPQFSYGLQTQAGGPRRSLLTKRVAAPQDGS
PRVPASETSPGPPPMGPPPPSSKAPRSPPVGSGPASGVEPTSFPVSEEARLMEDVLRPLE
QALEDCRGHTRKQVCDDISRRLALLQEQWAGGKLSIPVKKRMALLVQELSSHRWDAADDI
HRSLMVDHVTEVSQWMVGKRLIAEKRSLEEEAANEKSAATAEKNHTIPGFQQAS

signal sequence
none

Transmembrane domain
none

N-glycosylation site.
227-230

N-myristoylation site.
91-94
97-100
151-154

GGGGGTAGCTGGCGGAGCCAGAGCCGGTAGCGAGGTTGGGAGAGACGGAGCGGACCTCAGC
GCTGAAGCAGAAAGTCCCCGGAGCTGCGGTCTCCCCGCCGCGGCTGAGCCATTCCGGCTCCC
TGACCTGAGACCCTGGACCTCCCTGCTGCTGGTGACGCGGCTTTACTGTGGCTGCTTCA
GGGCCCTCTGGGGACTTTGCTTCCTCAAGGGCTGCCAGGACTATGGCTGGAGGGGACCCT
GCGGCTGGGAGGGCTGTGGGGGCTGCTAAAGCTAAGAGGGCTGCTGGGATTTGTGGGGAC
ACTGCTGCTCCCGCTCTGTCTGGCCACCCCCCTGACTGTCTCCCTGAGAGCCCTGGTCGC
GGGGGCCCTCACGTGCTCCCCCAGCCAGAGTCGCTTCAGCCCCCTTGGAGCTGGCTGCTGGT
GGGGTACGGGGCTGCGGGGCTCAGCTGGTCACTGTGGGCTGTTCTGAGCCCTCCTGGAGC
CCAGGAGAAGGAGCAGGACCAGGTGAACAACAAAGTCTTGATGTGGAGGCTGCTGAAGCT
CTCCAGGCCGGACCTGCCTCTCCTCGTTGCCGCCCTTCTTCTTCTTCTTGTCTTGTGTTTT
GGGTGAGACATTAATCCCTCACTATTCTGGTCGTGTGATTGACATCCTGGGAGGTGATTT
TGACCCCCATGCCTTTTGCCAGTGCCATCTTCTTCATGTGCCTCTTCTCCTTTGGCAGCTC
ACTGTCTGCAGGCTGCCGAGGAGGCTGCTTCACCTACACCATGTCTCGAATCAACTTGCG
GATCCGGGAGCAGCTTTTCTCCTCCCTGCTGCGCCAGGACCTCGGTTTCTTCCAGGAGAC
TAAGACAGGGGAGCTGAACTCACGGCTGAGCTCGGATACCACCCTGATGAGTAACTGGCT
TCCTTTAAATGCCAATGTGCTCTTGCGAAGCCTGGTGAAAGTGGTGGGGCTGTATGGCTT
CATGCTCAGCATATCGCCTCGACTCACCTCCTTTCTCTGCTGCACATGCCCTTCACAAT
AGCAGCGGAGAAGGTGTACAACACCCGCCATCAGGAAGTGCTTCGGGAGATCCAGGATGC
AGTGGCCAGGGCGGGGCAGGTGGTGCGGGAAGCCGTTGGAGGGCTGCAGACCGTTCGCAG
TTTTTGGGGCCGAGGAGCATGAAGTCTGTGCTATAAAGAGGCCCTTGAACAATGTGCGCA
GCTGTATTGGCGGAGAGACCTGGAACGCGCCTTGTTACCTGCTCGTAAGGAGGGTGCTGCA
CTTGGGGGTGCAGATGCTGATGCTGAGCTGTGGGCTGCAGCAGATGCAGGATGGGGAGCT
CACCCAGGGCAGCCTGCTTTCCTTTATGATCTACCAGGAGAGCGTGGGGAGCTATGTGCA
GACCCTGGTATACATATATGGGGATATGCTCAGCAACGTGGGAGCTGCAGAGAAGGTTTT
CTCCTACATGGACCGACAGCCAAATCTGCCTTCACCTGGCACGCTTGCCCCCACCCTCT
GCAGGGGGTGTGAAATTCCAAGACGTCTCCTTTGCATATCCCAATCGCCCTGACAGGCC
TGTGCTCAAGGGGCTGACGTTTACCCTACGTCTTGGTGAGGTGACGGCGCTGGTGGGACC
CAATGGGTCTGGGAAGAGCACAGTGGCTGCCCTGCTGCAGAATCTGTACCAGCCACAGG
GGGACAGGTGCTGCTGGATGAAAAGCCCATCTCACAGTATGAACTGCTACCTGCACAG
CCAGGTGGTTTTAGTTGGGCAGGAGCCTGTGCTGTTCTCCGGTTCTGTGAGGAACAACAT
TGCTTATGGGCTGCAGAGCTGCGAAGATGATAAGGTGATGGCGGCTGCCCAGGCTGCCCA
CGCAGATGACTTCATCCAGGAAATGGAGCATGGAATATACACAGATGTAGGGGAGAAGGG
AAGCCAGCTGGCTGCGGGACAGAAACAACGTCTGGCCATTGCCCGGGCCCTTGTACGAGA
CCCGCGGGTCTCATCCTGGATGAGGCTACTAGTGCCCTAGATGTGCAGTGCGAGCAGGC
CCTGCAGGACTGGAATTCCCGTGGGGATCGCACAGTGCTGGTGATTGCTCACAGGCTGCA
GACAGTTCAGCGCGCCACCAGATCCTGGTGCTCCAGGAGGGCAAGCTGCAGAAGCTTGC
CCAGCTCTAGGAGGGACAGGACCTCTATTCCCGCCTGGTGACGACGCGCTGATGGACTG
AGGCCCCAGGGATACTGGGCCCTCTTCTCAGGGGCGTCTCCAGGACCAGAGCTGTTCTC
GCTTTGAGTTTCCCTAGAGCTGTGCGGCCAGATAGCTGTTCTGAGTTGCAGGCACGATG
GAGATTTGGACACTGTGTGCTTTTGGTGGGGTAGAGAGGTGGGGTGGGGTGGGGTGGGGG
CTGTCTGTGTCCAGGAACTTAATTCCCTGGTGACTAGAGCTTTGCCTGGTGATGAGGAG
TATTTTGTGGCATAATACATATATTTTAAATATTTTCTTCTTACATGAACTGTATACA
TTCATATAGAAAATTTAGACAATATAAAAAGTACAAAGAAGAAAAGTAAAAGTACCCAT
TGTTTTCACTTCTTGGAGATAACCATAGTTGCTATTTTGTGCTGCCTGTCCCATCAGTCGTTT
ATCTGTTGTTTGGAGATAGAAATTAACCAAAAATGACATAAATATTCATGAGATTGCCTTC
CTATATCCTTCTTGTTCCTACCAGTGTCTGCTATTTTGAAGAAGCTAGGGTCTGGAGGG
ACAGAGAACAGTTCCTTGATTAACAGTATTAATAGCGACATTGGTAACAGCTACCATTTA
TAGAGTTTTAATGGGAGTAGGAGCTATGCTAAGTGTTTTTTCATGTATTATCGTTTTTAAAT
CATTATCCCCAACCTATGANN
NNNGGTGGAGTTGGAGTTTGAACACA
GGCCTGACCCTAGAGTCCACACCCCTGACCCAATCAATTATATTGCATCTTGGGTCCATAA
ACCCTAATCCATAATCCCATCAAGAAAAGCTCTGCTGCTCTTAGCTCTAAATAATTGAGA
ATCTATTCTCTTCTCTCCAGTCCCGTTGTTATAGTCTTCACTCATAGACTTAAGATGATC
CCATCACAGAGAGGTTTTCTTACCATTAGCTTCCCTCTTCCGGCCATTCTTCACAAAGT
CATTTTTCTAAATTCTGTGTCACATACGATGATGGCATTCTGGAAATTCCTTCAGGTGC
TCTCAAGCCCTGCTGCAGAGATCCTTTTCAGAGCACACACTGTTCCAGCCCATCTGTCTC

FIGURE 59B

ACCCTCTCCTGTTGTATCCAGCTCCACGACAACTTCTGCCTTCCCCAACACCTTTGTGC
CTTTGTCATATGGTGTCTTTCTTGCCCATTTTCTGCTCGACTCGCCCCTGATTTTCAAGTTC
AAGACTTAACTCAGGGTTCAGGTCTTCCAGGAGGCCCTTACTTATGTGCTCAGTCTGGGGA
ACTCTCCATGTGCTTCTATCACTGTGCGGTACCTCTTTCACAGCCCTTTTAAAGTTCTA
TCTTCCCTTTCCACCTTTTGTGACCTTCCACTAGACCATGAGCACCTGGGCGGAAAGCC
ATATATCTTATTAAGCTTTATATCTGCTACCTGGCCGAGGGCCTAATTCATAGTGGAGAA
TAAATAGTCAATTGAATAAATGAATAAATATCTCCACCATCGTACTAATCTTAATCCTCC
CTGCCCCTCCACCACTGAAAATGCAACATGTACACATCACTGGTTGTTGGGAGGGAC
TTACCTTGGAAAGTTGCTATTCTAGGAAAGAGAAACCTTCATATTCCTGGAAACAGCAGG
TAGTTTCCAGTGTGCTGGCAATGAATTCCCCAGAACTGCTGTTTTGGATTTTTTCTTGCTG
GCAGCTGTTGGGAGCAGGGTGCAGTGAGGATGGGGTGAGAGTGGGCAGTTTCTTGTCAG
ATTTGCCTTTCTTTCATCCTGGGGCTGACTTGCGAGCTCCACACCCATCCATCTCTCAAT
TTCACAGAGGGTAAAATAGGCATTTGGAGAGAAAGAACTCTGGCCTGATTCCTTTCTCTC
CCACAAATGTCCTTTATTCATAAAACAGGAATAATAATTCCTGTATCTCCCAACTACATG
GAAGCTGCAGCCCTCACAGAAGAAGATGATCTGAGAAATTCCTTGATTCCTCAGTACAG
TTATACCCATGCATCATAATACTTTAAGCCTGGAAGGCATCTTAAAAATAATGCAACAGT
CAAACCTAATTTTACAGAGAACTGACATGAAATCACGCAGCTAATCATGATAAAGCTGG
GTGGAAACTTATCTTGATGGGCAGTACAGGAAGATGCAGTAGACCTTAAGATGTCCTGA
AAGTTTCTTATCTCAGGGGAACTCCAGGTAGGCTTTATGTGAGGGACACAGAAAAATG
CTCCCTGAAAGTCAAAATATTCGGGCTAGACAGACAAATTCCTGTAAGTGTGGTTTGTCT
GGGAACACAGATGTCACTAATCCTGGTTTGCTCCAGAGTTCTTTTTGTTCACCTCCTACC
CCCCATCACCATTTGATTGATCTCCTTACCCTGTAATTTCCCTTCTTGTCGCTTACCTG
CAGTATCTTTCCACCCAGGCATGCCTTATTCTTTCTAAAGGAAAGTATGAATGGAGAGG
GGAAAGCTTGGGAACTGATAGATTTCTTGGATGCCAAAACACCTCCATAGCCTGTCTG
CCCGGCCCTATGTGGAAACAGCATTGAGTTTCAAGTCCTTTATGCCTCCACCCAGGGATA
GCCACTTGGAAATCCACATGGCAATTGTGAAACAAGCAGGAAATGCGTAATTGTCAGAATT
TTGTGGGGAAAGGACTAGGGAATAAGGAAAAACAAGATCTTCCTTGTTGTTTTAGAGCTGT
CAGCTAGAGGAGCACCTGCTTGAGTCTGATGCCATCTAATGGTCCCAGAAGAACTGGGT
TTTGAACCTAGAGTTCCATGGACTCTTAGGAATTAGACTACTACTACTAAGCATTCA
CTGGTGCTTACTATGTGCTATTGCTGTGCCAAGTATCTGAAACCTGTCTTCTTACCTTAT
TTTTCAAGATAATTCTATGTGGCAGGTATTACTATCTCAATTCTAAGAGTGAGAAAAATGG
AGTTTTAGAAACATTTACTAAGTTGCCTGGGTACATAGCTAAGGAAGAGGTGGACTTGC
CCAGCTTTGCATAAACTCCTCAAAAGAGTTGCCTATACTCCCTGACTCCACTTATCTTC
CTACTATCCTCTTTTTTAAATATATTTATTTATTTTAAATAAGCAATATATGAATGTG
GTTTGAAATTCAAAAGACACAAAGAAGTATACAGAGGAAAGCCTCACTCTCAATCCTTCT
CAAGGTTTGCTAATTCCTCTTGCTAGGCAATCCGTTCTTCCAGCTTTGTGTTTATCTTT
CCAGAGAAGTTTACTGTGTATTAAGCAAATATGTATATCTTTATTCTTGCTCAGTATTTT
CGCAAACAGCAGCTGTCTAAGTTCACTGTTCTGAACCTTTATTTTTTAAATTAAAAATATA
TGGCTATGTAGTATTCTATTTTATGGAAGTTCCATATTTCAATTTATCCTGTTTCTTCTA
CTGATGGCTAGTTAGGTTATTGGAAGTCTTTTGCTGTTGCTAGTTAGTCTTGTATAGACA
TTGTAATGCACATGTGCAAAAATACAAGTATGATACAATCTTAAAA

FIGURE 60

MRLPDLRPWTSLLLVDALLWLLQGPLGTLLPQGLPGLWLEGTLRLGGLWGLLKLRGLLG
FVGTTTTPLCLATPLTVSLRALVAGASRAPPARVASAPWSWLLVGYGAAGLSWSLWAVLS
PPGAQEKEQDQVNNKVLWRLKLSRPDLPLLVAAFFFLVLAVLGETLI PHYSGRVIDIL
GGDFDPHAFASAIFFMCLFSFGSSLSAGCRGGCFTYTM SRINLRIREQLFSSLLRQDLGF
FQETKTGELNSRLSSDTTLM SNWLPLNANVLLRSIVKVVGLYGFMLSISPRLTLLSLHLM
PFTIAAEKVYNTRHQEVLREIQDAVARAGQVREAVGGLQTVRSFGAEHEVCRYKEALE
QCRQLYWRRDLERALYLLVRRVLHLGVQMLMLSCGLQQMQDGELTQGSLLSFMIYQESVG
SYVQTLVYIYGDMLSNVGAAEKVFSYMDRQPNLPSPGTLAPTTLQGVVKFQDVSFAYPNR
PDRPVLKGLTFTLRPGEV TALVGPNGSGKSTVAALLQONLYQPTGGQVLLDEKPI SQYEHC
YLHSQVSVSGQEPVLFSGSVRNNIAYGLQSCEDDKVMAAAQAAHADDFIQEMEHGIYTDV
GEKGSQLAAGQKORLA IARALVRDPRVLILDEATSALDVQCEQALQDWN SRGDRTVLVIA
HRLQTVQRAHQILVLQEGK LQKLAQL

signal sequence

none

transmembrane domain

5-25

46-66

62-82

98-118

146-166

185-205

N-glycosylation site.

505-508

Tyrosine kinase phosphorylation site.

368-376

N-myristoylation site.

47-52

110-115

202-207

208-213

211-216

337-342

407-412

488-493

506-511

558-563

567-572

604-609

Cell attachment sequence.

651-653

ATP/GTP-binding site motif A (P-loop).

503 -510

Leucine zipper pattern.

6-27

371-392

ABC transporter

496-678

FIGURE 61A

GAATTCCGAAAGCAAGGAGATGGCCACCAAGGAGAAGCTGCAGTGTCTGAAAGATTTCCA
CAAGGACATGGTGAAGCCCTCACCAGGGAAGAGCCCAGGCACGCGGCCTGAGGACGAGGC
TGAGGGAAAACCTCCGCAGAGGGAGAAGTGGTCTAGCAAGATCGACTTTGTGCTCTCTGT
GGCTGGCGGCTTCGTGGGCTTGGGCAACGTCTGGCGCTTCCCGTACCTCTGCTACAAGAA
TGGTGGAGGTGCGTTTCTCATACCGTATTTTATTTTCTGTTTGGGAGCGGCCTGCCTGT
GTTTTTCTTGGAGATCATCATAGGCCAGTACACCTCTGAAGGGGGCATCACCTGCTGGGA
AAAGATCTGCCCCCTTGTCTCTGGTATCGGCTATGCCTCCGTTGTAATTGTGTCCCTCCT
GAATGTCTACTACATCGTCATCCTGGCCTGGGCCACATACTACCTGTTCCAGTCCTTCCA
GAAGGAGCTGCCCTGGGCACACTGCAACCACAGCTGGAACACACCTCACTGCATGGAGGA
CACCATGCGCAAGAACAAGAGTGTCTGGATCACCATCAGCTCCACCAACTTCACCTCCCC
TGTCATCGAGTTCTGGGAGCGCAACGTGCTGAGCTTGTCCCCTGGAATCGACCACCCAGG
CTCTCTGAAATGGGACCTCGCTCTCTGCCTTCTTTTAGTCTGGCTAGTGTGTTTCTTCTG
CATCTGCAAGGGCGTCAGGTCCACTGGGAAGGTCGTCTACTTCACAGCCACTTTTCCATT
CGCCATGCTCCTGGTGTCTGCTGGTCCGAGGGCTGACGCTGCCGGGCGCGGGCCGAGGCAT
CAAGTCTATCTGTATCCTGACATCACCCGCCTTGAGGACCCACAGGTGTGGATTGACGC
TGGGACTCAGATATTCTTCTTATGCCATCTGCCTGGGGGCTATGACCTCGCTGGGGAG
CTACAACAAGTACAAGTATAACTCGTACAGGGACTGTATGCTGCTGGGATGCCTGAACAG
TGGTACCAGTTTTGTGTCTGGCTTCGCAATTTTTTCCATCCTGGGCTTCATGGCACAAGA
GCAAGGGGTGGACATTGCTGATGTGGCTGAGTCAGGTCCCTGGCCTGGCCTTCATTGCCTA
CCCAAAGCTGTGACAATGATGCCGCTGCCACATTTTGGTCCATTCTTTTTTTTATTAT
GCTTCTCTTGCTTGGACTGGATAGCCAGTTTGTGTAAGTTGAAGGACAGATCACATCCTT
GGTTGATCTTTACCCATCCTTCCTAAGGAAGGGTTATCGTCGGGAAATCTTCATCGCCTT
CGTGTGTAGCATCAGCTACCTGCTGGGGCTGACGATGGTGACGGAGGGTGGCATGTATGT
GTTTCAGCTCTTTGACTACTATGCAGCTAGCGGTGTATGCCTTTTGTGGGTTGCATTCTT
TGAATGTTTTGTATTGCCTGGATATATGGAGGTGATAACCTTTATGATGGTATTGAGGA
CATGATTGGCTATCGGCCCCGGGCCCTGGATGAAGTACAGCTGGGTGATCACTCCAGTTCT
CTGTGTTGGATGTTTCATCTTCTCGCTCGTCAAGTACGTACCCCTGACCTACAACAAAAC
ATACGTGTCCCCAACTTGGGGCATTGGGGCTGGGGCTGGAGCCTGGCCCTTTCCTCCATGCT
CTGCGTTCCCTTGGTCATCGTCATCCGCCTCTGCCAGACTGAGGGGGCCGTTCCCTTGTGAG
AGTCAAGTACCTGCTGACCCCAAGGGAACCCAACCGCTGGGCTGTGGAGCGCGAGGGAGC
CACACCTTACAACCTCTCGCACCGTCATGAACGGCGCTCTCGTGAAACCGACCCACATCAT
TGTGGAGACCATGATGTGAGCTCTCTCGGGTCGACGGGGCCGGCGGCTTTCCTGCTGTTT
ACTAACATTAGATTACATAGGACCAGGTTTACAGAGCTTTATATTTGCACTAGGATTTT
TTTTTTTTTTGTAATTGTACAGAAAATGTAATTGTGGGTATGTGTGCGTGCGTGTGTGTG
TGTGTGTGTGTGTATCGTGTGTGTGTGTTTTGTTTTGATTTGGGGGATATTTTGTACAAA
AAGAAAACCCACGGGAAGATGTCCGTGGAGAGGCAGAGCTTTCATACTGAATTAGATGTA
TTTTATGGGAATTTGGTAAATTTTTCTTTGTATTTTTTTTTTTTACATATAAGTATATATA
CACTTAGAGATTGTCATATACTTTTACCACCTGAATTGATCTTCTTGCCAGCAATAGATC
TCATTTTCAAAGCAATTCTTCGGTGTGTGTAGCTGGCAGAAAGTTCTGTCCAGTAAAC
GCAGGATGGAATTTTCTTGGGACTCTACACCCATCTTAAGGTGGTATACCTTCCAAATCC
TGGTTCAGATGGAAGAAATAGCAGGAGAGAGGACCCATTAGCTGGCAGACCCAGGGGAAG
AAAGGAGGGCTGTGAGGAGATACCTCATTAACTTGGCTTAGTGAAGAAGAGAGATGCCA
AAGGAATGAACCAACCCTTCACATAAAGGAGACTGGCTGAAGCTGAATGAGGAGGCCCTA
TAGCAGAAGTCTGATTCTAAGAGCAGTAGAACTTGTACCAGAAGCAAAATCCCACTTTT
AATTTTGAGATGGTGAGTGGATAGTCAGTAGACCGTCAGAACCACTGGCCAGAGAGGGAG
CTGCTAGAGATCCAAGAAGGCTGGCAGGAATGAGGCTCACAACCTCAGCCTCGCAAGAGGT
GGCAGAGGCACAGGAGGCCACAGTCCTTCTGGGGCATTCCAGGCAGAGAAGGAGCAGAG
GCTCTCCCGGCAGGAGCTGGGGTCTCAGGGCTCAGATGAGTCTGTTGCATTTGAATGGGG
TCATAGCAGGTTCTGGTCATTCCCCAAGCAACATCTCAGCATCTCTTAAAGTTGCCTGCA
GGAATGAAGCATGACATACCTGTTGAGGGACTAGGGGAGTGGTGGGGAGGTGAGTGGACC
AAAGGATATAGGCCCCAGGCATGCAGATGGGCCCGGTGTGGGGAGGGGTGCTTTCTTTC
CTCATCTCCCCACTCCCCACTCTCAGCCTGGGAGACTCCTGCCAAGCCCTCATTAAGAT
GCCACCCTGGGCTGCCCTGGCACCTAGCAAGGCACACCAAGAACAGCTTTTGAGTCGTAT
CCTCCACTGGGGAAGTGTCTCCAGTTTCAAGCAAGGGCAGCCCGTGGTGTGACCTAGGA
TATAACAAAGCTCTTCACTTCAAACCCCTGCAATAGCTGGGTTTACAGACATTTACCAC

FIGURE 61B

CTGGGGACCCAAAAGAGAAGGCCTAGGAGAGTTTTCTAGAAGGTTGGGATTGTCAGGGTC
CTGGCCCCCAGAACTGGCTTGATCAAGGGCCTTATGTGGAGCAGAGGTTGTCTCTGAAC
CAGGAGAGAAGGTACTATACCTTTCAAATCCCCAGGGCAGACACACCCCCACCCAGCCCC
TATTTGGACCTAAACTGTGCCATTTGAACAGTCACCTCCAAGCTCAGTCTAAATGAAACC
GAAACGTGACCACGCACAAAGGCAGTCACTGCTCGAGGGGTGCAGACCGCAGAATTTTCA
CAGCAGGGGCTCTTGGAACCTCTGGAAACCCCTTCTTAAATTTGGGAGGAGGAGTATGCC
TTTGGTGTCCCCCTCCAAGGGCAATTCTGAACCCCATCTTTGGCAGGCATACATATTTT
ACTGTTTCCAAAGCTATCTACTCTGCCAAACAACACCCAGTCCTATTCCAAACTCTCAAC
GATTCTATCTTGTTCCCTGTTTTTCTATGTATTTATGGTTGCCGTTTGTGTCTGATTTGAT
TTTACTGTTTTTTCCCTGATTTTATGGAGTAGCATTTGTGACCTGTTTTCTTTGTCTTAT
ATAACTTTAGTAACTAACCCTGTCAATGATTGAGGGCAGGTGGCACGTGGGGAAGAGG
GCGGAATTC

FIGURE 62A

MATKEKLQCLKDFHKDMVKPSPGKSPGTRPEDEAEGKPPQREKWSSKIDFVLSVAGGFVG
LGNVWRFPYLCYKNGGGAFLIPYFIFLFGSGLPVFFLEIIIGQYTSEGGITCWEKICPLF
SGIGYASVVIVSLLNVYYIVILAWATYYLFQSFQKELPWAHCNHSWNTPHCMEDTMRKNK
SVWITISSTNFTSPVIEFWERNVLSLSPGIDHPGSLKWDLALCLLLVWLVCFFCICKGVR
STGKVYFTATFPFAMLLVLLVRGLTLPAGARGIKFYLYPDITRLEDPOQWIDAGTQIFF
SYAICLGAMTSLGSYNKYKNSYRDCMLLGCLNSGTSFVSGFAIFSILGFMAQEQGVDA
DVAESGPGLAFAIAYPKAVTMMPLPTFWSILFFIMLLLLGLDSQFVEVEGQITSLVDLYPS
FLRKGYRREIFIAFVCSISYLLGLTMVTEGGMYVFQLEFDYYAASGVCLLWVAFFECFVIA
WIYGGDNLYDGIEDMIGYRPGPMMKYSWVITPVLVCGCFIFSLVKYVPLTYNKTYVSPTW
AIGLGWSLALSSMLCVPLVIVIRLCQTEGPFLVRVKYLLTPREPNRWAVEREGATPYNSR
TVMNGALVKPTHIIVETMM

signal sequence
none

transmembrane domain

47-67
71-91
87-107
122-142
216-236
249-269
291-311
327-347
382-402
426-446
463-483
505-525
544-564

N-glycosylation site.

163-166
179-182
190-193
532-535

Glycosaminoglycan attachment site.

121-124
365-368

N-myristoylation site.

56-61
102-107
108-113
122-127
238-243
269-274
307-312
330-335
356-361
409-414
543-548

FIGURE 62B

Sodium:neurotransmitter symporter family signature 1.
65-79

Sodium:neurotransmitter symporter family signature 2.
148-168

Sodium neurotransmitter symporter family
41-581

FIGURE 63

GCTCTAGCCGGCCGTCTGGTGGCCCGAGGTGGCGGCGGGCTGGGCGCGGGGCGCGATGAG
CGGCGCCTGCACGAGCTACGTGAGCGCAGAGCAGGAGGTGGTGC GCGGCTTCAGCTGCCC
GCGGCCGGGGGGCGAGGCGGCCGCTGTCTTCTGCTGCGGCTTCCGCGACCACAAGTACTG
CTGCGACGACCCGACAGCTTCTTCCCCTACGAGCACAGCTACATGTGGTGGCTCAGCAT
TGGCGCTCTCATAGGCCTGTCCGTAGCAGCAGTGGTTCTTCTCGCCTTCATTGTTACCGC
CTGTGTGCTCTGCTACCTGTTTCATCAGCTCTAAGCCCCACACAAAGTTGGACCTGGGCTT
GAGCTTACAGACAGCAGGCCCTGAGGAGGTTTCTCCTGACTGCCAAGGTGTGAACACAGG
CATGGCGGCAGAAGTGCCAAAAGTGAGCCCTCTCCAGCAGAGTTACTCCTGCTTGAACCC
GCAGCTGGAGAGCAATGAGGGGCAGGCTGTGAACTCCAACGCCTCCTCCATCATTGCTT
CATGGCCACAGTGACCACCAGTGACATTCAGGCAGCCCTGAGGAAGCCTCTGTACCCAA
CCCTGACCTATGTGGACCAGTCCCATAAACAT

FIGURE 64

MSGACTSYVSAEQEVVRGFSCPRPGGEAAAVFCCGFRDHKYCCDDPHSFFPYEHSYMWL
SIGALIGLSVAADVLLAFIVTACVLCYLFISSKPHTKLDLGLSLQTAGPEEVSPDCQGVN
TGMAAEVPKVSPLQQSYSCLNPQLESNEGQAVNSKRLHHCFMATVTTSDIPGSPPEASV
PNPDLCGPVP

Signal sequence
None

Transmembrane domain
61-81

N-myristoylation site.

3-8
25-30
63-68
67-73
118-123
149-154